cannabidiol profile

Cannabidiol: Compound isolated from Cannabis sativa extract. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cannabidiol : An cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Related Flora

Flora	Rank	Flora Definition	Family	Family Definition
Cannabis	genus	The plant genus in the Cannabaceae plant family, Urticales order, Hamamelidae subclass. The flowering tops are called many slang terms including pot, marijuana, hashish, bhang, and ganja. The stem is an important source of hemp fiber.[MeSH]	Cannabaceae	A plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. It is most notable for the members, Cannabis and Hops.[MeSH]
Cannabis sativa	species	[no description available]	Cannabaceae	A plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. It is most notable for the members, Cannabis and Hops.[MeSH]

ID Source	ID
PubMed CID	644019
CHEMBL ID	190461
CHEBI ID	69478
SCHEMBL ID	119679
MeSH ID	M0003266

Synonym
cannabidiol (7ci)
2-[3-methyl-6-(methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol
d1(2)-trans-cannabidiol
(3r,4r)-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol
(-)-cannabidiol
resorcinol, 2-p-mentha-1,8-dien-3-yl-5-pentyl-, trans-(-)- (8ci)
(-)-trans-cannabidiol
(-)-trans-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol
1,3-benzenediol, 2-[(1r,6r)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-
resorcinol, 2-p-mentha-1,8-dien-3-yl-5-pentyl-, (-)-(e)-
cannabidiol
C07578
13956-29-1
CBD ,
2-(3-methyl-6-prop-1-en-2-yl-1-cyclohex-2-enyl)-5-pentyl-benzene-1,3-diol
2-[1r-3-methyl-6r-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol
epidiolex
bdbm50121429
2-(6-isopropenyl-3-methyl-cyclohex-2-enyl)-5-pentyl-benzene-1,3-diol (cannabidiol)
2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
chebi:69478 ,
(-)-cbd
gwp-42003-p
.delta.1(2)-trans-cannabidiol
cardiolrx
btx-1204
gwp42003
gwp42003-p
gwp-42003
btx-1503
CHEMBL190461 ,
2-((1r,6r)-6-isopropenyl-3-methyl-cyclohex-2-enyl)-5-pentyl-benzene-1,3-diol
bdbm50318484
19gbj60sn5 ,
zyn002
unii-19gbj60sn5
cannabidiol [usan]
delta1(2)-trans-cannabidiol
cannabidiolum
delta(1(2))-trans-cannabidiol
(1'r,2'r)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydrobiphenyl-2,6-diol
sativex (cbd + thc, fixed-dose oral spray)
2-[(1r,6r)-3-methyl-6-prop-1-en-2-yl-1-cyclohex-2-enyl]-5-pentylbenzene-1,3-diol
gtpl4150
nabiximols (cbd + thc, fixed-dose oral spray)
2-((1r,6r)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl)-5-pentylbenzene-1,3-diol
cannabidiol [who-dd]
cannabidiol [orange book]
cannabidiol [usp-rs]
2-((1r,6r)-3-methyl-6-(1-methylethenyl)cyclohex-2-enyl)-5-pentylbenzene-1,3-diol
cannabidiol [inci]
cannabidiol [mart.]
cannabidiol [inn]
1,3-benzenediol, 2-((1r,6r)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-
cannabidiol [mi]
SCHEMBL119679
2-(4-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol trans-
1,3-benzenediol, 2-(4-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, trans-
3556-78-3
resorcinol, 2-p-mentha-1,8-dien-3-yl-5-pentyl-, (+-)-
AC-34022
(-)-cannabidiol 1.0 mg/ml in methanol
epidiolex (tn)
D10915
cannabidiol (usan/inn)
DB09061
AKOS032948358
DTXSID00871959 ,
HB2785
Q422917
p0t ,
(1'R,2'R)-5'-METHYL-4-PENTYL-2'-(PROP-1-EN-2-YL)-1',2',3',4'-TETRAHYDRO-[1,1'-BIPHENYL]-2,6-DIOL
NCGC00386518-01
(-)-cannabidiol (cbd) 100 microg/ml in methanol
(-)-cannabidiol (cbd) 1000 microg/ml in methanol
(1'r,2'r)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydro[1,1'-biphenyl]-2,6-diol
(-)-cannabidiol (cbd) 250 microg/ml in acetonitrile
(-)-cannabidiol (synthetic)
DTXSID301038839
(+/-)-cannabidiol
leafpro cbdmed softgels t-fs qd 20
cannabidiol (usp-rs)
1000mg cbd daily support
leafpro cbdmed softgels fs qp 20
sativex (cbd + thc, fixed-doseoral spray)
melody cloverstrip
nanocdb
n03ax24
cannabidiol (mart.)
2000mg cbd daily support
nabiximols (cbd + thc, fixed-doseoral spray)
dtxcid401436151
FS-10329
16 - cannabidiol in supplements
849 - cannabidiol (cbd) in food
cannabidiol, 1mg/ml in methanol

Excerpt	Reference	Relevance
" Minor adverse events were slightly more frequent and severe during active treatment, and toxicity symptoms, which were generally mild, were more pronounced in the active phase."	( Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Gattlen, B; Hagen, U; Heinzel-Gutenbrunner, M; Jobin, P; Reif, M; Schnelle, M; Tschopp, F; Vaney, C, 2004)	0.32
" The large majority of adverse effects were mild or moderate, and there were no adverse effect-related withdrawals or serious adverse effects in the active treatment group."	( Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Blake, DR; Ho, M; Jubb, RW; McCabe, CS; Robson, P, 2006)	0.33
" A comparative in vivo study in mice has shown HU-331 to be less toxic and more effective than the commonly used doxorubicin."	( HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity. Kogan, NM; Peters, M, 2007)	0.34
" When combined with its ability to target the brain and its lack of toxic side effects, CBD may represent a promising new anti-prion drug."	( Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity. Chabry, J; Dirikoc, S; Marella, M; Priola, SA; Zsürger, N, 2007)	0.34
" Cannabidiol, a safe and non-psychotropic ingredient of marijuana, exerts pharmacological effects (e."	( Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. Aviello, G; Borrelli, F; Capasso, F; Capasso, R; Di Marzo, V; Guadagno, F; Izzo, AA; Maiello, F; Orlando, P; Petrosino, S; Romano, B, 2009)	0.35
" Most drug-related adverse events were mild/moderate in severity."	( Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Burnell-Nugent, M; Fallon, MT; Ganae-Motan, ED; Johnson, JR; Lossignol, D; Potts, R, 2010)	0.36
" High numbers of subjects experienced at least one adverse event, but most were mild to moderate in severity and all drug-related serious adverse events resolved."	( Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Collin, C; Duncombe, P; Stott, C; Wade, DT, 2010)	0.36
" Tolerability was measured as the number of withdrawals from the study during the titration period because of adverse events (AEs)."	( Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Abanades, S; Arriola, E; Capellà, D; Duran, M; Farré, M; Laporte, JR; Majem, M; Pastor, A; Pérez, E; Rabanal, M; Rams, N; Saura, C; Vidal, X, 2010)	0.36
" However, little is known about its safety and side effect profile in animals and humans."	( Safety and side effects of cannabidiol, a Cannabis sativa constituent. Bergamaschi, MM; Crippa, JA; Queiroz, RH; Zuardi, AW, 2011)	0.37
" Furthermore, following withdrawal of Sativex, symptoms often return, but, beyond this, sudden cessation is generally safe with no evidence of physiological or psychological dependence."	( Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough? Wade, D, 2012)	0.38
" The majority of patients (84%) did not report adverse events."	( Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Flachenecker, P; Henze, T; Zettl, UK, 2014)	0.4
" The primary outcome was the Systematic Assessment for Treatment Emergent Events (SAFTEE) to assess safety and adverse effects."	( Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. Barnes, AJ; Bergamaschi, MM; Hernandez, S; Huestis, MA; Hurd, YL; Jutras-Aswad, D; Manini, AF; Olmedo, R; Sinha, R; Winkel, G; Yiannoulos, G, )	0.13
"Cannabidiol does not exacerbate adverse effects associated with intravenous fentanyl administration."	( Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. Barnes, AJ; Bergamaschi, MM; Hernandez, S; Huestis, MA; Hurd, YL; Jutras-Aswad, D; Manini, AF; Olmedo, R; Sinha, R; Winkel, G; Yiannoulos, G, )	0.13
" Confusion/ideomotor slowing, fatigue and dizziness were the most frequent side effects; no major adverse events were reported."	( Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study. Colombo, B; Comi, G; Esposito, F; Ferrè, L; Keller Sarmiento, IJ; Leocani, L; Martinelli Boneschi, F; Martinelli, V; Moiola, L; Nuara, A; Pavan, G; Radaelli, M; Rodegher, M, 2016)	0.43
" The incidence of adverse events (AEs) was 40."	( Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients. D'Onghia, M; Di Lecce, V; Direnzo, V; Iaffaldano, A; Manni, A; Paolicelli, D; Tortorella, C; Trojano, M; Zoccolella, S, 2016)	0.43
" The aim of our study was to describe Sativex effectiveness and adverse events profile in a large population of Italian patients with MS in the daily practice setting."	( Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. Amato, MP; Bergamaschi, R; Bonavita, S; Brescia Morra, V; Bruno Bossio, R; Cavalla, P; Centonze, D; Comi, G; Costantino, GF; Cottone, S; Danni, M; Francia, A; Gajofatto, A; Gasperini, C; Ghezzi, A; Iudice, A; Lus, G; Maniscalco, GT; Marrosu, MG; Matta, M; Messina, S; Mirabella, M; Montanari, E; Patti, F; Pozzilli, C; Rovaris, M; Sessa, E; Solaro, C; Spitaleri, D; Trojano, M; Valentino, P; Zappia, M, 2016)	0.43
"2%) and/or adverse events (n=268, 18."	( Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. Amato, MP; Bergamaschi, R; Bonavita, S; Brescia Morra, V; Bruno Bossio, R; Cavalla, P; Centonze, D; Comi, G; Costantino, GF; Cottone, S; Danni, M; Francia, A; Gajofatto, A; Gasperini, C; Ghezzi, A; Iudice, A; Lus, G; Maniscalco, GT; Marrosu, MG; Matta, M; Messina, S; Mirabella, M; Montanari, E; Patti, F; Pozzilli, C; Rovaris, M; Sessa, E; Solaro, C; Spitaleri, D; Trojano, M; Valentino, P; Zappia, M, 2016)	0.43
"Sativex can be a useful and safe option for patients with MS with moderate to severe spasticity resistant to common antispastic drugs."	( Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. Amato, MP; Bergamaschi, R; Bonavita, S; Brescia Morra, V; Bruno Bossio, R; Cavalla, P; Centonze, D; Comi, G; Costantino, GF; Cottone, S; Danni, M; Francia, A; Gajofatto, A; Gasperini, C; Ghezzi, A; Iudice, A; Lus, G; Maniscalco, GT; Marrosu, MG; Matta, M; Messina, S; Mirabella, M; Montanari, E; Patti, F; Pozzilli, C; Rovaris, M; Sessa, E; Solaro, C; Spitaleri, D; Trojano, M; Valentino, P; Zappia, M, 2016)	0.43
"In this study of moderately active Crohn's disease, CBD was safe but had no beneficial effects."	( Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial. Benjaminov, F; Bronshtain, M; Gabay, G; Konikoff, FM; Laish, I; Marii, A; Mechulam, R; Naftali, T; Stein, A, 2017)	0.46
" Adverse events (AEs) were documented at each visit."	( Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results. Beal, JC; Bebin, EM; Checketts, D; Comi, AM; De Boer, LM; Devinsky, O; Joshi, C; Laux, LC; Lopez, M; Lyons, PD; Patel, AD; Szaflarski, JP; Wechsler, R; Wong, MH; Zentil, PP, 2018)	0.48
"The objective of this study was to characterize the changes in adverse events, seizure severity, and frequency in response to a pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex®) in a large, prospective, single-center, open-label study."	( Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Bebin, EM; Cutter, G; DeWolfe, J; Dure, LS; Gaston, TE; Kankirawatana, P; Liu, Y; Singh, R; Standaert, DG; Szaflarski, JP; Thomas, AE; Ver Hoef, LW, 2018)	0.48
" Main outcomes included the ≥ 50% reduction in baseline drop and non-drop seizure frequency, and the incidence of treatment withdrawal and adverse events (AEs)."	( Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis. Brigo, F; Cagnetti, C; Lattanzi, S; Silvestrini, M; Trinka, E, 2018)	0.48
" Main outcomes included the percentage change and the proportion of patients with ≥ 50% reduction in monthly seizure frequency during the treatment period and the incidence of treatment withdrawal and adverse events (AEs)."	( Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. Brigo, F; Cagnetti, C; Del Giovane, C; Lattanzi, S; Silvestrini, M; Trinka, E; Zaccara, G, 2018)	0.48
" Diaries of seizure frequency and adverse events were reviewed at each visit."	( Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US. Caminha Nunes, E; Cilio, MR; Oldham, MS; Rahdari, S; Sands, TT; Tilton, N, 2019)	0.51
" Adverse events were reported in 21 patients (80."	( Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US. Caminha Nunes, E; Cilio, MR; Oldham, MS; Rahdari, S; Sands, TT; Tilton, N, 2019)	0.51
"8% had adverse events, including 23."	( Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US. Caminha Nunes, E; Cilio, MR; Oldham, MS; Rahdari, S; Sands, TT; Tilton, N, 2019)	0.51
" No serious adverse effects occurred."	( Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Comi, G; Comola, M; Falzone, Y; Fazio, R; Ferraro, OE; Leocani, L; Lunetta, C; Mora, G; Riva, N; Sorarù, G, 2019)	0.51
" Before planning large interventional studies, it is important to ensure that cannabis taken orally is safe and well tolerated in people living with HIV."	( Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation. Brouillette, MJ; Chomont, N; Costiniuk, CT; Cox, J; Jenabian, MA; Klein, MB; Lebouché, B; Mandarino, E; Margolese, S; Routy, JP; Saneei, Z; Singer, J; Szabo, J, 2019)	0.51
" Side effects occurred, but severe adverse effects were mentioned in single cases only."	( How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. Friemel, CM; Hasan, A; Hoch, E; Niemann, D; Pogarell, O; Preuss, UW; Schneider, M; von Keller, R, 2019)	0.51
" In this review, we summarize the major findings of several recent large-scale studies using this product with a focus on its adverse effects."	( Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects. Pack, A; Sekar, K, 2019)	0.51
" CBD was well tolerated, and there were no serious adverse events reported during the trial."	( A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment. Crockett, J; Morrison, G; Taylor, L; Tayo, B, 2019)	0.51
" Adverse events (AEs) were monitored and summarized for the safety analysis set (SAS) through 144 weeks."	( Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Bebin, EM; Checketts, D; Chez, M; Flamini, R; Laux, LC; Marsh, ED; Miller, I; Nichol, K; Park, Y; Segal, E; Seltzer, L; Szaflarski, JP; Thiele, EA; Weinstock, A, 2019)	0.51
" Preclinical and clinical studies also report adverse effects (AEs) and toxicity following CBD intake."	( Cannabidiol Adverse Effects and Toxicity. Busardò, FP; Carlier, J; Huestis, MA; Pacifici, R; Pichini, S; Solimini, R, 2019)	0.51
" Disease characteristics, psychological parameters, demographics, comorbidities, lifestyle factors, blood samples and serious adverse events are collected at baseline, after 12 and 24 weeks of treatment, and at a follow-up visit at 36 weeks."	( Efficacy and safety of cannabidiol followed by an open label add-on of tetrahydrocannabinol for the treatment of chronic pain in patients with rheumatoid arthritis or ankylosing spondylitis: protocol for a multicentre, randomised, placebo-controlled study Andersen, TE; Bachmann, AG; Bojesen, AB; Christiansen, AA; Ellingsen, T; Hauge, EM; Hendricks, O; Horsted, TI; Krogh, NS; Loft, AG; Lund Hetland, M; Petersen, KH; Primdahl, J; Roessler, KK; Østergaard, M, 2019)	0.51
"The majority of treatment-emergent AEs (reported by 85% of participants) were mild in severity (70%), and no serious adverse events were reported."	( A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. Bonn-Miller, MO; Cohen, J; Du, W; Heussler, H; O'Neill, C; Sebree, T; Silove, N; Tich, N, 2019)	0.51
" Safety assessments monitored vital signs, adverse effects, physical and neurological exams, and laboratory tests."	( The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study. Chernuha, V; Deutsch, L; Fattal-Valevski, A; Hausman Kedem, M; Heffetz, D; Kramer, U; Mitelpunkt, A; Orbach, R; Sacks, H; Zilbershot Fink, E, 2019)	0.51
" Most commonly reported treatment-related adverse effects were sleep disturbance/insomnia, (4 (25."	( The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study. Chernuha, V; Deutsch, L; Fattal-Valevski, A; Hausman Kedem, M; Heffetz, D; Kramer, U; Mitelpunkt, A; Orbach, R; Sacks, H; Zilbershot Fink, E, 2019)	0.51
"PTL-101 was safe and tolerable for use and demonstrated a potent seizure-reducing effect among pediatric patients with TRE."	( The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study. Chernuha, V; Deutsch, L; Fattal-Valevski, A; Hausman Kedem, M; Heffetz, D; Kramer, U; Mitelpunkt, A; Orbach, R; Sacks, H; Zilbershot Fink, E, 2019)	0.51
"This paper aimed to systematically examine the efficacy and adverse event (AE) profile of cannabidiol and medicinal cannabis by analyzing qualitative and meta-analytic data."	( Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis. Almeida, KJ; Bor-Seng-Shu, E; da Silva Lopes, L; de Carvalho Reis, R; de Melo Mendes, CM, 2020)	0.56
" However severe life-threatening reactions can also occur, and are often related to the non-controlled toxic combination with other antiseizure drugs that are widely used in this type of patients like sodium valproate or clobazam."	( Adverse effects of cannabinoids. Anciones, C; Gil-Nagel, A, 2020)	0.56
" Main outcomes included ≥ 50% reduction in baseline convulsive seizure frequency and the incidence of treatment withdrawal and adverse events (AEs)."	( Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety. Brigo, F; Del Giovane, C; Lattanzi, S; Silvestrini, M; Striano, P; Trinka, E; Zaccara, G, 2020)	0.56
" We conducted the first systematic review and meta-analysis of the adverse effects of CBD across all medical indications."	( Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Chesney, E; Englund, A; Freeman, TP; Green, A; McGuire, P; Oliver, D; Sovi, S; Wilson, J, 2020)	0.56
"Recent trials using cannabidiol (CBD) have shown that most acute and prolonged adverse effects of CBD are mild to moderate, with rare serious adverse effects (SAEs)."	( Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials. Crippa, JAS; Dos Santos, RG; Guimarães, FS; Hallak, JEC; Rocha, JM; Rossi, GN; Zuardi, AW, 2020)	0.56
" Adverse events were predominantly mild or moderate in severity; however, three cases of hallucinations were reported."	( Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial. Checketts, D; Fairhurst, C; Kumar, R; Tayo, B; Turner, S, 2020)	0.56
"Nabiximols was generally well tolerated; however, neuropsychiatric adverse events were observed."	( Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial. Checketts, D; Fairhurst, C; Kumar, R; Tayo, B; Turner, S, 2020)	0.56
" Data relating to adverse events, vital signs, clinical laboratory assessments, 12-lead ECGs, physical examinations and concomitant medications were collected to assess safety and tolerability."	( A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers. Butler, J; Cox, S; Francis, B; Lilley, B; Mcintosh, M; Nguyen, TH; Ong, K; Perkins, D, 2020)	0.56
" The most frequently reported treatment emergent adverse events (TEAEs) were headache (17%) and diarrhoea (8%)."	( A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers. Butler, J; Cox, S; Francis, B; Lilley, B; Mcintosh, M; Nguyen, TH; Ong, K; Perkins, D, 2020)	0.56
" In addition, a number of studies suggest that, at least at high doses, there may be serious adverse effects or drug interactions associated with CBD."	( Cannabidiol (CBD) in Dietary Supplements: Perspectives on Science, Safety, and Potential Regulatory Approaches. ElSohly, MA; Gurley, BJ; Khan, I; Kingston, R; Koturbash, I; Walker, LA; Yates, CR, 2020)	0.56
" The primary objective is to assess the effect of escalating doses of a 1:1 THC/CBD cannabinoid preparation against placebo on change in total symptom score, with secondary objectives including establishing a patient-determined effective dose, the change in total physical and emotional sores, global impression of change, anxiety and depression, opioid use, quality of life and adverse effects."	( Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol ( Gogna, G; Good, P; Greer, R; Hardy, J; Haywood, A; Martin, J; Yates, P, 2020)	0.56
"The extract was generally well tolerated by participants when administered in either wafer or oil form, with some adverse events, including mild or moderate somnolence, sedation and altered mood."	( A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. Hosseini, A; Lickliter, JD; McLachlan, AJ, 2021)	0.62
" The occurrence of adverse events (AEs) was also recorded."	( Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program. Diamond, MP; Flamini, JR; Linder, DF; Long, SA; Moretz, K; Park, YD; Pope, J, 2020)	0.56
" Three serious adverse events (SAE) were reported but were not associated with the treatment."	( Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis. Ab, O; Bs, R; F, S; Hb, S; K, L; Ps, S; R, T; S, G, 2021)	0.62
"Treatment with medical cannabis oils was safe and well tolerated, and resulted in a reduction in pain intensity, spasticity and sleep disturbances in MS patients."	( Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis. Ab, O; Bs, R; F, S; Hb, S; K, L; Ps, S; R, T; S, G, 2021)	0.62
" Adverse Events were reported at/between study visits as required, and participants also completed Adverse Events Profile (AEP) which generates a numerical representation of AEs."	( Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. Ampah, SB; Cutter, GR; Gaston, TE; Grayson, LP; Hernando, K; Martina Bebin, E; Szaflarski, JP, 2021)	0.62
" The most commonly reported adverse events in the study period were diarrhea, sedation, and decreased appetite."	( Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. Ampah, SB; Cutter, GR; Gaston, TE; Grayson, LP; Hernando, K; Martina Bebin, E; Szaflarski, JP, 2021)	0.62
" In addition, CBD was generally well tolerated with minority of participants experiencing adverse events resulting in stopping CBD."	( Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. Ampah, SB; Cutter, GR; Gaston, TE; Grayson, LP; Hernando, K; Martina Bebin, E; Szaflarski, JP, 2021)	0.62
" Treatment-emergent adverse events (TEAEs); plasma and urine concentrations of THC, CBD and metabolites; and self-reported subjective effects were collected."	( Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants. Bonn-Miller, MO; Land, MH; MacNair, L; Mosesova, I; Peters, EN; Turcotte, C; Vandrey, R; Ware, MA, 2022)	0.72
" Aligning with the known safety profile of nabiximols as demonstrated in randomized controlled trials, common adverse events reported consistently across studies conducted under clinical practice conditions were dizziness, fatigue and somnolence."	( Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports. Prieto González, JM; Vila Silván, C, 2021)	0.62
" All observed adverse events (AEs) were mild, transient and resolved without medical intervention."	( Safety and tolerability of escalating cannabinoid doses in healthy cats. Eglit, GM; Kulpa, JE; Paulionis, LJ; Vaughn, DM, 2021)	0.62
" All treatment-emergent adverse events (TEAEs) (65/65) were of mild-to-moderate severity; none was serious."	( Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants. Bonn-Miller, MO; Land, MH; MacNair, L; Mosesova, I; Peters, EN; Turcotte, C; Vandrey, R; Ware, MA, 2022)	0.72
" Adverse events were mild in severity."	( Randomized, placebo-controlled, 28-day safety and pharmacokinetics evaluation of repeated oral cannabidiol administration in healthy dogs. Kulpa, JE; Paulionis, LJ; Vaughn, DM, 2021)	0.62
" Oral CBD was safe and well tolerated, producing small decreases in blood pressure (P < ."	( A placebo-controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans. Arout, CA; Bedi, G; Cooper, ZD; Haney, M; Herrmann, ES, 2022)	0.72
" Risk of adverse events, serious adverse events and withdrawals was computed as the incidence rate (IR)."	( Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies. Bhattacharyya, S; McGoohan, K; Pisani, S; Velayudhan, L, 2021)	0.62
" THC had a very low incidence of all-cause and treatment-related adverse events (IR: 122."	( Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies. Bhattacharyya, S; McGoohan, K; Pisani, S; Velayudhan, L, 2021)	0.62
"Although cannabinoid-based medications were generally safe and acceptable to adults aged over 50 years, these estimates are limited by the lack of a control condition and considerable heterogeneity."	( Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies. Bhattacharyya, S; McGoohan, K; Pisani, S; Velayudhan, L, 2021)	0.62
"To describe the adverse events (AEs) of recreational cannabis use in France between 2012 and 2017."	( Adverse events of recreational cannabis use reported to the French addictovigilance network (2012-2017). Bouquet, E; Eiden, C; Fauconneau, B; Jouanjus, E; Pain, S; Pérault-Pochat, MC; Richard, N, 2021)	0.62
" Adverse events (AEs) occurred in 96% of patients, serious AEs in 42%, and AE-related discontinuations in 12%."	( Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial. Checketts, D; Chin, RF; Devinsky, O; Dunayevich, E; Gil-Nagel, A; Gunning, B; Halford, JJ; Mazurkiewicz-Bełdzińska, M; Mitchell, W; Patel, AD; Scott Perry, M; Thiele, EA; Weinstock, A, 2021)	0.62
" Moreover, there were no reports of adverse effects associated with unfavorable inflammatory sequalae."	( A pilot safety, tolerability and pharmacokinetic study of an oro-buccal administered cannabidiol-dominant anti-inflammatory formulation in healthy individuals: a randomized placebo-controlled single-blinded study. Butcher, B; Hall, S; Henson, JD; Rutolo, D; Vitetta, L, 2021)	0.62
" However, 5 participants, all of whom were in the treatment group, experienced serious adverse events: 4 cases of elevated liver enzymes (1 critical and 3 mild, with the mild elevations reported at the final 28-day assessment) and 1 case of severe pharmacodermia."	( Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical Trial. Andraus, MH; Campos, AC; Crippa, JAS; de Lima Osório, F; Dos Santos, RG; Esposito, DLA; Ferreira, RR; Fonseca, BAL; Guimarães, FS; Hallak, JEC; Kapczinski, F; Loureiro, SR; Mancini Costa, KC; Mechoulam, R; Pacheco, JC; Pereira-Lima, K; Pires-Dos-Santos, I; Scarante, FF; Scomparin, DS; Sen, S; Souza, JDS; Ushirohira, JM; Zuardi, AW, 2021)	0.62
" However, it is necessary to balance the benefits of CBD therapy with potential undesired or adverse effects."	( Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical Trial. Andraus, MH; Campos, AC; Crippa, JAS; de Lima Osório, F; Dos Santos, RG; Esposito, DLA; Ferreira, RR; Fonseca, BAL; Guimarães, FS; Hallak, JEC; Kapczinski, F; Loureiro, SR; Mancini Costa, KC; Mechoulam, R; Pacheco, JC; Pereira-Lima, K; Pires-Dos-Santos, I; Scarante, FF; Scomparin, DS; Sen, S; Souza, JDS; Ushirohira, JM; Zuardi, AW, 2021)	0.62
"Safety and tolerability assessments included adverse events (AEs) and examination of skin."	( Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial. Ali, S; Griesser, J; Gutterman, DL; Hulihan, J; Keenan, N; Messenheimer, J; Sadleir, LG; Scheffer, IE; Sebree, T, 2021)	0.62
" Fewer patients treated with NBX than LAO experienced treatment-related adverse events (25."	( Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry. Essner, U; Mueller-Schwefe, GHH; Ueberall, MA; Vila Silván, C, 2022)	0.72
" The efficacy and safety were reported in terms of an at least 50% monthly seizure frequency reduction in drop seizures, dropout, and serious adverse events."	( Efficacy and safety of antiseizure medication for Lennox-Gastaut syndrome: a systematic review and network meta-analysis. Wang, C; Wang, J; Zhang, L, 2022)	0.72
" Yet some key data gaps concerning the safe use of CBD still remain."	( The current understanding of the benefits, safety, and regulation of cannabidiol in consumer products. Bruner, L; Carvajal, R; Kaminski, NE; Li, J, 2021)	0.62
"To estimate the timing of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]) onset, we conducted a post hoc analysis of GWPCARE6 (NCT02544763), a randomized, placebo-controlled, phase 3 trial in patients with drug-resistant epilepsy associated with tuberous sclerosis complex (TSC)."	( Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6. Checketts, D; Cock, HR; Devinsky, O; Joshi, C; Miller, I; Roberts, CM; Sahebkar, F; Sanchez-Carpintero, R; Wu, JY, 2022)	0.72
"This review underlines that acute pancreatitis is a potential adverse effect of cannabinoid use."	( Cannabinoid-Related Acute Pancreatitis: An Update from International Literature and Individual Case Safety Reports. Azam, C; Buscail, L; Culetto, A; Lapeyre-Mestre, M, 2022)	0.72
" ≥50% reduction in drop seizure frequency from baseline and occurrence of treatment-emergent adverse events (TEAEs) were the primary efficacy and safety outcomes."	( Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: A network meta-analysis. Ameen, R; Bansal, D; Devi, N; Madaan, P; Sahu, JK, 2022)	0.72
" A search of scientific literature was conducted to evaluate what is known about safe dose in food applications and determine what information is still needed to inform a standard or regulated limit."	( Regulating for Safety: Cannabidiol Dose in Food: A Review. Moyer, DC; Nyland, CR, 2022)	0.72
" A search of scientific literature was conducted to evaluate what is known about safe dose in food applications and determine what information is still needed to inform a standard or regulated limit."	( Regulating for Safety: Cannabidiol Dose in Food: A Review. Moyer, DC; Nyland, CR, 2022)	0.72
"Artisanal cannabidiol-enriched cannabis may be an effective and safe long-term treatment for refractory epilepsy."	( The Long-Term Effectiveness and Safety of Cannabidiol-Enriched Oil in Children With Drug-Resistant Epilepsy. Ben Zeev, B; Hamed, N; Heimer, G; Rabinowicz, S; Tzadok, M; Zohar-Dayan, E, 2022)	0.72
" The aim of the present national survey was to describe adverse events (AEs) of recreational cannabis use during pregnancy reported to the French Addictovigilance Network (FAN)."	( Adverse events of recreational cannabis use during pregnancy reported to the French Addictovigilance Network between 2011 and 2020. Bouquet, E; Eiden, C; Fauconneau, B; Pain, S; Pérault-Pochat, MC; Pion, C, 2022)	0.72
" The mainstay of treatment is with multiple anti-seizure medications (ASMs); however, the ASMs themselves can be associated with psychobehavioural adverse events, and effects (negative or positive) on cognition and sleep."	( Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies. Schubert-Bast, S; Strzelczyk, A, 2022)	0.72
" The key outcomes were reduction in seizure frequency, differences in 50% responder rates, adverse events, and interactions with clobazam as co-therapy."	( Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Aparasu, R; Estes, E; Reddy, DS; Talwar, A, 2023)	0.91
" Isolated cannabinoids illustrated different toxic effects on the viability of cells derived from colorectal polyps."	( The Cytotoxic Effect of Isolated Cannabinoid Extracts on Polypoid Colorectal Tissue. Ben-Ami Shor, D; Gluck, N; Hochman, I; Scapa, E; Shibolet, O, 2022)	0.72
"Robust assessment of potential adverse outcomes is needed to determine a safe cannabidiol (CBD) intake level for consumer use."	( Cannabidiol Safety Data: A Systematic Mapping Study. Franke, KS; Franzen, A; Henderson, RG; Payne, LE, 2023)	0.91
" While cannabidiol was generally safe and well tolerated even in high doses among the included studies, clearer dosing guidelines and increased regulation of cannabidiol products are also needed."	( The Effectiveness and Safety of Cannabidiol in Non-seizure-related Indications: A Systematic Review of Published Randomized Clinical Trials. Rudisill, TM; Tang, Y; Tonkovich, KL, 2022)	0.72
"3% experienced treatment related adverse events."	( A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years. Ernenwein, T; Kennedy, J; Roth, S; Vickery, AW; Washer, P, 2022)	0.72
"Oral MC was demonstrated to be safe and well-tolerated for a sustained period in a large complex cohort of cannabis-naïve, multimorbid patients with polypharmacy."	( A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years. Ernenwein, T; Kennedy, J; Roth, S; Vickery, AW; Washer, P, 2022)	0.72
"This study aimed to explore the incidence of adverse events (AEs) reported by patients when initiating medicinal cannabis treatment for chronic pain, and the association of cannabis constituents, dose and concomitant medicines with AE incidence."	( Medicinal cannabis for patients with chronic non-cancer pain: analysis of safety and concomitant medications. Alffenaar, JC; Barlow, JW; Johnstone, MT; Schubert, EA; Wheate, NJ, 2023)	0.91
" Adverse events (AEs) were documented at each visit."	( Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: Four-year results from the expanded access program. Checketts, D; Devinsky, O; Lopez, M; Park, YD; Patel, AD; Sahebkar, F; Szaflarski, JP; Thiele, EA; Wechsler, RT; Zentil, PP, 2023)	0.91
" THC use appears to be associated with a higher proportion of serious adverse effects, including neuropsychological and cardiovascular effects."	( Place of therapeutic cannabis in France and safety data: A literature review. Bacle, A; Corso, B; Demay, E; Gicquel, T; Le Daré, B; Mercerolle, M; Pelletier, R, 2023)	0.91
"The literature reports several frequent but rarely serious adverse effects of CBD during chronic use as well as a significant risk of drug interactions."	( Place of therapeutic cannabis in France and safety data: A literature review. Bacle, A; Corso, B; Demay, E; Gicquel, T; Le Daré, B; Mercerolle, M; Pelletier, R, 2023)	0.91
"Cannabidiol-associated liver enzyme elevations and DILI meet the criteria of common adverse drug events."	( Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. Barr, AM; Boivin, M; Christiansen, A; Eadie, L; Kim, DD; Lo, LA; MacCallum, CA; Strickland, JC, 2023)	0.91
" We reviewed the scientific evidence on CBD-related toxicity and adverse events (AEs) in 2019, at the beginning of the spike in clinical studies involving CBD."	( Update on Cannabidiol Clinical Toxicity and Adverse Effects: A Systematic Review. Busardò, FP; Carlier, J; Giorgetti, R; Kapoor, A; Madeo, G, 2023)	0.91
" Thus, the exact same dose and preparation of cannabis may be beneficial for some but toxic to others."	( An Individuality of Response to Cannabinoids: Challenges in Safety and Efficacy of Cannabis Products. Kitdumrongthum, S; Trachootham, D, 2023)	0.91
" Cannabidiol (CBD) has been approved for the treatment of epilepsy, but its use has been associated with several different adverse events (AEs)."	( Adverse Events of Cannabidiol Use in Patients With Epilepsy: A Systematic Review and Meta-analysis. Fazlollahi, A; Gharagozli, K; Golabi, B; Kolahi, AA; Nejadghaderi, SA; Safiri, S; Sullman, MJM; Zahmatyar, M; ZareDini, M, 2023)	0.91
" Additional studies are needed to determine the safe and effective CBD dosage for treating epilepsy."	( Adverse Events of Cannabidiol Use in Patients With Epilepsy: A Systematic Review and Meta-analysis. Fazlollahi, A; Gharagozli, K; Golabi, B; Kolahi, AA; Nejadghaderi, SA; Safiri, S; Sullman, MJM; Zahmatyar, M; ZareDini, M, 2023)	0.91
" While currently available studies suggest that CBD is relatively safe for human consumption, data from publicly available studies on CBD conducted according to modern testing guidelines are lacking."	( Oral toxicity evaluation of cannabidiol. Bonn-Miller, MO; Borghoff, SJ; Heintz, MM; Henderson, RG; Lefever, TW; Trexler, KR, 2023)	0.91
" Concomitant CBD use was recorded, and treatment-emergent adverse events (TEAEs) were collected."	( Concomitant cannabidiol does not impact safety and effectiveness of diazepam nasal spray for seizure clusters: Post hoc analysis of a phase 3 safety study. Carrazana, E; Misra, SN; Peters, JM; Puri, V; Rabinowicz, AL; Segal, E, 2023)	0.91
" Cognitive adverse events were collected."	( Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms. Adkins, M; Bainbridge, J; Domen, CH; Klawitter, J; Leehey, MA; Liu, Y; Rajkovic, S; Sempio, C; Sillau, S, 2023)	0.91
" Adverse cognitive events were reported at least twice as often by the CBD/THC than the placebo group."	( Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms. Adkins, M; Bainbridge, J; Domen, CH; Klawitter, J; Leehey, MA; Liu, Y; Rajkovic, S; Sempio, C; Sillau, S, 2023)	0.91
" The most common adverse events reported were diarrhea (14 patients), fatigue (8 patients), headache (8 patients), and nausea (7 patients)."	( A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis. BouSaba, J; Burton, D; Busciglio, I; Camilleri, M; Carlson, P; Dilmaghani, S; Harmsen, WS; Ryks, M; Taylor, A; Torres, M; Zheng, T, 2023)	0.91
"To evaluate the addition of CBD to antiseizure drugs (ASDs) on seizure frequency and to report adverse events in dogs with drug-resistant IE."	( The efficacy and safety of cannabidiol as adjunct treatment for drug-resistant idiopathic epilepsy in 51 dogs: A double-blinded crossover study. Bartner, LR; Corsato Alvarenga, I; Gustafson, DL; Kusick, BR; McGrath, S; Rao, S; Rozental, AJ; Weisbeck, BG, )	0.13
"There was one adverse event (AE) in the active group (diarrhea) and two AEs in placebo (dry mouth; eye rash/swollen eye)."	( A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOM Antonio, J; Bonn-Miller, MO; Eglit, GML; Harrison, A; Peters, EN; Turcotte, C; Yardley, H, 2023)	0.91
" Using data from the FAERS database between 2018 and 2023, this study analyzed 13,275 Epidiolex-related adverse events."	( Adverse events of epidiolex: A real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database. Du, Z; Jiang, Y; Qu, K; Shen, Y; Zhang, X; Zhou, Q; Zhu, H, 2023)	0.91

Excerpt	Reference	Relevance
" The apparent terminal half-life of CBD calculated from the slope of the sigma minus plot was significantly shorter (2 h) than the half-life of CBD calculated from plasma data (8 h), and the apparent terminal half-life of the metabolites was similar to that of the CBD calculated from plasma data, indicating that the elimination of these metabolites was formation rate limited."	( Pharmacokinetics of urinary metabolites of cannabidiol in the dog. Bialer, M; Harvey, DJ; Samara, E, 1990)	0.28
" It has a terminal half-life of 9 hr."	( Pharmacokinetics of cannabidiol in dogs. Bialer, M; Mechoulam, R; Samara, E, )	0.13
" As a reason, pharmacodynamic as well as pharmacokinetic mechanisms were suggested."	( Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Fronk, EM; Nadulski, T; Pragst, F; Roser, P; Schnelle, M; Stadelmann, AM; Weinberg, G, 2005)	0.33
" A drug's pharmacokinetics determines the onset, magnitude, and duration of its pharmacodynamic effects."	( Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Huestis, MA, 2005)	0.33
" There are indications that CBD modulates THC's effects, but it is unclear if this is due to a pharmacokinetic and/or pharmacodynamic interaction."	( Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Darwin, WD; Goodwin, RS; Huestis, MA; Karschner, EL; Wright, S, 2011)	0.37
"These data suggest that CBD modulation of THC's effects is not due to a pharmacokinetic interaction at these therapeutic doses."	( Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Darwin, WD; Goodwin, RS; Huestis, MA; Karschner, EL; Wright, S, 2011)	0.37
"We here determined pharmacokinetic profiles of the above phytocannabinoids after acute single-dose intraperitoneal and oral administration in mice and rats."	( Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behavi Amada, N; Arthur, M; Close, S; Deiana, S; Dorward, P; Fleming, S; Pigliacampo, B; Platt, B; Riedel, G; Watanabe, A; Woodcock, H; Yamasaki, Y, 2012)	0.38
" CBD inhibited obsessive-compulsive behaviour in a time-dependent manner matching its pharmacokinetic profile."	( Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behavi Amada, N; Arthur, M; Close, S; Deiana, S; Dorward, P; Fleming, S; Pigliacampo, B; Platt, B; Riedel, G; Watanabe, A; Woodcock, H; Yamasaki, Y, 2012)	0.38
"The mean Cmax values (<12 ng/mL) recorded in this study were well below those reported in patients who smoked/inhaled cannabis, which is reassuring since elevated Cmax values are linked to significant psychoactivity."	( A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Guy, GW; Stott, CG; White, L; Wilbraham, D; Wright, S, 2013)	0.39
"This review examines the characteristics of nabiximols, its pharmacokinetic properties and data on efficacy and tolerability in MS-related neuropathic pain."	( Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain. Constantinescu, CS; Tanasescu, R, 2013)	0.39
" Therefore, it is important that research into therapies is undertaken, particularly focusing on an understanding of the pharmacokinetic properties of compounds in this cachexic population."	( Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome. Martin, JH; Reuter, SE, 2016)	0.43
" Study objectives were to evaluate the safety and tolerability of PTL101 containing 10 and 100 mg CBD, following single administrations to healthy volunteers and to compare the pharmacokinetic profiles and relative bioavailability of CBD with Sativex oromucosal spray (the reference product) in a randomized, crossover study design."	( Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology. Atsmon, J; Deutsch, F; Deutsch, L; Heffetz, D; Sacks, H, 2018)	0.48
"Model-based prediction on clinical doses for cannabinoids therapy is beneficial in the clinical setting, especially for seriously ill patients with both altered pharmacokinetics and pharmacodynamic responses."	( Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling. Liu, Z; Martin, JH, 2018)	0.48
" As both THC and CBD are hepatically metabolized, the potential exists for pharmacokinetic drug interactions via inhibition or induction of enzymes or transporters."	( The pharmacokinetics and the pharmacodynamics of cannabinoids. Galettis, P; Lucas, CJ; Schneider, J, 2018)	0.48
" Higher systemic exposures were observed with the oral CBD-infused oil formulation and the half-life after a 75-mg and 150-mg dose was 199."	( Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs. Bartner, LR; Hyatt, LK; McGrath, S; Rao, S; Wittenburg, LA, 2018)	0.48
" Pharmacokinetic parameters (primarily maximum measured plasma concentration, area under the plasma concentration-time curve from time zero to time t, area under the concentration-time curve from time zero to infinity, time to maximum plasma concentration, and terminal half-life) of CBD and its major metabolites were derived using non-compartmental analysis."	( A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment. Crockett, J; Morrison, G; Taylor, L; Tayo, B, 2019)	0.51
" Serum and brain levels of antiepileptic drugs and cannabidiol were determined by using HPLC in order to ascertain any pharmacokinetic contribution to the observed behavioral effects."	( Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies. Nieoczym, D; Socała, K; Szafarz, M; Wlaź, P; Wyska, E, 2019)	0.51
" However, the intrinsic anticonvulsant activity of CBD has been questioned due to a pharmacokinetic interaction between CBD and a first-line medication, clobazam."	( Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Abelev, SV; Absalom, NL; Anderson, LL; Arnold, JC; Chebib, M; Doohan, PT; Low, IK; Martin, LJ; McGregor, IS, 2019)	0.51
"Our study highlights the involvement of both pharmacodynamic and pharmacokinetic interactions between CBD and clobazam that may contribute to its efficacy in Dravet syndrome."	( Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Abelev, SV; Absalom, NL; Anderson, LL; Arnold, JC; Chebib, M; Doohan, PT; Low, IK; Martin, LJ; McGregor, IS, 2019)	0.51
" However, few controlled clinical laboratory studies have evaluated the pharmacodynamic effects of oral or vaporized CBD or CBD-dominant cannabis."	( Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users. Bigelow, GE; Cone, EJ; Flegel, RR; Goffi, E; Mitchell, JM; Spindle, TR; Vandrey, R; Weerts, EM; Winecker, RE, 2020)	0.56
" Both the safety and the pharmacokinetic populations of the stiripentol arm comprised 14 patients (2 placebo; 12 cannabidiol)."	( A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy. Arenas Cabrera, CM; Ben-Menachem, E; Critchley, D; Crockett, J; Gunning, B; Morrison, G; Tayo, B; Toledo, M; VanLandingham, K; Wray, L, 2020)	0.56
" Plasma samples had been collected and analyzed for CBZ and CBZE, then their noncompartmental pharmacokinetic parameters before and after CBD administration were determined."	( The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats. Darweesh, RS; El-Elimat, T; Khamis, TN, 2020)	0.56
" The plasma half-life of THC is 1 to 3 days in occasional users and 5 to 13 days in chronic users."	( Mechanisms of Action and Pharmacokinetics of Cannabis. Chayasirisobhon, S, 2020)	0.56
"Due to a lack of published pharmacokinetic (PK) and/or pharmacodynamic (PD) data, decision-making surrounding appropriate dosing of cannabis used for medical purposes is limited."	( Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants. Bonn-Miller, MO; Land, MH; MacNair, L; Mosesova, I; Peters, EN; Turcotte, C; Vandrey, R; Ware, MA, 2022)	0.72
" The terminal half-life for CBD was 10."	( Pharmacokinetics and effects on arachidonic acid metabolism of low doses of cannabidiol following oral administration to horses. Kass, PH; Knych, HK; McKemie, DS; Puschner, B; Ryan, D, 2021)	0.62
"Due to a lack of published pharmacokinetic (PK) and/or pharmacodynamic (PD) data, informed physician and patient decision-making surrounding appropriate dosing of cannabis for medical purposes is limited."	( Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants. Bonn-Miller, MO; Land, MH; MacNair, L; Mosesova, I; Peters, EN; Turcotte, C; Vandrey, R; Ware, MA, 2022)	0.72
" Blood samples were collected at various time points to estimate 24-hour pharmacokinetic profiles of CBD and selected metabolites (7-carboxy-CBD and 7-hydroxy-CBD)."	( Randomized, placebo-controlled, 28-day safety and pharmacokinetics evaluation of repeated oral cannabidiol administration in healthy dogs. Kulpa, JE; Paulionis, LJ; Vaughn, DM, 2021)	0.62
"This pharmacokinetic (PK) drug-interaction trial investigated the effects of repeated dosing of a plant-derived pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex in the United States and Epidyolex in Europe; 100 mg/mL oral solution) on caffeine clearance via modulation of cytochrome P450 (CYP) 1A2 activity in healthy adults."	( A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. Critchley, D; Tayo, B; Thai, C, 2021)	0.62
"3 h, n = 18), and oral dose formulation significantly impacted mean Cmax (Epidiolex = 1,274 ng/mL, capsule = 776 ng/mL, syrup = 151 ng/mL, n = 6/group) with little difference in Tmax."	( Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. Bigelow, GE; Cone, EJ; Flegel, RR; Goffi, E; Kuntz, D; Mitchell, JM; Sholler, DJ; Spindle, TR; Vandrey, R; Winecker, RE, 2022)	0.72
"Further pharmacokinetic examination of the interaction between CBD and citalopram/escitalopram is clearly warranted, and clinicians should be vigilant around the possibility of treatment-emergent adverse effects when CBD is introduced to patients taking these antidepressants."	( Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. Amminger, GP; Anderson, LL; Arnold, JC; Berger, M; Doohan, PT; Kevin, RC; McGregor, IS; Oldfield, L, )	0.13
" The most important pharmacokinetic parameters of the chosen 29 AEDs, mechanism of action and clinical application, as well as their biotransformation, are presented."	( Pharmacokinetic Drug-Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients. Główka, AK; Główka, FK; Karaźniewicz-Łada, M; Mikulska, AA, 2021)	0.62
" CBD concentrations were determined using a validated liquid chromatography-mass spectrometry method, and pharmacokinetic parameters were calculated using noncompartmental analysis."	( Plasma and joint tissue pharmacokinetics of two doses of oral cannabidiol oil in guinea pigs (Cavia porcellus). Gustafson, DL; Helbling, JE; McGrath, S; Sadar, MJ; Santangelo, KS; Spittler, AP, 2021)	0.62
" Resulting pharmacokinetic parameters of CBD were compared to those obtained following administration of CBD in two oil-based formulations: a medium-chain triglyceride oil vehicle (MCT-CBD), and a sesame oil-based formulation similar in composition to an FDA-approved formulation of CBD, Epidiolex® (SO-CBD)."	( Development and pharmacokinetic evaluation of a self-nanoemulsifying drug delivery system for the oral delivery of cannabidiol. Ahmed, L; Allen, C; Bannigan, P; Dubins, D; Dunne, M; Evans, JC; Kok, LY; Regenold, M; Sanaee, F, 2022)	0.72
" The aim of this study was to investigate similar dosing of CBG and CBGA from hemp plants that have been used for cannabidiol pharmacokinetic studies."	( Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation. Amstutz, K; Ellis, K; Gomez, B; Lyubimov, A; Schwark, WS; Venator, KP; Wakshlag, JJ; Zakharov, A, 2022)	0.72
"Cannabidiol (CBD) products are widely marketed to horse owners, trainers, and veterinarians and are readily available to the consumer despite minimal pharmacokinetic or safety data being available."	( Pharmacokinetics, Safety, and Synovial Fluid Concentrations of Single- and Multiple-Dose Oral Administration of 1 and 3 mg/kg Cannabidiol in Horses. Contino, EK; Gustafson, DL; O'Fallon, ES; Yocom, AF, 2022)	0.72
" This within-subject, double-blind, double-dummy, placebo-controlled laboratory study analyzed the pharmacokinetic profile of CBD, ∆9-tetrahydrocannabinol (∆9-THC) and related metabolites in blood and oral fluid (OF) after participants (n = 18) administered 100 mg of CBD in each of the following formulations: (1) oral CBD, (2) vaporized CBD and (3) vaporized CBD-dominant cannabis containing 10."	( Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products. Bergeria, CL; Bigelow, GE; Cone, EJ; Flegel, R; Goffi, E; Mitchell, JM; Sholler, D; Spindle, TR; Vandrey, R; Winecker, RE, 2022)	0.72
" The rise in tissue CBD was closely related to specific pharmacokinetic parameters, and adipose tissue levels were ~10 to ~100 fold greater than liver or muscle."	( Cannabidiol (CBD) Dosing: Plasma Pharmacokinetics and Effects on Accumulation in Skeletal Muscle, Liver and Adipose Tissue. Child, RB; Tallon, MJ, 2022)	0.72
" Since pharmacokinetic profiles are important in understanding the pharmacological and toxicological effects at the target sites, physiologically based pharmacokinetic (PBPK) modeling was used to predict the plasma and tissue concentrations of 17 cannabinoids in humans."	( Physiologically based pharmacokinetic modeling and simulation of cannabinoids in human plasma and tissues. Liu, Y; Sprando, RL, 2023)	0.91
" The Cmax and AUC increased in a dose-proportional fashion across all dosing groups."	( Pharmacokinetics of escalating single-dose administration of cannabidiol to cats. Bartner, LR; Castro, SC; Gustafson, DL; Kusick, BR; McGrath, S; Rozental, AJ, 2023)	0.91
" To consider an adult physiologically-based pharmacokinetic (PBPK) model for pediatric scaling, we assessed in vitro-derived cytochrome P450 (CYP) and uridine 5'-diphospho-glucuronosyltransferase (UGT) enzyme contributions to CBD clearance in human."	( Verifying in vitro-determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically-based pharmacokinetic modeling. Beers, JL; Edginton, AN; Jackson, KD; Yeung, CHT, 2023)	0.91
" Relative to CYP cocktail + Δ9-THC, CYP cocktail + Δ9-THC + CBD produced a higher Cmax and area under the plasma concentration vs time curve for Δ9-THC, 11-OH-Δ9-THC, and Δ9-THC-COOH."	( Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial. Bansal, S; Paine, MF; Spindle, TR; Surujunarain, R; Unadkat, JD; Vandrey, R; Weerts, EM; Zamarripa, CA, 2023)	0.91
" Cannabidiol, Δ9-tetrahydrocannabinol, cannabinol, cannabichromene, cannabigerol, cannabidiolic acid, cannabigerolic acid, Δ9-tetrahydrocannabinolic acid, and 5 specific metabolites were measured by liquid chromatography-tandem/mass-spectrometry, and pharmacokinetic parameters were calculated."	( Twice-daily oral administration of a cannabidiol and cannabidiolic acid-rich hemp extract was well tolerated in orange-winged Amazon parrots (Amazona amazonica) and has a favorable pharmacokinetic profile. Beaufrère, H; Gomez, B; Guzman, DS; Knych, H; Lyubimov, A; Sosa-Higareda, M; Zakharov, A, 2023)	0.91
" For the multiple-dose study, cannabidiol/cannabidiolic acid mean Cmax was 337."	( Twice-daily oral administration of a cannabidiol and cannabidiolic acid-rich hemp extract was well tolerated in orange-winged Amazon parrots (Amazona amazonica) and has a favorable pharmacokinetic profile. Beaufrère, H; Gomez, B; Guzman, DS; Knych, H; Lyubimov, A; Sosa-Higareda, M; Zakharov, A, 2023)	0.91
"The goal of pharmacokinetic (PK) studies is to provide a basis for appropriate dosing regimens with novel therapeutic agents."	( A One Health perspective on comparative cannabidiol and cannabidiolic acid pharmacokinetics and biotransformation in humans and domestic animals. Schwark, WS; Wakshlag, JJ, 2023)	0.91
" Such interactions can be predicted in healthy and hepatically-impaired (HI) adults and in children through physiologically based pharmacokinetic (PBPK) modeling and simulation."	( A Physiologically-Based Pharmacokinetic Model for Cannabidiol in Healthy Adults, Hepatically-Impaired Adults, and Children. Bansal, S; Ladumor, MK; Paine, MF; Unadkat, JD, 2023)	0.91
"When highly purified cannabidiol (CBD; Epidiolex) and the mammalian target of rapamycin inhibitor everolimus are used concomitantly in the treatment of tuberous sclerosis complex, there is evidence of a pharmacokinetic (PK) interaction, leading to increased everolimus systemic exposure."	( Pharmacokinetic Drug-Drug Interaction With Coadministration of Cannabidiol and Everolimus in a Phase 1 Healthy Volunteer Trial. Berwaerts, J; Chen, C; Critchley, D; Hyland, K; Tayo, B; Thai, C; Wray, L, 2023)	0.91
" A systematic pharmacokinetic study was performed to determine whether there are differences in the pharmacokinetic parameters and systemic exposure of CBD after oral dosing as an isolate, broad-spectrum, or full-spectrum product."	( Comparative Pharmacokinetics of Commercially Available Cannabidiol Isolate, Broad-Spectrum, and Full-Spectrum Products. Berthold, EC; Chiang, YH; Kamble, SH; Kanumuri, SRR; Kuntz, MA; McCurdy, CR; McMahon, LR; Senetra, AS; Sharma, A, 2023)	0.91

Excerpt	Reference	Relevance
" There was no demonstrable effect of CBD, either alone or in combination with ethanol."	( The effect of cannabidiol, alone and in combination with ethanol, on human performance. Belgrave, BE; Bird, KD; Chesher, GB; Jackson, DM; Lubbe, KE; Starmer, GA; Teo, RK, 1979)	0.26
"A headspace solid-phase microextraction combined with GC-MS method was developed for the extraction and analysis of cannabinoids from Cannabis samples."	( Extraction and analysis of different Cannabis samples by headspace solid-phase microextraction combined with gas chromatography-mass spectrometry. Christen, P; Ilias, Y; Mathieu, P; Rudaz, S; Veuthey, JL, 2005)	0.33
" Because CLB and CBD are both metabolized in the cytochrome P450 (CYP) pathway, we predicted a drug-drug interaction, which we evaluate in this article."	( Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Bruno, PL; Geffrey, AL; Pollack, SF; Thiele, EA, 2015)	0.42
"To determine, via narrative, non-systematic review of pre-clinical and clinical studies, whether the effect of cannabis on hepatic biotransformation pathways would be predicted to result in clinically significant drug-drug interactions (DDIs) with commonly prescribed psychotropic agents."	( Drug-drug interactions as a result of co-administering Δ Alageel, A; Almatham, F; Carmona, NE; Ho, RC; Lee, YL; Mansur, R; McIntyre, RS; Pan, Z; Ragguett, RM; Rong, C; Rosenblat, JD; Shekotikhina, M; Subramaniapillai, M, 2018)	0.48
"Nabiximols in combination with MET/CBT was well tolerated and allowed for reduction of cannabis use."	( Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. Barnes, AJ; Fischer, B; George, TP; Huestis, MA; Le Foll, B; Quilty, LC; Rehm, J; Selby, P; Soliman, A; Staios, G; Streiner, DL; Trigo, JM, 2018)	0.48
"Following administration of a daily dosage of 10 mg delta-9-tetrahydrocannabinol combined with 20 mg cannabidiol (CBD), the patient showed a rapid and highly significant improvement in the Yale Global Tic Severity Scale."	( Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report. Kawohl, W; Pichler, EM; Roser, P; Seifritz, E, 2019)	0.51
" This open-label, fixed-sequence, drug-drug interaction, healthy volunteer trial investigated the impact of cannabidiol on steady-state pharmacokinetics of clobazam (and N-desmethylclobazam), stiripentol, and valproate; the reciprocal effect of clobazam, stiripentol, and valproate on cannabidiol and its major metabolites (7-hydroxy-cannabidiol [7-OH-CBD] and 7-carboxy-cannabidiol [7-COOH-CBD]); and cannabidiol safety and tolerability when coadministered with each antiepileptic drug."	( A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects. Blakey, G; Crockett, J; Morrison, G; Sommerville, K, 2019)	0.51
" We report for the first time a significant drug-drug interaction between the purified CBD product and tacrolimus."	( Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. Alloway, RR; Emoto, C; Fukuda, T; Leino, AD; Privitera, M; Vinks, AA, 2019)	0.51
"Topoisomerase II (Topo2) inhibitors in combination with cisplatin represent a common treatment modality used for glioma patients."	( Comparison of the effect of three different topoisomerase II inhibitors combined with cisplatin in human glioblastoma cells sensitized with double strand break repair inhibitors. Galita, G; Kopa, P; Macieja, A; Majsterek, I; Pastwa, E; Poplawski, T, 2019)	0.51
" In the secondary analyses, participants were divided into groups depending on whether they were taking at least 1/4 of the other AEDs shown to interact with CBD (iAED)."	( Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program. Ampah, SB; Bebin, EM; Cutter, GR; Gaston, TE; Grayson, LP; Liu, Y; Szaflarski, JP, 2019)	0.51
" This can be administered in combination with CBD, to prevent CRC secondary spread and enhance the synergistic efficacy of CRC treatment outcomes, with less side effects."	( Possible Enhancement of Photodynamic Therapy (PDT) Colorectal Cancer Treatment when Combined with Cannabidiol. Abrahamse, H; Kruger, CA; Nkune, NW, 2021)	0.62
" This case report illustrates the potential for cannabidiol to interact with stable medication regimens."	( Clinically Significant Drug-Drug Interaction Between Methadone and Cannabidiol. Bruera, E; Madden, K; Tanco, K, 2020)	0.56
"In this work, we evaluated, for the first time, the antitumor effect of cannabidiol (CBD) as monotherapy and in combination with conventional chemotherapeutics in ovarian cancer and developed PLGA-microparticles as CBD carriers to optimize its anticancer activity."	( Enhancing ovarian cancer conventional chemotherapy through the combination with cannabidiol loaded microparticles. Cohen, M; Delie, F; Fernández-Carballido, A; Figini, M; Fraguas-Sánchez, AI; Martin-Sabroso, C; Mezzanzanica, D; Satta, A; Torres-Suárez, AI, 2020)	0.56
" It is important to consider the possibility of drug-drug interactions (DDIs)."	( Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. Critchley, D; Gidal, B; Morrison, G; Patsalos, PN; Szaflarski, JP; VanLandingham, K, 2020)	0.56
" In this study, widely employed inflammatory and noninflammatory animal pain models, such as the hot plate test, visceral pain model (writhing test), and carrageenan-induced rat paw edema model, were utilized to evaluate the antinociceptive and anti-inflammatory activity of CBD alone and in combination with standardized bioflavonoid compositions."	( Antinociceptive and Anti-Inflammatory Properties of Cannabidiol Alone and in Combination with Standardized Bioflavonoid Composition. Brownell, L; Hong, M; Horm, T; Jia, Q; Jiao, P; O'Neal, A; Rossiter, S; Yimam, M, 2021)	0.62
"The microencapsulation method combined with a permeation enhancer, DCA increased the short-term bioavailability of CBD in plasma and brain."	( Sodium alginate microencapsulation improves the short-term oral bioavailability of cannabidiol when administered with deoxycholic acid. Al-Salami, H; Al-Sallami, H; Brook, E; Eden, E; Galettis, P; Lam, V; Majimbi, M; Mamo, JCL; Mooranian, A; Takechi, R, 2021)	0.62
"The legalization of cannabis in many parts of the United States and other countries has led to a need for a more comprehensive understanding of cannabis constituents and their potential for drug-drug interactions."	( Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions. Lazarus, P; Nasrin, S; Perez-Paramo, YX; Watson, CJW, 2021)	0.62
" The purpose of this review is to present data from the last few years on drug-drug interactions among of AEDs, as well as AEDs with other drugs, nutrients and food."	( Pharmacokinetic Drug-Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients. Główka, AK; Główka, FK; Karaźniewicz-Łada, M; Mikulska, AA, 2021)	0.62
"To assess drug-drug interactions between cannabidiol (CBD) and phenobarbital (PB) when simultaneously administered to healthy dogs."	( Drug-drug interaction between cannabidiol and phenobarbital in healthy dogs. Bartner, LR; Cribb, AE; Doran, CE; Gustafson, DL; McGrath, S; Thomas, B, 2021)	0.62
"This is a patient case exploring the importance of evaluating herbal and dietary supplements and how they may impact drug-drug and drug-gene implications based on pharmacogenomics test results."	( Implications of Cannabidiol in Pharmacogenomic-Based Drug Interactions with CYP2C19 Substrates. Crosby, S; Engeleit, A; Schuh, MJ, 2021)	0.62
"To describe the presence, type, and management of drug-drug interactions (DDIs) at prescription cannabidiol (CBD) therapy initiation."	( Prescription cannabidiol for seizure disorder management: Initial drug-drug interaction management by specialty pharmacists. Choi, L; DeClercq, J; Dial, H; Johnson, K; Owens, W; Shah, NB; Zuckerman, AD, 2022)	0.72
" In light of the increasing appearance of phytocannabinoids in beauty products without rigorous research on their rejuvenation efficacy, we decided to investigate the potential role of phytocannabinoids in combination with nutrient signaling regulators in skin rejuvenation."	( The Effects of Nutrient Signaling Regulators in Combination with Phytocannabinoids on the Senescence-Associated Phenotype in Human Dermal Fibroblasts. Gerasymchuk, M; Kovalchuk, I; Kovalchuk, O; Robinson, GI, 2022)	0.72
" A single dose of everolimus 5 mg was well tolerated when administered with multiple doses of CBD."	( Pharmacokinetic Drug-Drug Interaction With Coadministration of Cannabidiol and Everolimus in a Phase 1 Healthy Volunteer Trial. Berwaerts, J; Chen, C; Critchley, D; Hyland, K; Tayo, B; Thai, C; Wray, L, 2023)	0.91
"The aim of this study was to assess potential drug-drug interactions between highly purified cannabidiol (CBD) and anti-seizure medications (ASMs)."	( Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program. Bebin, EM; Cutter, GR; Gaston, TE; Grayson, L; Szaflarski, JP, 2023)	0.91

Excerpt	Reference	Relevance
" In the other three, the oral bioavailability ranged from 13 to 19%."	( Pharmacokinetics of cannabidiol in dogs. Bialer, M; Mechoulam, R; Samara, E, )	0.13
" In the other four, the oral bioavailability was 3, 21, 39, and 43%, respectively."	( Pharmacokinetics of the dimethylheptyl homolog of cannabidiol in dogs. Bialer, M; Samara, E, )	0.13
" In four subjects who received intravenous and oral hexobarbital, systemic clearance was 36% lower while bioavailability was 10% greater during CBD."	( Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Bachman, J; Benowitz, NL; Herning, RI; Jones, RT; Nguyen, TL, 1980)	0.26
" The absolute bioavailability (F) of THC decreased in the following order: sublingual THC/RM-beta-CD solution (F = 12."	( Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits. Jarho, P; Järvinen, K; Järvinen, T; Mannila, J; Tarvainen, M, 2005)	0.33
" It is suggested that the inhibition of hepatic metabolism determined an increased bioavailability of cannabidiol resulting in a greater effect."	( Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved. Bettoni, I; Colleoni, M; Comelli, F; Costa, B; Giagnoni, G, 2008)	0.35
"CBD was absorbed intranasally within 10 minutes with a bioavailability of 34-46%, except with 100% polyethylene glycol formulation in rats."	( Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Agu, RU; Hammell, DC; Paudel, KS; Stinchcomb, AL; Valiveti, S, 2010)	0.36
" Relative bioavailability was calculated to determine the relative rate and extent of THC absorption; 5 and 15 mg oral THC bioavailability was 92."	( Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Darwin, WD; Goodwin, RS; Huestis, MA; Karschner, EL; Wright, S, 2011)	0.37
"To assess the effect of food on the single-dose bioavailability of delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) spray, an endocannabinoid system modulator, when administered to healthy male subjects."	( A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. Guy, GW; Stott, CG; White, L; Wilbraham, D; Wright, S, 2013)	0.39
" The bioavailability of THC was greater than CBD at single and multiple doses, and there was no evidence of accumulation for any analyte with multiple dosing."	( A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Guy, GW; Stott, CG; White, L; Wilbraham, D; Wright, S, 2013)	0.39
" A high-quality, rigorous, phase I/II study to elicit pharmacokinetic dose-concentration and concentration-response data, with a clinically acceptable mode of delivery to reduce intrapatient variability and enable more consistent bioavailability is needed in this population."	( Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome. Martin, JH; Reuter, SE, 2016)	0.43
"" Lack of standardization, bioavailability issues, and ultimately prohibition were all factors in cannabis-based medicines failing to maintain mainstream usage in seizure treatment, but investigation was resumed in the 1970s with interesting signals noted in both laboratory and clinical settings."	( Cannabis and epilepsy: An ancient treatment returns to the fore. Russo, EB, 2017)	0.46
" Study objectives were to evaluate the safety and tolerability of PTL101 containing 10 and 100 mg CBD, following single administrations to healthy volunteers and to compare the pharmacokinetic profiles and relative bioavailability of CBD with Sativex oromucosal spray (the reference product) in a randomized, crossover study design."	( Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology. Atsmon, J; Deutsch, F; Deutsch, L; Heffetz, D; Sacks, H, 2018)	0.48
" Their pharmacokinetics are complex, and bioavailability is variable, resulting in difficulty in developing a suitable formulation for oral delivery."	( Cannabinoids for epilepsy: What do we know and where do we go? Ben-Menachem, E; Brodie, MJ, 2018)	0.48
" The oral bioavailability of THC and CBD is very low due to extensive "first-pass" metabolism."	( PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers. Atsmon, J; Cherniakov, I; Deutsch, F; Deutsch, L; Domb, AJ; Heffetz, D; Hoffman, A; Izgelov, D; Sacks, H, 2018)	0.48
" A larger AUC was found in the fasted group; the relative oral bioavailability in fed animals was 48."	( Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study. Chericoni, S; Giorgi, M; Lisowski, A; Owen, H; Poapolathep, A; Stefanelli, F; Łebkowska-Wieruszewska, B, 2019)	0.51
" CBD has complex and variable pharmacokinetics, with a prominent first-pass effect and a low oral bioavailability that increases fourfold when CBD is taken with a high-fat/high-calorie meal."	( Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. Franco, V; Perucca, E, 2019)	0.51
" However, current formulations suffer from low bioavailability and side effects."	( The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study. Chernuha, V; Deutsch, L; Fattal-Valevski, A; Hausman Kedem, M; Heffetz, D; Kramer, U; Mitelpunkt, A; Orbach, R; Sacks, H; Zilbershot Fink, E, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" A dose-exposure proportionality assessment was performed, and a population-based meta-analysis of CBD pharmacokinetics and systemic bioavailability was conducted with a nonlinear mixed-effects modeling."	( Model-Based Analysis of Cannabidiol Dose-Exposure Relationship and Bioavailability. Lim, SY; Sharan, S; Woo, S, 2020)	0.56
"Oral solution CBD exposures increased less than proportionally with doses of 750 mg or greater, and bioavailability (6."	( Model-Based Analysis of Cannabidiol Dose-Exposure Relationship and Bioavailability. Lim, SY; Sharan, S; Woo, S, 2020)	0.56
"5-fold increase in oral bioavailability of CBD compared to control group without piperine."	( The effect of piperine on oral absorption of cannabidiol following acute vs. chronic administration. Domb, AJ; Hoffman, A; Izgelov, D, 2020)	0.56
" Thus, a higher and less variable bioavailability can be obtained."	( Prolonged oral transmucosal delivery of highly lipophilic drug cannabidiol. Barasch, D; Domb, AJ; Hoffman, A; Itin, C, 2020)	0.56
" Here, we evaluated CBD for its ability to modulate the production of proinflammatory cytokines in vitro and in murine models of induced inflammation and further validated the ability of a liposomal formulation to increase bioavailability in mice and in humans."	( A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Blair, E; Decker, WK; Dunner, K; Halpert, MM; Hofferek, CJ; Konduri, V; Salimpour, P; Vazquez-Perez, J; Verrico, CD; Wesson, S, 2020)	0.56
" However, these vehicles not only affect drug bioavailability but may also have an impact on gastric emptying, drug disposition, lymphatic absorption and be affected by lipid digestion mechanisms."	( Using the Absorption Cocktail Approach to Assess Differential Absorption Kinetics of Cannabidiol Administered in Lipid-Based Vehicles in Rats. Domb, AJ; Hoffman, A; Izgelov, D; Regev, A, 2020)	0.56
" In-vivo investigation of CBD containing formulation in the freely moving rat model proved a prolonged absorption phase with a substantial increase in bioavailability compared to CBD solution."	( Investigation of cannabidiol gastro retentive tablets based on regional absorption of cannabinoids in rats. Freidman, M; Hoffman, A; Izgelov, D, 2020)	0.56
" Although detailed studies have not been published, the available data suggest that the absolute bioavailability of CBD after oral dosing under fasting conditions is approximately 6%, and increases fourfold when the medication is co-administered with a high-fat meal."	( Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. Bialer, M; Perucca, E, 2020)	0.56
" Increasing intestinal lymphatic transport provides an effective strategy to improve oral bioavailability when hepatic first-pass metabolism is a major rate-limiting step hampering access to the systemic circulation after oral dosing."	( The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. Bialer, M; Franco, V; Gershkovich, P; Perucca, E, 2020)	0.56
" Cannabidiol is rapidly absorbed and its bioavailability increases when administered with high fat meals."	( Clinical pharmacology of cannabidiol in refractory epilepsy. Cáceres-Guido, P; Maldonado, C; Riva, N; Schaiquevich, P; Vázquez, M, 2020)	0.56
" The relative bioavailability of CBD after administration as a sublingual wafer was comparable with that of oil solution with 90% confidence interval of 83-131%."	( A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. Hosseini, A; Lickliter, JD; McLachlan, AJ, 2021)	0.62
" However, the oral bioavailability of CBD is low owing to its high lipophilicity and extensive first-pass metabolism."	( Mucoadhesive nanostructured lipid carriers as a cannabidiol nasal delivery system for the treatment of neuropathic pain. Bonfílio, R; Carvalho, FC; Elisei, LMS; Galdino, G; Matarazzo, AP; Pereira, GR; Ruela, ALM, 2021)	0.62
" The bioavailability and pharmacokinetics of CBD are not well understood, and proper dosing schemes have not been adequately developed for its clinical use."	( Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: A systematic review of clinical studies. Capparelli, EV; Rosania, GR; Silmore, LH; Willmer, AR, 2021)	0.62
" The bioavailability of inhaled THC is 10% to 35%."	( Mechanisms of Action and Pharmacokinetics of Cannabis. Chayasirisobhon, S, 2020)	0.56
" Previous studies have shown that natural sesame oil promotes the intestinal lymphatic transport and oral bioavailability of the highly lipophilic drug cannabidiol (CBD)."	( Natural sesame oil is superior to pre-digested lipid formulations and purified triglycerides in promoting the intestinal lymphatic transport and systemic bioavailability of cannabidiol. Barrett, DA; Berton, M; Bettonte, S; Chu, Y; Constantinescu, CS; Feng, W; Fischer, PM; Gershkovich, P; Lee, JB; Qin, C; Stocks, MJ; Zgair, A, 2021)	0.62
" These include low oral bioavailability due to hepatic degradation, gastric instability, poor water solubility, and the side effects experienced upon the use of high doses of psychotropic cannabinoids associated with heightened plasma concentrations of the drug."	( Delivering therapeutic cannabinoids via skin: Current state and future perspectives. Chukwunyere, UI; Frempong, D; Mishra, D; Puri, A; Thakur, D; Tijani, AO, 2021)	0.62
" However, the potential therapeutic use of cannabis and cannabinoids for the treatment of respiratory diseases has not been widely investigated, in part because of local irritation of airways by needing to smoke the cannabis, poor bioavailability when administered orally due to the lipophilic nature of cannabinoids, and the psychoactive effects of Δ9-Tetrahydrocannabinol (Δ9-THC) found in cannabis."	( The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination. Clarkson, N; Horniman, N; Keir-Rudman, S; Page, C; Robaina Cabrera, CL, 2021)	0.62
" However, CBD is lipophilic and highly photooxidative with low oral bioavailability in plasma and brain."	( Sodium alginate microencapsulation improves the short-term oral bioavailability of cannabidiol when administered with deoxycholic acid. Al-Salami, H; Al-Sallami, H; Brook, E; Eden, E; Galettis, P; Lam, V; Majimbi, M; Mamo, JCL; Mooranian, A; Takechi, R, 2021)	0.62
"The microencapsulation method combined with a permeation enhancer, DCA increased the short-term bioavailability of CBD in plasma and brain."	( Sodium alginate microencapsulation improves the short-term oral bioavailability of cannabidiol when administered with deoxycholic acid. Al-Salami, H; Al-Sallami, H; Brook, E; Eden, E; Galettis, P; Lam, V; Majimbi, M; Mamo, JCL; Mooranian, A; Takechi, R, 2021)	0.62
" Animal and human studies have shown its poor oral bioavailability in vivo, and the impact of consuming lipid-soluble CBD with and without food on gut bioaccessibility has not been explored."	( The Effects of Food on Cannabidiol Bioaccessibility. Guzman, I; Holguin, FO; Kovar, SE; Lucker, BF; Mozaffari, K; Willette, S, 2021)	0.62
" These data indicate that DPI CBD provided more rapid onset and increased bioavailability than oral CBD and support further investigations on the use of DPI CBD for acute indications."	( Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study. Devinsky, O; Fein, M; Kraft, K; Leone-Bay, A; Rusch, L, 2021)	0.62
" These absorption obstacles are responsible for low and variable oral bioavailability of CBD."	( Enhanced Intramuscular Bioavailability of Cannabidiol Using Nanocrystals: Formulation, In Vitro Appraisal, and Pharmacokinetics. Chen, K; Fan, H; Fu, X; Kou, L; Li, Z; Wang, Y; Xie, Z; Xu, S; Zhang, S, 2022)	0.72
" CBD had dose-dependent, but variable, oral bioavailability at 1 mg/kg and 3 mg/kg daily dosing and was consistently detectable at steady state in synovial fluid at the higher dose."	( Pharmacokinetics, Safety, and Synovial Fluid Concentrations of Single- and Multiple-Dose Oral Administration of 1 and 3 mg/kg Cannabidiol in Horses. Contino, EK; Gustafson, DL; O'Fallon, ES; Yocom, AF, 2022)	0.72
" However, its low solubility and bioavailability impede its applications in functional foods."	( Nutraceutical potential of industrial hemp ( Chen, B; Rao, J; Zheng, H, 2022)	0.72
"Nanoparticle encapsulation is an attractive approach to improve the oral bioavailability of hydrophobic therapeutics."	( Development of an Caggiano, NJ; Priestley, RD; Prud'homme, RK; Wilson, BK, 2022)	0.72
"Although natural sesame oil has been shown to facilitate the lymphatic delivery and oral bioavailability of the highly lipophilic drug cannabidiol (CBD), considerable variability remains an unresolved challenge."	( Vegetable oils composition affects the intestinal lymphatic transport and systemic bioavailability of co-administered lipophilic drug cannabidiol. Abdelrazig, S; Bai, Z; Barrett, DA; Chu, Y; Constantinescu, CS; Darwish, R; Feng, W; Fischer, PM; Gershkovich, P; Gray, DA; Ji, L; Qin, C; Raji, M; Stocks, MJ, 2022)	0.72
"Pharmacokinetics and bioavailability of CBD in senior horses were determined, and there were no adverse effects of administering either the oral or IV dose of CBD evaluated."	( Pharmacokinetics of cannabidiol in a randomized crossover trial in senior horses. Adams, AA; Knych, HK; Turner, SE, 2022)	0.72
"Cannabidiol (CBD) is a prescribed drug for epilepsy but has low oral bioavailability and gastric instability."	( Development of cannabidiol nanoemulsion for direct nose to brain delivery: statistical optimization, Ahmed, B; Akhtar, MS; Amin, S; Mir, SR; Rizwanullah, M, 2022)	0.72
" Pharmacokinetic studies in dogs have demonstrated a low oral bioavailability of CBD and a high first-pass effect through the liver."	( Cannabidiol in canine epilepsy. Bhatti, SFM; McGrath, S; Potschka, H; Tipold, A, 2022)	0.72
" The water-soluble cannabis-based medicine provided acceptable bioavailability for Δ9-THC/CBD, appeared safe and tolerable in advanced incurable cancers with uncontrolled pain with preliminary evidence of analgesic efficacy."	( Pilot clinical and pharmacokinetic study of Δ9-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain. Butcher, BE; Clarke, S; Hall, S; Henson, JD; McLachlan, AJ; Rutolo, D; Vitetta, L, 2022)	0.72
"Intravenous pharmacokinetics and oral bioavailability of cannabidiol (CBD) with different formulations have not been investigated in horses and may represent a starting point for clinical studies."	( Pharmacokinetics and oral bioavailability of cannabidiol in horses after intravenous and oral administration with oil and micellar formulations. Becero, M; Díez de Castro, E; Ferreiro-Vera, C; García-Valverde, MT; Muñoz, A; Saitua, A; Sánchez de Medina, A; Sánchez de Medina, V; Serrano-Rodríguez, JM, 2023)	0.91
" Oral bioavailability was close to 14% for both oral administrations."	( Pharmacokinetics and oral bioavailability of cannabidiol in horses after intravenous and oral administration with oil and micellar formulations. Becero, M; Díez de Castro, E; Ferreiro-Vera, C; García-Valverde, MT; Muñoz, A; Saitua, A; Sánchez de Medina, A; Sánchez de Medina, V; Serrano-Rodríguez, JM, 2023)	0.91
"Oral bioavailability was low at the doses studied but fell within the range described for horse and other species."	( Pharmacokinetics and oral bioavailability of cannabidiol in horses after intravenous and oral administration with oil and micellar formulations. Becero, M; Díez de Castro, E; Ferreiro-Vera, C; García-Valverde, MT; Muñoz, A; Saitua, A; Sánchez de Medina, A; Sánchez de Medina, V; Serrano-Rodríguez, JM, 2023)	0.91
" Due to the slow absorption and low bioavailability with the current oral CBD therapy, more efficient routes of administration to bypass hepatic metabolism, particularly pulmonary delivery, should be considered."	( Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration. Arnold, JC; Chan, HK; Kwok, PCL; Tai, W; Yau, GTY, 2023)	0.91
"An emulsion delivery system may be affected significantly by oil phase composition in terms of digestion behavior and bioavailability of the delivered substance."	( Digestion behavior, in vitro and in vivo bioavailability of cannabidiol in emulsions stabilized by whey protein-maltodextrin conjugate: Impact of carrier oil. Dong, C; Freeman, K; Guo, M; Lu, Y; Wang, C, 2023)	0.91
" However, the poor solubility and low bioavailability limit its clinical application."	( Cannabidiol-Loaded Poly Lactic-Co-Glycolic Acid Nanoparticles with Improved Bioavailability as a Potential for Osteoarthritis Therapeutic. Jin, Z; Qin, Z; Wei, Q; Xu, S; Zhan, Y; Zheng, L, 2023)	0.91
" Our previous studies proved the effectiveness of cannabidiol (CBD) against PTSD, but low water solubility, low brain targeting efficiency and poor bioavailability restricted its applications."	( Cannabidiol-loaded biomimetic macrophage membrane vesicles against post-traumatic stress disorder assisted by ultrasound. Dai, J; Du, L; Gao, P; Hu, J; Jiao, W; Jin, Y; Li, Q; Song, X; Tang, Z; Wang, C; Wu, Y, 2023)	0.91
"There was an increase in the oral bioavailability of CBD (12% and 21% in male and female rats, respectively) when administered as a full-spectrum product compared with the isolate and broad-spectrum products."	( Comparative Pharmacokinetics of Commercially Available Cannabidiol Isolate, Broad-Spectrum, and Full-Spectrum Products. Berthold, EC; Chiang, YH; Kamble, SH; Kanumuri, SRR; Kuntz, MA; McCurdy, CR; McMahon, LR; Senetra, AS; Sharma, A, 2023)	0.91
"2% THC increased the oral bioavailability of CBD in male and female rats, indicating that full-spectrum products may produce increased effectiveness of CBD due to a greater exposure available systemically."	( Comparative Pharmacokinetics of Commercially Available Cannabidiol Isolate, Broad-Spectrum, and Full-Spectrum Products. Berthold, EC; Chiang, YH; Kamble, SH; Kanumuri, SRR; Kuntz, MA; McCurdy, CR; McMahon, LR; Senetra, AS; Sharma, A, 2023)	0.91
" However, its high lipophilicity, chemical instability, and extensive metabolism impair its bioavailability and clinical use."	( Cannabidiol nanoemulsion for eye treatment - Anti-inflammatory, wound healing activity and its bioavailability using in vitro human corneal substitute. Cejnar, P; Hynek, R; Kaštánek, P; Kronusová, O; Ruml, T; Šach, J; Strnad, O; Sukupová, A; Šuman, J; Tran, VN; Veverková, T; Viktorová, J, 2023)	0.91
" Degradation in the gastrointestinal (GI) tract, first-pass metabolism, and low water solubility restrain bioavailability of CBD to only 6% in current oral administration."	( Archaeosomes facilitate storage and oral delivery of cannabidiol. Horn, C; Quehenberger, J; Sedlmayr, V; Spadiut, O; Wurm, DJ, 2023)	0.91
" This limitation necessitates the exploration of various approaches to enhance the bioavailability of CBD, thus helping to maximize its therapeutic potential."	( Current Challenges and Opportunities for Improved Cannabidiol Solubility. Alghalayini, A; Hossain, KR; Valenzuela, SM, 2023)	0.91
" However, due to their low water solubility and prominent first-pass metabolism, their oral bioavailability is moderate, which is unfavorable for medicinal use."	( Mannich-type modifications of (-)-cannabidiol and (-)-cannabigerol leading to new, bioactive derivatives. Ádám, D; Bácskay, I; Bereczki, I; Borbás, A; Herczeg, M; Herczegh, P; Hodek, J; Lőrincz, EB; Minorics, R; Nagy, L; Oláh, A; Ostorházi, E; Spolárics, J; Tóth, G; Weber, J; Zouboulis, CC; Zupkó, I, 2023)	0.91

Excerpt	Relevance	Reference
" Food and water consumption were dramatically reduced by each test drug at feeding periods immediately following and in some instances up to 4 days after dosing in all 3 groups."	( Comparative effects of various naturally occurring cannabinoids on food, sucrose and water consumption by rats. Knobloch, LC; Sofia, RD, 1976)	0.26
"The acute dose-response effects of delta-9-tetrahydrocannabinol (THC), cannabinol (CBN) and cannabidiol (CBD) on gonadotropin and testosterone (T) secretion and on hypothalamic norepinephrine (NE) metabolism were tested in adult male rats."	( Effects of psychoactive and nonpsychoactive cannabinoids on the hypothalamic-pituitary axis of the adult male rat. Bartke, A; Murphy, LL; Smith, MS; Steger, RW, 1990)	0.28
" Cannabinol (CBN) showed the same activity but required a dosage of approximately eight times that of THC to produce an equivalent effect."	( The quasi-morphine withdrawal syndrome: effect of cannabinol, cannabidiol and tetrahydrocannabinol. Chesher, GB; Jackson, DM, 1985)	0.27
"A Langendorff perfused rat heart preparation was designed to process dose-response effects of cardioactive drugs on rate, coronary flow, and supraaortic differential pressure (delta P; an index of cardiac performance)."	( Effects and interactions of natural cannabinoids on the isolated heart. Nahas, G; Trouve, R, 1985)	0.27
"5 days after dosing with THC."	( Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. Bachman, J; Herning, RI; Hunt, CA; Jones, RT, 1981)	0.26
" In contrast, cannabidiol, over a wide dosage range, caused only depression."	( Excitatory and depressant effects of delta 9-tetrahydrocannabinol and cannabidiol on cortical evoked responses in the conscious rat. Karler, R; Turkanis, SA, 1981)	0.26
" In animals initially anesthetized with pentobarbital, delta-9-THC over a wide dosage range produced only an enhancement of the reflex, whereas in methohexital-treated animals only depression was elicited."	( Influence of different barbiturate anesthetics on delta-9-tetrahydrocannabinol effects on spinal monosynaptic reflexes. Karler, R; Turkanis, SA, 1983)	0.27
"In audiogenic seizure (AGS) susceptible rats, the acute (intraperitoneal and intravenous) dose-response effects of (--)-cannabidiol (CBD) for preventing AGS and for causing rototod neurotoxicity (ROT) were determined."	( Antiepileptic potential of cannabidiol analogs. Consroe, P; Martin, A; Singh, V, )	0.13
" Three patients had transient hypotension and intoxication with rapid initial dosing of THC-containing CME."	( A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Aram, J; House, H; Makela, P; Robson, P; Wade, DT, 2003)	0.32
" Sativex is a sublingual spray on Cannabis extract basis, and is equipped with an electronic tool to facilitate accurate dosing and to prevent misuses."	( [A novel analgesics made from Cannabis]. Szendrei, K, 2004)	0.32
" Regimens for the use of the sublingual spray emerged and a wide range of dosing requirements was observed."	( Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Miller, R; Newport, S; Notcutt, W; Phillips, C; Price, M; Sansom, C; Simmons, S, 2004)	0.32
" Patients self titrate their overall dose and pattern of dosing according to their response to and tolerance of the medicine."	( Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Barnes, MP, 2006)	0.33
" No tolerance to the benefit of Sativex on pain or sleep, nor need for dosage increases have been noted in safety extension studies of up to four years, wherein 40-50% of subjects attained good or very good sleep quality, a key source of disability in chronic pain syndromes that may contribute to patients' quality of life."	( Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Guy, GW; Robson, PJ; Russo, EB, 2007)	0.34
"CBD injected into the dlPAG produced anxiolytic-like effects in the EPM with a bell-shaped dose-response curve."	( Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Campos, AC; Guimarães, FS, 2008)	0.35
"Sulphasalazine, THC and CBD proved beneficial in this model of colitis with the dose-response relationship for the phytocannabinoids showing a bell-shaped pattern on the majority of parameters (optimal THC and CBD dose, 10 mg."	( The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Jamontt, JM; Molleman, A; Parsons, ME; Pertwee, RG, 2010)	0.36
"Nine cannabis smokers completed all 5 dosing sessions."	( Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Darwin, WD; Goodwin, RS; Huestis, MA; Karschner, EL; Wright, S, 2011)	0.37
" In an experimental mouse model of MS-related spasticity, Sativex dose-dependently improved hind limb flexion/stiffness and a dosage of 10 mg/kg was shown to be as effective as the most widely established anti-spasticity treatment baclofen (5 mg/kg)."	( Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction. Di Marzo, V, 2011)	0.37
" CBD also displayed significant potency (in a bell-shaped dose-response curve) at enhancing the ability of 8-OH-DPAT to stimulate [(35) S]GTPγS binding to rat brainstem membranes in vitro."	( Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Anavi-Goffer, S; Bolognini, D; Cascio, MG; Fletcher, PJ; Limebeer, CL; Mechoulam, R; Parker, LA; Pertwee, RG; Rock, EM, 2012)	0.38
" The objective of the present work was to assess the feasibility of developing cannabinoid loaded poly-ε-caprolactone (PCL) microparticles prepared by the oil-in-water emulsion-solvent evaporation technique as a suitable dosage form for their administration."	( Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: development, characterization and in vitro evaluation of their antitumoral efficacy. Aberturas, MR; Di Marzo, V; Gil-Alegre, ME; Hernán Pérez de la Ossa, D; Ligresti, A; Molpeceres, J; Torres Suárez, AI, 2012)	0.38
" Secondary outcomes were to determine evidence of developing tolerance and to assess the long-term dosing profile of Sativex."	( Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. Collin, C; Notcutt, W; Serpell, MG, 2013)	0.39
" Finally, activation of TRPV1 channels may help us to explain the antipsychotic effect and the bell-shaped dose-response curves commonly observed with CBD."	( Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Campos, AC; Del Bel, EA; Gomes, FV; Guimarães, FS; Moreira, FA, 2012)	0.38
"5 h after dosing and analyzed for THC, CBD, cannabinol (CBN), and 11-nor-9-carboxy-THC (THCCOOH)."	( Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration? Barnes, AJ; Goodwin, RS; Huestis, MA; Karschner, EL; Lee, D; Milman, G, 2013)	0.39
" THCCOOH/THC ratios increased throughout each dosing session."	( Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration? Barnes, AJ; Goodwin, RS; Huestis, MA; Karschner, EL; Lee, D; Milman, G, 2013)	0.39
" There was evidence of dose-proportionality in the single but not the multiple dosing data sets."	( A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Guy, GW; Stott, CG; White, L; Wilbraham, D; Wright, S, 2013)	0.39
"Neuropathic pain caused by chemotherapy limits dosing and duration of potentially life-saving anti-cancer treatment and impairs quality of life."	( A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Cesar-Rittenberg, P; Hohmann, AG; Lynch, ME, 2014)	0.4
" The mean dosage was 4 sprays/day."	( Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity. Feneberg, W; Koehler, J; Meier, M; Pöllmann, W, 2014)	0.4
" Oral fluid was tested prior to and immediately after dosing with either Sativex(®) or placebo at intervals up to 2h after the dose."	( The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS. Allsop, DJ; Copeland, J; Fu, S; Lewis, J; Molnar, A, 2014)	0.4
" A dose-response curve was performed to establish a sublethal dose of CBD with antioxidant activity (2."	( Cannabidiol Exposure During Neuronal Differentiation Sensitizes Cells Against Redox-Active Neurotoxins. Bristot, IJ; Castro, MA; Crippa, JA; De Bastiani, MA; de Medeiros, LM; Kapczinski, F; Klamt, F; Lopes, FM; Parsons, RB; Schönhofen, P, 2015)	0.42
" CBD promoted an inverted U-shaped dose-response curve in the anxiety task; in the memory assessment, CBD in the dose of 5mg/Kg promoted the strongest effects without interfering with social and aggressive behavior."	( Caffeine protects against memory loss induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (Danio rerio). Antonioli, R; Bonan, CD; Capiotti, KM; Crippa, JA; da Silva, RS; Hallak, JE; Nazario, LR; Zuardi, AW, 2015)	0.42
" Meaningful symptomatic improvement was achieved within the recommended dosage limit of ≤12 sprays per day."	( Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis. Dechant, KL; Meuth, SG; Vila, C, 2015)	0.42
" Open-label studies performed to date with a focus on effectiveness have indicated that about one-half to two-thirds of patients initiated on THC:CBD oromucosal spray continue to derive benefit after 3 months' treatment at a mean dosage of 5-7 sprays/day."	( Advances in the management of MS symptoms: real-life evidence. Trojano, M, 2015)	0.42
" Stretch reflex responders were taking a significantly higher number of puffs, whereas no differences were found in the responders by the other scales, suggesting that a higher dosage would add benefit if tolerated."	( The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity. Abbruzzese, G; Bandini, F; Canneva, S; Capello, E; Colombano, F; Currà, A; Fattapposta, F; Marinelli, L; Mori, L; Trompetto, C, 2016)	0.43
" No significant symptomatic effects were detected at the prescribed dosage and for a 12-week period."	( A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease. Alonso Arias, MA; Fernández Ruiz, J; Galve-Roperh, I; García Caldentey, J; García de Yébenes Prous, J; García de Yébenes, MJ; García Ribas, G; García-Bermejo, ML; Guzmán, M; López-Sendón Moreno, JL; Ortega-Gutierrez, S; Resel, E; Ruiz Romero, C; Sagredo, O; Tolón, RM; Trigo Cubillo, P; Valdeolivas, S, 2016)	0.43
" Our results show that the cannabidiol (5μM) and moringin (5μM) combination outperformed the single constituents that, at this dosage had only a moderate efficacy on inflammatory (Tumor necrosis factor-α, Interleukin-10) and oxidative markers (inducible nitric oxide synthase, nuclear factor erythroid 2-related factor 2, nitrotyrosine)."	( Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages. Bramanti, P; De Nicola, GR; Giacoppo, S; Grassi, G; Iori, R; Mazzon, E; Pollastro, F; Rajan, TS, 2016)	0.43
"Sativex was well-tolerated by all participants (average dosage 77."	( Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series. Barnes, AJ; Fischer, B; George, TP; Huestis, MA; Le Foll, B; Quilty, L; Rehm, J; Selby, P; Soliman, A; Staios, G; Trigo, JM, )	0.13
" THC:CBD mean dosage was 6 sprays/day."	( Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice. Trojano, M; Vermersch, P, 2016)	0.43
" We lack valid data on the safety, efficacy, and dosing of artisanal preparations available from dispensaries in the 25 states and District of Columbia with MMJ programs and online sources of CBD and other cannabinoids."	( Cannabinoids in treatment-resistant epilepsy: A review. Devinsky, O; Gloss, D; O'Connell, BK, 2017)	0.46
", methods of administration (smoking, vaporisation, oral), and dosing recommendations."	( Practical considerations in medical cannabis administration and dosing. MacCallum, CA; Russo, EB, 2018)	0.48
" The dosage of CBD was gradually increased to at least 8mg/kg/day."	( Cannabidiol for treatment of refractory childhood epilepsies: Experience from a single tertiary epilepsy center in Slovenia. Neubauer, D; Osredkar, D; Perković Benedik, M, 2018)	0.48
" Mechanism-based PK and PD models are promising for improved predictive dosing performance for ill and comorbid patients."	( Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling. Liu, Z; Martin, JH, 2018)	0.48
" This paper provides an overview of the available cannabinoid-based formulations, a summary of the highest quality evidence for the use of cannabinoids for treating spasticity and pain associated with multiple sclerosis (MS), and a discussion of possible dosing regimens based on information from these studies."	( Cannabinoids for Treatment of MS Symptoms: State of the Evidence. Cameron, M; Rice, J, 2018)	0.48
" This study will provide the first high quality analysis of safety of CBD-enriched Cannabis herbal extract in pediatric patients in relation to dosage and pharmacokinetics of the active cannabinoids."	( The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study. Acton, B; Alcorn, J; Carmant, L; Corley, S; Huh, L; Huntsman, RJ; Leung, E; Lim, HJ; Lyon, AW; Mousseau, DD; Prosser-Loose, E; Reithmeier, D; Seifert, B; Tang-Wai, R; Tellez-Zenteno, J, 2018)	0.48
"We aimed to assess the potential relationship between intrasubject 9-tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray plasma profiles and clinical effects elicited by subacute dosing in chronically treated patients with multiple sclerosis (MS)."	( Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship. Contin, M; Foschi, M; Lugaresi, A; Mancinelli, L; Mohamed, S; Perrone, A; Riva, R; Sabattini, L; Scandellari, C; Vacchiano, V, )	0.13
" No significant effect of cannabinoids dosing could be appreciated according to posturographic and motor tests."	( Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship. Contin, M; Foschi, M; Lugaresi, A; Mancinelli, L; Mohamed, S; Perrone, A; Riva, R; Sabattini, L; Scandellari, C; Vacchiano, V, )	0.13
" Although preliminary, they suggest that subacute dosing might elicit a subjective clinically significant effect on MS-related spasticity, paralleling cannabinoids measurable plasma concentrations."	( Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship. Contin, M; Foschi, M; Lugaresi, A; Mancinelli, L; Mohamed, S; Perrone, A; Riva, R; Sabattini, L; Scandellari, C; Vacchiano, V, )	0.13
"Following administration of a daily dosage of 10 mg delta-9-tetrahydrocannabinol combined with 20 mg cannabidiol (CBD), the patient showed a rapid and highly significant improvement in the Yale Global Tic Severity Scale."	( Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report. Kawohl, W; Pichler, EM; Roser, P; Seifritz, E, 2019)	0.51
" We initiated CBD in 72 children and 60 adults with treatment-resistant epilepsy (TRE) at 5 mg/kg/day and titrated it up to a maximum dosage of 50 mg/kg/day."	( Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Bebin, EM; Cutter, G; DeWolfe, J; Dure, LS; Gaston, TE; Kankirawatana, P; Liu, Y; Singh, R; Standaert, DG; Szaflarski, JP; Thomas, AE; Ver Hoef, LW, 2018)	0.48
"Cannabidiol (CBD), one of the non-psychotomimetic compounds of Cannabis sativa, causes anxiolytic-like effects in animals, with typical bell-shaped dose-response curves."	( Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Crippa, JA; Guimarães, FS; Linares, IM; Mechoulam, R; Pereira, LC; Queiroz, RH; Zuardi, AW, )	0.13
"Our findings confirm the anxiolytic-like properties of CBD and are consonant with results of animal studies describing bell-shaped dose-response curves."	( Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Crippa, JA; Guimarães, FS; Linares, IM; Mechoulam, R; Pereira, LC; Queiroz, RH; Zuardi, AW, )	0.13
" Hence, the incorporation of CBD in lipid nanocapsules (LNCs) will contribute to overcome the dosing problems associated with cannabinoids."	( Lipid nanocapsules decorated and loaded with cannabidiol as targeted prolonged release carriers for glioma therapy: In vitro screening of critical parameters. Aparicio-Blanco, J; Benoit, JP; Sebastián, V; Torres-Suárez, AI, 2019)	0.51
" CBD was given on an open-label, flexible dosing regimen to patients diagnosed with PTSD by a mental health professional."	( Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series. Elms, L; Hughes, S; Lewis, N; Shannon, S, 2019)	0.51
" Without independent laboratory verification, it is impossible to know whether the labeled CBD dosage in non-FDA-approved CBD products is correct, that the delta-9-tetrahydrocannabinol content is <0."	( A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential. White, CM, 2019)	0.51
" Blood samples were collected until 48 hours after dosing and evaluated by liquid chromatography and tandem mass spectrometry."	( A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment. Crockett, J; Morrison, G; Taylor, L; Tayo, B, 2019)	0.51
" Highly purified grade CBD (Epidiolex®) dosing was weight-based and could be increased every 2 weeks by 5 mg/kg/day up to a maximum dosage of 50 mg/kg/day depending on tolerance and seizure control."	( Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol. Ampah, SB; Bebin, EM; Gaston, TE; Grayson, LE; Hernando, K; Moreadith, R; Szaflarski, JP, 2019)	0.51
"In this open-label study, we found evidence of a linear correlation between CBD dosage and plasma levels, and that higher dose/levels are associated with a higher response rate for seizure improvement."	( Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol. Ampah, SB; Bebin, EM; Gaston, TE; Grayson, LE; Hernando, K; Moreadith, R; Szaflarski, JP, 2019)	0.51
" Patients received a single dose (5, 10, or 20 mg/kg) on day 1 and twice-daily dosing on days 4 through 10 (10-mg/kg [cohort 1], 20-mg/kg [cohort 2], or 40-mg/kg [cohort 3] total daily dose)."	( Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy. Cilio, MR; Dlugos, D; Miller, I; Oh, DA; Parikh, N; Phillips, S; Renfroe, JB; Roberts, CM; Saeed, I; Sparagana, SP; Wheless, JW; Yu, J, 2019)	0.51
" Approximately 2-6 days of twice-daily dosing provided steady-state concentrations of cannabidiol."	( Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy. Cilio, MR; Dlugos, D; Miller, I; Oh, DA; Parikh, N; Phillips, S; Renfroe, JB; Roberts, CM; Saeed, I; Sparagana, SP; Wheless, JW; Yu, J, 2019)	0.51
" Given the correlation between plasma CBD concentration and seizure frequency, additional research is warranted to determine whether a higher dosage of CBD would be effective in reducing seizure activity by ≥ 50%."	( Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. Bartner, LR; Gustafson, DL; McGrath, S; Packer, RA; Rao, S, 2019)	0.51
" From this literature review, dosage for treatment and management is provided."	( Medical Marijuana in the Pediatric Population With Epilepsy-What You Should Know. Markle, M; Nativio, DG, )	0.13
" Crystalline extract CBD powder (98-99% pure) in an oil artisanal formulation was added to the baseline AED regimen at a dosage of 2-5 mg/kg/day divided for twice-daily administration, then up-titrated until intolerance or a maximum dosage of 25 mg/kg/day was reached."	( Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy. Calabrese, C; Cappelletti, S; Carfì Pavia, G; de Palma, L; Ferretti, A; Pietrafusa, N; Specchio, N; Tondo, I; Trivisano, M; Vigevano, F, 2019)	0.51
" Also, due to the complex pharmacology of cannabinoids, interindividual genetic differences in the metabolisation of ∆9-tetrahydrocannabinol (THC), the individual structure and function of the cannabinoid receptors, as well as differences in receptor density and distribution, the dosage and frequency of application must be individually determined."	( [Cannabis for medical purposes and its prescription]. Bussick, D; Eckert-Lill, C; Hörnig, M; Kiefer, A; Reimann, H, 2019)	0.51
" Only 2 of 39 participants were able to give an exact dosage used in milligrams."	( Marijuana use among patients with epilepsy at a tertiary care center. Ernst, L; Kellogg, M; Kerr, A; Walston, V; Wong, VSS, 2019)	0.51
"The results observed in this study are useful for guiding future pharmacokinetic studies of medicinal cannabinoids, and for development of dosing guidelines for medical use of cannabis in the 'real-world' setting."	( Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration. Broyd, SJ; de Krey, P; Galettis, P; Greenwood, LM; Liu, Z; Martin, JH; Schneider, J; Solowij, N; Steigler, A; van Hell, H; Zhu, X, 2020)	0.56
" Despite supra-physiological dosing being shown to be tolerable in various pathologies, optimization of CBD absorption has obvious benefits for general health and recreational usage."	( Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study. Ainslie, PN; Banic, I; Dujić, Ž; Marendic, M; Mijacika, T; Patrician, A; Sutlović, D; Versic-Bratincevic, M, 2019)	0.51
" Further studies are needed to establish the mechanisms of action of this technology and to explore the therapeutic potential of acute and chronic dosing on more at-risk populations."	( Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study. Ainslie, PN; Banic, I; Dujić, Ž; Marendic, M; Mijacika, T; Patrician, A; Sutlović, D; Versic-Bratincevic, M, 2019)	0.51
" There was considerable heterogeneity in dose, route of administration and THC:CBD ratio across studies and no clear dose-response profile emerged."	( How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Curran, HV; Freeman, AM; Freeman, TP; Hindocha, C; Lees, R; Mokrysz, C; Petrilli, K; Saunders, R, 2019)	0.51
" These data indicate that acute dosing of pure CBD will not result in a positive urine drug test using current federal workplace drug testing guidelines (50-ng/mL IA cutoff with 15-ng/mL confirmatory cutoff)."	( Urinary Pharmacokinetic Profile of Cannabinoids Following Administration of Vaporized and Oral Cannabidiol and Vaporized CBD-Dominant Cannabis. Bigelow, GE; Cone, EJ; Flegel, R; Kuntz, D; Mitchell, JM; Spindle, TR; Vandrey, R, 2020)	0.56
"Two reviewers independently extracted the following data from the articles: year of publication; study design; patient characteristics (sex; type of anxiety disorder; use of concomitant anxiolytic therapy); dosing strategy and route of CBD administration; and safety and efficacy outcomes."	( Use of cannabidiol in anxiety and anxiety-related disorders. Curren, Z; Deas, CM; Ennis, J; Skelley, JW, )	0.13
" However, more studies with standardized approaches to dosing and clinical outcome measurements are needed to determine the appropriate dosing strategy for CBD and its place in therapy."	( Use of cannabidiol in anxiety and anxiety-related disorders. Curren, Z; Deas, CM; Ennis, J; Skelley, JW, )	0.13
"Palliative medicine physicians are challenged by lack of guidance regarding effectiveness and dosing of cannabis products in the setting of their emerging popularity."	( Tetrahydrocannabinol and Cannabidiol Use in an Outpatient Palliative Medicine Population. Highet, BH; Johnson, PW; Kaur, JS; Lesser, ER, 2020)	0.56
"We administered Cannabidiol (CBD) capsules in different dosages (starting dosage 100 mg up to 600 mg over 8 weeks) after unsuccessful treatment with antidepressants."	( Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression. Felnhofer, A; Klier, CM; Kothgassner, OD; Laczkovics, C, 2021)	0.62
" This study aims to establish the CBD dose-exposure relationship and to evaluate the effects of dosage forms, food, and doses on CBD absorption."	( Model-Based Analysis of Cannabidiol Dose-Exposure Relationship and Bioavailability. Lim, SY; Sharan, S; Woo, S, 2020)	0.56
" Dosage form, food, and dose were assessed for covariation."	( Model-Based Analysis of Cannabidiol Dose-Exposure Relationship and Bioavailability. Lim, SY; Sharan, S; Woo, S, 2020)	0.56
"The effects of doses, dosage forms, and feeding status on CBD pharmacokinetics were quantified and should be taken into consideration for dose optimization."	( Model-Based Analysis of Cannabidiol Dose-Exposure Relationship and Bioavailability. Lim, SY; Sharan, S; Woo, S, 2020)	0.56
" The aim of this study was to assess the effects of repeated CBD dosing on haemodynamics."	( The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: A randomised controlled trial. England, TJ; O'Sullivan, SE; Sultan, SR, 2020)	0.56
" Cardiovascular parameters were assessed at rest and in response to isometric exercise after acute and repeated dosing using Finometer®, Vicorder® and Duplex ultrasound."	( The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: A randomised controlled trial. England, TJ; O'Sullivan, SE; Sultan, SR, 2020)	0.56
" Within the CBD group, repeated dosing reduced arterial stiffness by day 7 (pulse wave velocity; MD -0."	( The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: A randomised controlled trial. England, TJ; O'Sullivan, SE; Sultan, SR, 2020)	0.56
" The reduction in arterial stiffness and improvements in endothelial function after repeated CBD dosing are findings that warrant further investigation in populations with vascular diseases."	( The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: A randomised controlled trial. England, TJ; O'Sullivan, SE; Sultan, SR, 2020)	0.56
" Patients received plant-derived highly purified CBD in oral solution in addition to their baseline medications at an initial dosage of 5 mg/kg/day, which was increased by 5 mg/kg/day every week to an initial target dosage of 25 mg/kg/day."	( Cannabidiol in treatment of refractory epileptic spasms: An open-label study. Barnett, J; Bruno, P; Geffrey, AL; Herlopian, A; Hess, EJ; Pollack, SF; Skirvin, L; Sourbron, J; Thiele, EA, 2020)	0.56
"The method fulfilled the criteria in terms of specificity, calibration curve, precision, trueness and dosing range."	( Validation of an UHPLC/DAD method for the determination of cannabinoids in seized materials: Analysis of 213 samples sold in Belgian CBD shops. Charlier, C; Denooz, R; Deville, M; Dubois, N, 2020)	0.56
"6 mg Δ9-tetrahydrocannabinol (THC) in a randomized, placebo-controlled, within-subject dosing design."	( Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users. Abulseoud, OA; Andersson, M; Barnes, AJ; Blount, BC; Huestis, MA; Newmeyer, MN; Schroeder, J; Sempio, C; Smith, ML, 2020)	0.56
" Those formulations which are approved are dosed several times a day, creating an unmet need for controlled release (CR) formulations of cannabinoids."	( Investigation of cannabidiol gastro retentive tablets based on regional absorption of cannabinoids in rats. Freidman, M; Hoffman, A; Izgelov, D, 2020)	0.56
" Although detailed studies have not been published, the available data suggest that the absolute bioavailability of CBD after oral dosing under fasting conditions is approximately 6%, and increases fourfold when the medication is co-administered with a high-fat meal."	( Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. Bialer, M; Perucca, E, 2020)	0.56
" The reasons behind this popularity is the compound's therapeutic properties, alongside a safe profile of administration lacking addictive properties such as euphoric state of mind and a wide dosing range."	( Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers. Barasch, D; Davidson, E; Domb, AJ; Hoffman, A; Izgelov, D; Regev, A, 2020)	0.56
"8 years; 7 male) performed fMRI Sternberg task before receiving CBD ("PRE") and after reaching stable dosage of CBD (15-25 mg/kg/day; "ON")."	( Effects of highly purified cannabidiol (CBD) on fMRI of working memory in treatment-resistant epilepsy. Allendorfer, JB; Bebin, EM; Gaston, TE; Grayson, LP; Martin, RC; Nair, S; Szaflarski, JP, 2020)	0.56
" This allows for simultaneously printing an individual dose and encapsulating information relevant to the end-users and other stakeholders in a single dosage unit, which is readable by a standard smartphone."	( Data-enriched edible pharmaceuticals (DEEP) of medical cannabis by inkjet printing. Bøtker, J; Cornett, C; Frokjaer, S; Genina, N; Hansen, H; Öblom, H; Rades, T; Rantanen, J, 2020)	0.56
" Dose-response relationships were calculated using Probit analysis and statistical significance was assessed with a two-sample z-test."	( Cannabidiolic acid exhibits entourage-like improvements of anticonvulsant activity in an acute rat model of seizures. Beenhakker, M; Goerl, B; Metcalf, C; Smith, M; Watkins, S, 2021)	0.62
" Test compounds should be compared by sub-chronic dosing in the MES test in order to assess safety and pharmacokinetic profiles."	( Cannabidiolic acid exhibits entourage-like improvements of anticonvulsant activity in an acute rat model of seizures. Beenhakker, M; Goerl, B; Metcalf, C; Smith, M; Watkins, S, 2021)	0.62
" The 25-mg/kg/day dosage had a better safety profile than the 50-mg/kg/day dosage."	( Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. Bebin, EM; Bhathal, H; Checketts, D; Jansen, FE; Knappertz, V; Kotulska, K; Lawson, JA; O'Callaghan, FJ; Sahebkar, F; Thiele, EA; Wong, M, 2021)	0.62
" Evidence in rodent models of EAE strongly supports CBD as effective, while clinical evidence is still limited and usually negative, due to paucity of studies and possibly to the use of suboptimal dosing regimens."	( Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review. Cosentino, M; Ferrari, M; Furgiuele, A; Marino, F, 2021)	0.62
" Data from this study show that for clinically meaningful efficacy against OA, CBD may have to be delivered in higher dosage or formulated with other medicinal plants with similar activities."	( Antinociceptive and Anti-Inflammatory Properties of Cannabidiol Alone and in Combination with Standardized Bioflavonoid Composition. Brownell, L; Hong, M; Horm, T; Jia, Q; Jiao, P; O'Neal, A; Rossiter, S; Yimam, M, 2021)	0.62
" The bioavailability and pharmacokinetics of CBD are not well understood, and proper dosing schemes have not been adequately developed for its clinical use."	( Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: A systematic review of clinical studies. Capparelli, EV; Rosania, GR; Silmore, LH; Willmer, AR, 2021)	0.62
"Daily high dosing with THC compromised performance on a task of cognition, and reduced activity in adolescent primates, with tolerance developing within weeks."	( Effects of daily Δ Bergman, J; Charles, S; Eisold, JE; George, SR; Gumbert, AB; Kangas, BD; Madras, BK; Withey, SL, 2021)	0.62
"Due to a lack of published pharmacokinetic (PK) and/or pharmacodynamic (PD) data, decision-making surrounding appropriate dosing of cannabis used for medical purposes is limited."	( Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants. Bonn-Miller, MO; Land, MH; MacNair, L; Mosesova, I; Peters, EN; Turcotte, C; Vandrey, R; Ware, MA, 2022)	0.72
" Among the participants who had used or were using at least 1 CBD product, the most commonly used dosage form was sublingual, followed by topical: 46 (46/63 [73%]) and 34 (34/63 [54%]) participants, respectively."	( Assessment of hemp oil-based cannabidiol use in a community-based pharmacy setting. Gatewood, SS; Gicewicz, E; Goode, JR; Kaefer, TN; Nadpara, P, )	0.13
"Due to a lack of published pharmacokinetic (PK) and/or pharmacodynamic (PD) data, informed physician and patient decision-making surrounding appropriate dosing of cannabis for medical purposes is limited."	( Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants. Bonn-Miller, MO; Land, MH; MacNair, L; Mosesova, I; Peters, EN; Turcotte, C; Vandrey, R; Ware, MA, 2022)	0.72
" In dose-response studies, adult, male CD1 mice were injected intraperitoneally with (1) CBD alone (0-96 mg/kg), (2) THC alone (0-6."	( Effects of cannabidiol and Δ9-tetrahydrocannabinol in the elevated plus maze in mice. Burnham, WM; Liu, J; Scott, BW, 2022)	0.72
" There was no dose-response observed for CBD, suggesting a ceiling effect at the doses used and the potential for lower effective doses of CBD."	( Cannabidiol reduces withdrawal symptoms in nicotine-dependent rats. Boomhower, B; Carrette, LLG; Dowling, J; Fitzgerald, RL; George, O; Hanham, K; Hoffman, M; Kallupi, M; Momper, JD; Sepulveda, Y; Smith, LC; Suhandynata, RT; Tieu, L, 2021)	0.62
"This pharmacokinetic (PK) drug-interaction trial investigated the effects of repeated dosing of a plant-derived pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex in the United States and Epidyolex in Europe; 100 mg/mL oral solution) on caffeine clearance via modulation of cytochrome P450 (CYP) 1A2 activity in healthy adults."	( A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. Critchley, D; Tayo, B; Thai, C, 2021)	0.62
" FDA authorization for the commercial use of four cannabinoid-derived products, available as oral dosage forms is a significant progress already."	( Delivering therapeutic cannabinoids via skin: Current state and future perspectives. Chukwunyere, UI; Frempong, D; Mishra, D; Puri, A; Thakur, D; Tijani, AO, 2021)	0.62
"Medicinal cannabis is generally well tolerated when dosed appropriately."	( A primer on medicinal cannabis safety and potential adverse effects. Arnold, JC, 2021)	0.62
" Risk mitigation strategies such as appropriate chemovar (strain) selection, routes of administration, and dosing are reviewed."	( "Is medical cannabis safe for my patients?" A practical review of cannabis safety considerations. Boivin, M; Lo, LA; MacCallum, CA, 2021)	0.62
" Urine specimens were collected before and for 58 h after dosing on a residential research unit."	( Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. Bigelow, GE; Cone, EJ; Flegel, RR; Goffi, E; Kuntz, D; Mitchell, JM; Sholler, DJ; Spindle, TR; Vandrey, R; Winecker, RE, 2022)	0.72
" Our granular investigation reveals variability of CBD product dosing practices for fibromyalgia, and how past-year HTC use influences CBD product use."	( Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia. Boehnke, KF; Gagnier, JJ; Matallana, L; Williams, DA, 2022)	0.72
" This study presents a dose-response curve to understand better the effects of low doses (3 mg/kg) on CBD's antiallodynic and anxiolytic effects."	( Cannabidiol effectively reverses mechanical and thermal allodynia, hyperalgesia, and anxious behaviors in a neuropathic pain model: Possible role of CB1 and TRPV1 receptors. Crippa, JA; Garcia-Cairasco, N; Hallak, JE; Lazarini-Lopes, W; Leite-Panissi, CRA; Silva-Cardoso, GK; Zuardi, AW, 2021)	0.62
"We demonstrate that commercial CBD products, especially aqueous beverages, can show inconsistent labeling, vary largely from their label claims should they make them, and show lot-to-lot variability making dosing unpredictable."	( Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners. Elder, EJ; Gidal, BE; Jones, KJ; Miller, OS, 2022)	0.72
" Sigmoidal non-linear dose-response relationships are of grave concern."	( Geotemporospatial and causal inference epidemiological analysis of US survey and overview of cannabis, cannabidiol and cannabinoid genotoxicity in relation to congenital anomalies 2001-2015. Hulse, GK; Reece, AS, 2022)	0.72
" This practical guide provides an overview of these main ASMs including their indications/contraindications, mechanism of action, efficacy, safety and tolerability profile, dosage requirements, and laboratory and clinical parameters to be evaluated."	( A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. Schubert-Bast, S; Strzelczyk, A, 2022)	0.72
" Our results showed that a well-designed CBD ocular dosage form can be stabilized for an extended shelf life."	( The dose-dependent effect of a stabilized cannabidiol nanoemulsion on ocular surface inflammation and intraocular pressure. Benita, S; Frušić-Zlotkin, M; Nassar, T; Ofri, R; Rebibo, L, 2022)	0.72
" The aim of this study was to investigate similar dosing of CBG and CBGA from hemp plants that have been used for cannabidiol pharmacokinetic studies."	( Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation. Amstutz, K; Ellis, K; Gomez, B; Lyubimov, A; Schwark, WS; Venator, KP; Wakshlag, JJ; Zakharov, A, 2022)	0.72
" Future research should focus on longer term symptom relief, including nausea-free intervals and dosing frequency; the risks of consumption of medical cannabis, especially among high-risk populations, such as pregnant women and children; and potential interactions between cannabis, conventional antiemetics, other medications, food, tobacco, alcohol, and street drugs among specific patient populations."	( The Effectiveness of Common Cannabis Products for Treatment of Nausea. Brockelman, F; Hall, B; Keeling, K; Li, X; Lopez, V; Orozco, J; Stith, SS; Vigil, JM, 2022)	0.72
" CBD had dose-dependent, but variable, oral bioavailability at 1 mg/kg and 3 mg/kg daily dosing and was consistently detectable at steady state in synovial fluid at the higher dose."	( Pharmacokinetics, Safety, and Synovial Fluid Concentrations of Single- and Multiple-Dose Oral Administration of 1 and 3 mg/kg Cannabidiol in Horses. Contino, EK; Gustafson, DL; O'Fallon, ES; Yocom, AF, 2022)	0.72
" We will begin with an overview of the legal and commercial environment, examine recent preclinical and clinical evidence on CBD, explore questions concerning CBD raised by healthcare professionals and patients, investigate dosing regimens and methods of administration, and address current challenges in the accumulation of sound evidence."	( Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain). Boehnke, KF; Fitzcharles, MA; Häuser, W, 2022)	0.72
" Dosing for symptom relief has not yet been established."	( Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain). Boehnke, KF; Fitzcharles, MA; Häuser, W, 2022)	0.72
" Future clinical trials may investigate different dosage regimens."	( Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial. Baas, JM; Batelaan, NM; Cath, DC; Duits, P; Eikelenboom, M; Groenink, L; Kwee, CM; Moerbeek, M; van Balkom, AJ; van der Flier, FE; van der Veen, DC, 2022)	0.72
" CBD was fed relative to body mass at 0 (control), 30, 115, or 230 mg/Kg/day for 28 days; with 6 males and 6 females per dosing group."	( Cannabidiol (CBD) Dosing: Plasma Pharmacokinetics and Effects on Accumulation in Skeletal Muscle, Liver and Adipose Tissue. Child, RB; Tallon, MJ, 2022)	0.72
" Management of the 260 DDIs detected included counseling only (89% [n = 232 interactions]), discontinuation of the interacting agent [9% (n = 22 interactions]), and dosage change for the interacting agent [2% (n = 6 interactions])."	( Prescription cannabidiol for seizure disorder management: Initial drug-drug interaction management by specialty pharmacists. Choi, L; DeClercq, J; Dial, H; Johnson, K; Owens, W; Shah, NB; Zuckerman, AD, 2022)	0.72
" Analyzing the biological effects of CBD on MDA-MB-231, we have demonstrated that both CBD dosage and serum concentrations in the culture medium influence its outcomes; furthermore, light scattering studies demonstrated that serum impacts the CBD aggregation state by acting as a surfactant agent."	( Cannabidiol Antiproliferative Effect in Triple-Negative Breast Cancer MDA-MB-231 Cells Is Modulated by Its Physical State and by IGF-1. Ceriani, M; Costa, B; D'Aloia, A; Sacco, E; Stucchi, S; Tisi, R, 2022)	0.72
"Concentrations of CBD and metabolites (7-COH CBD and 7-COOH CBD) were detected in all plasma samples up to 8 hours after dosing (oral and IV), with 7-COOH CBD being the most predominant metabolite."	( Pharmacokinetics of cannabidiol in a randomized crossover trial in senior horses. Adams, AA; Knych, HK; Turner, SE, 2022)	0.72
" Further studies are currently ongoing to confirm dosing and effectiveness in other orthopaedic conditions."	( Buccally Absorbed Cannabidiol Shows Significantly Superior Pain Control and Improved Satisfaction Immediately After Arthroscopic Rotator Cuff Repair: A Placebo-Controlled, Double-Blinded, Randomized Trial. Alaia, MJ; Britton, B; Gonzalez-Lomas, G; Hurley, ET; Jazrawi, LM; Kaplan, K; Markus, DH; Rokito, AS; Vasavada, K, 2022)	0.72
" These data may be useful in determining appropriate dosing of cannabinoids in the domestic rabbit."	( Feeding decreases the oral bioavailability of cannabidiol and cannabidiolic acid in hemp oil in New Zealand White rabbits (Oryctolagus cuniculus). Carpenter, JW; Gardhouse, SM; KuKanich, B; Magnin, GC; Rooney, TA; Tully, TN, 2022)	0.72
" This continuing education article summarizes available efficacy and safety data involving cannabidiol, stiripentol, and fenfluramine and provides a practical review of dosing strategies, pharmacokinetics, and monitoring interventions relevant to their use."	( Treatment-Refractory Dravet Syndrome: Considerations for Novel Medications. Blackmer, AB; Lopez, JC; Orth, LE; Pare, JR, )	0.13
" Heterogeneity in cannabis types, doses, timing of administration, and sleep outcome measures limit the ability to make specific dosing recommendations."	( Cannabis dosing and administration for sleep: a systematic review. Boerkoel, P; Cullen, K; Hawkins, M; Lai, WW; Malas, A; Roesler, J; Velzeboer, R, 2022)	0.72
", dosage >12 sprays per day and/or not administered primarily for treatment of spasticity."	( Effects of Sativex Dykukha, I; Essner, U; Penner, IK; Raithel, LM; Schreiber, H, 2022)	0.72
" Here we assessed CBD dose-response effects in the Genetically Epilepsy Prone Rats (GEPR-3) strain, which exhibits two types of epileptic seizures, brainstem-dependent generalized tonic-clonic seizures and limbic seizures."	( Cannabidiol attenuates generalized tonic-clonic and suppresses limbic seizures in the genetically epilepsy-prone rats (GEPR-3) strain. Campos-Rodriguez, C; Forcelli, PA; Garcia-Cairasco, N; Lazarini-Lopes, W; N'Gouemo, P, 2023)	0.91
" Therefore, two different dose-response studies were performed, one for generalized tonic-clonic seizures and the other for limbic seizures."	( Cannabidiol attenuates generalized tonic-clonic and suppresses limbic seizures in the genetically epilepsy-prone rats (GEPR-3) strain. Campos-Rodriguez, C; Forcelli, PA; Garcia-Cairasco, N; Lazarini-Lopes, W; N'Gouemo, P, 2023)	0.91
" Other factors, including dosage and clobazam co-therapy, were significantly associated with a greater effect on seizure control and side effects of CBD."	( Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Aparasu, R; Estes, E; Reddy, DS; Talwar, A, 2023)	0.91
" Randomized controlled canine trials with large sample sizes are needed to determine the range of therapeutic plasma concentrations, develop evidence-based dosing regimens, determine the efficacy of cannabidiol in drug-refractory epilepsy, and explore potential associations between treatment effects and different etiologies, epilepsy types, and drug combinations."	( Cannabidiol in canine epilepsy. Bhatti, SFM; McGrath, S; Potschka, H; Tipold, A, 2022)	0.72
" Dosing guidelines to inform future human studies are however lacking."	( Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration-effect relations using the IB-de-risk tool. Baas, JM; Bongaerts, FL; Cath, DC; Groenink, L; Jacobs, G; Kwee, CM; van Gerven, JM, 2022)	0.72
"A straightforward dosing recommendation was not possible, given variable concentration-effect relations across species, and no consistent linear effect of CBD on anxiety reduction."	( Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration-effect relations using the IB-de-risk tool. Baas, JM; Bongaerts, FL; Cath, DC; Groenink, L; Jacobs, G; Kwee, CM; van Gerven, JM, 2022)	0.72
" While cannabidiol was generally safe and well tolerated even in high doses among the included studies, clearer dosing guidelines and increased regulation of cannabidiol products are also needed."	( The Effectiveness and Safety of Cannabidiol in Non-seizure-related Indications: A Systematic Review of Published Randomized Clinical Trials. Rudisill, TM; Tang, Y; Tonkovich, KL, 2022)	0.72
" Eight cats were randomized into six dosing groups of four cats each."	( Pharmacokinetics of escalating single-dose administration of cannabidiol to cats. Bartner, LR; Castro, SC; Gustafson, DL; Kusick, BR; McGrath, S; Rozental, AJ, 2023)	0.91
" Using currently available data, likely drug interactions of which prescribers of cannabidiol need to be aware, at the doses likely to cause clinically significant interactions, and drug dosing changes that may be needed are highlighted."	( Cannabidiol drug interaction considerations for prescribers and pharmacists. Graham, M; Lucas, CJ; Martin, JH; Murnion, B; Schneider, J, 2022)	0.72
" For an individual patient, there are inherent limitations in providing clinical guidance due to gaps in specific drug dose-response data and knowledge of individual pharmacokinetic profiles, including different co-morbidities, and concurrent medicines."	( Cannabidiol drug interaction considerations for prescribers and pharmacists. Graham, M; Lucas, CJ; Martin, JH; Murnion, B; Schneider, J, 2022)	0.72
" However, most use a mixture of CBD and the psychoactive, tetrahydrocannabinol (THC), and/or use variable dosing that is not consistent between individual patients."	( Role of Cannabidiol for Improvement of the Quality of Life in Cancer Patients: Potential and Challenges. Green, R; Khalil, R; Mohapatra, S; Mohapatra, SS, 2022)	0.72
"" Reports that provided dosing regimens and patient outcomes were included."	( Cannabidiol in refractory status epilepticus: A review of clinical experiences. Duda, J; Reinert, JP, 2022)	0.72
" Dosing of CBD ranged between 5-25 mg/kg/day and was titrated based on patient response to therapy."	( Cannabidiol in refractory status epilepticus: A review of clinical experiences. Duda, J; Reinert, JP, 2022)	0.72
" Additional research is necessary to determine a definitive dosing strategy for this agent."	( Cannabidiol in refractory status epilepticus: A review of clinical experiences. Duda, J; Reinert, JP, 2022)	0.72
" First, we determined the analgesic effect of CBD and BCP individually by establishing dose-response studies."	( Cannabidiol and Beta-Caryophyllene in Combination: A Therapeutic Functional Interaction. Benamar, K; Blanton, H; Duong, J; Yin, L, 2022)	0.72
" Current literature poses the challenge that it does not provide standardized guidance on dosing for the above potential indications and cannabis use is dominated by recreational purposes."	( Therapeutic and Supportive Effects of Cannabinoids in Patients with Brain Tumors (CBD Oil and Cannabis). Butowski, N; Rodriguez-Almaraz, JE, 2023)	0.91
" Overall, this study indicates that CBG is promising for developing a transdermal dosage for pain management."	( The antinociceptive activity and mechanism of action of cannabigerol. Li, R; Lin, G; Wang, Z; Wen, Y; Zhang, J; Zhang, R; Zhu, Y, 2023)	0.91
"The goal of pharmacokinetic (PK) studies is to provide a basis for appropriate dosing regimens with novel therapeutic agents."	( A One Health perspective on comparative cannabidiol and cannabidiolic acid pharmacokinetics and biotransformation in humans and domestic animals. Schwark, WS; Wakshlag, JJ, 2023)	0.91
" Additional studies are needed to determine the safe and effective CBD dosage for treating epilepsy."	( Adverse Events of Cannabidiol Use in Patients With Epilepsy: A Systematic Review and Meta-analysis. Fazlollahi, A; Gharagozli, K; Golabi, B; Kolahi, AA; Nejadghaderi, SA; Safiri, S; Sullman, MJM; Zahmatyar, M; ZareDini, M, 2023)	0.91
" Maximum concentration and area under the concentration-time curve (AUC) from time of dosing to the last measurable concentration and extrapolated to infinity, of everolimus in whole blood were estimated using noncompartmental analysis, with geometric mean ratios and 90% confidence intervals for the ratios of everolimus dosed with CBD to everolimus dosed alone."	( Pharmacokinetic Drug-Drug Interaction With Coadministration of Cannabidiol and Everolimus in a Phase 1 Healthy Volunteer Trial. Berwaerts, J; Chen, C; Critchley, D; Hyland, K; Tayo, B; Thai, C; Wray, L, 2023)	0.91
"We found heterogeneity regarding cannabidiol dosage and dosing frequency."	( Assessment of cannabidiol use in pets according to a national survey in the USA. Corsato Alvarenga, I; Duerr, F; Elam, LH; MacQuiddy, B; McGrath, S, 2023)	0.91
" Age- and weight-based dosing of diazepam nasal spray were administered during a 12-month treatment period."	( Concomitant cannabidiol does not impact safety and effectiveness of diazepam nasal spray for seizure clusters: Post hoc analysis of a phase 3 safety study. Carrazana, E; Misra, SN; Peters, JM; Puri, V; Rabinowicz, AL; Segal, E, 2023)	0.91
"2) days, with dosage escalating to twice per day."	( Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms. Adkins, M; Bainbridge, J; Domen, CH; Klawitter, J; Leehey, MA; Liu, Y; Rajkovic, S; Sempio, C; Sillau, S, 2023)	0.91
"Our findings indicate that acute dosing of cannabidiol over 24 h can lower blood pressure and arterial stiffness in individuals with untreated hypertension."	( The Influence of Oral Cannabidiol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Untreated Hypertension: A Double-Blind, Placebo-Controlled, Cross-Over Pilot Study. Brown, CV; Dragun, T; Dujić, Ž; Obad, A; Tulppo, MP, 2023)	0.91
" Altogether, these results demonstrated that proliposomes may be a valuable intermediate for the preparation of deformable liposome-based cutaneous dosage forms, improving the stability without compromising the overall performances."	( Micelles-in-Liposome Systems Obtained by Proliposomal Approach for Cannabidiol Delivery: Structural Features and Skin Penetration. Casiraghi, A; Cilurzo, F; Del Favero, E; Franzè, S; Rama, F; Ricci, C, 2023)	0.91
" A systematic pharmacokinetic study was performed to determine whether there are differences in the pharmacokinetic parameters and systemic exposure of CBD after oral dosing as an isolate, broad-spectrum, or full-spectrum product."	( Comparative Pharmacokinetics of Commercially Available Cannabidiol Isolate, Broad-Spectrum, and Full-Spectrum Products. Berthold, EC; Chiang, YH; Kamble, SH; Kanumuri, SRR; Kuntz, MA; McCurdy, CR; McMahon, LR; Senetra, AS; Sharma, A, 2023)	0.91
" However, there is a significant need for more research that accurately reflects CBD dosing and administration regimens used in a real-world context."	( Cannabidiol as a Harm Reduction Strategy for People Who Use Drugs: A Rapid Review. Fehr, F; Koehn, M; Lo, LA; MacCallum, CA; Milloy, MJ; Mitchell, I; Nanson, K; Walsh, Z, 2023)	0.91
"Results indicated no effect of acute CBD dosing on worry severity or anxiety symptoms."	( The effects of cannabidiol on worry and anxiety among high trait worriers: a double-blind, randomized placebo controlled trial. Bilsky, S; Ferretti, ML; Gournay, LR; Leen-Feldner, EW; Mann, E; Nguyen, AM; Vance, E; Williams, P, 2023)	0.91
" Mouse proteome profiler cytokine/chemokine array revealed upregulation of complement C5/5a (anaphylatoxin), soluble intracellular adhesion molecule-1 (sICAM-1) and IL-1 receptor antagonist (IL-1RA) in animals dosed with β-CP (10 mg/mL)."	( Epicutaneous Sensitization to the Phytocannabinoid β-Caryophyllene Induces Pruritic Inflammation. Baltazar, CT; Inan, S; Javed, E; Nayak, AP; Peruggia, GA; Ward, SJ, 2023)	0.91
" The 5 mg/kg/day dosage met futility requirements after 12 dogs, and a dosage of 9 mg/kg/day was used in the next 39 dogs."	( The efficacy and safety of cannabidiol as adjunct treatment for drug-resistant idiopathic epilepsy in 51 dogs: A double-blinded crossover study. Bartner, LR; Corsato Alvarenga, I; Gustafson, DL; Kusick, BR; McGrath, S; Rao, S; Rozental, AJ; Weisbeck, BG, )	0.13

Role	Description
plant metabolite	Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
antimicrobial agent	A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
resorcinols	Any benzenediol in which the two hydroxy groups are meta to one another.
olefinic compound	Any organic molecular entity that contains at least one C=C bond.
phytocannabinoid	A class of cannabinoid which are C21 terpenophenolic compounds isolated primarily from Cannabis sativa.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
cannabinoid biosynthesis	1	22
CBD synthetic pathway	0	8
Cannabinoid receptor signaling	0	20

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
PPM1D protein	Homo sapiens (human)	Potency	32.9993	0.0052	9.4661	32.9993	AID1347411
Interferon beta	Homo sapiens (human)	Potency	32.9993	0.0033	9.1582	39.8107	AID1347411
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Acetylcholinesterase	Electrophorus electricus (electric eel)	IC50 (µMol)	17.0700	0.0000	0.9453	9.9400	AID1773262
L-lactate dehydrogenase A chain	Homo sapiens (human)	Ki	24.0000	0.0500	3.7650	8.5000	AID1782666
Cytochrome P450 1A1	Homo sapiens (human)	Ki	0.1600	0.0120	0.9469	3.8000	AID1692707
Cytochrome P450 1A2	Homo sapiens (human)	Ki	2.6900	0.0056	1.1534	9.0000	AID1692708
Cytochrome P450 2C11	Rattus norvegicus (Norway rat)	Ki	20.7000	0.0003	0.0003	0.0003	AID1692721
Cytochrome P450 3A4	Homo sapiens (human)	Ki	1.0000	0.0001	1.4162	9.9000	AID1692724
Cytochrome P450 2D6	Homo sapiens (human)	Ki	2.4200	0.0001	1.1986	8.0000	AID1692723
Cytochrome P450 2A6	Homo sapiens (human)	Ki	55.0000	0.0056	1.5271	7.5000	AID1692718
Cytochrome P450 2C9	Homo sapiens (human)	Ki	5.6000	0.0003	1.6842	10.0000	AID1692720
Fatty acid-binding protein, liver	Mus musculus (house mouse)	Ki	0.1670	0.0210	0.3483	2.0000	AID1802031
Alpha-2B adrenergic receptor	Homo sapiens (human)	Ki	3.2000	0.0002	0.7257	10.0000	AID1692686
Alpha-2C adrenergic receptor	Homo sapiens (human)	Ki	3.7000	0.0003	0.4834	10.0000	AID1692688
Cannabinoid receptor 1	Rattus norvegicus (Norway rat)	Ki	10.0000	0.0002	0.5665	10.0000	AID260287
Cytochrome P450 2B6	Homo sapiens (human)	Ki	0.6900	0.0004	1.4160	10.0000	AID1692719
Cytochrome P450 3A5	Homo sapiens (human)	Ki	0.1900	0.0220	2.6040	7.6000	AID1692725
Cannabinoid receptor 1	Homo sapiens (human)	Ki	3.1397	0.0001	0.5077	9.6000	AID1127482; AID1625146; AID1692636; AID482748
D(1A) dopamine receptor	Homo sapiens (human)	Ki	2.7000	0.0001	0.8363	10.0000	AID1692684
Cytochrome P450 3A7	Homo sapiens (human)	Ki	12.3000	0.0220	5.0740	7.6000	AID1692726
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	Ki	1.1000	0.0001	0.9549	10.0000	AID1692681
Cytochrome P450 2C19	Homo sapiens (human)	Ki	0.7900	0.0001	0.8300	10.0000	AID1692722
Cannabinoid receptor 2	Homo sapiens (human)	Ki	4.0230	0.0000	0.4156	10.0000	AID1127483; AID1625147; AID1692637; AID482749
Mu-type opioid receptor	Homo sapiens (human)	Ki	1.3000	0.0000	0.4197	10.0000	AID1692682
Delta-type opioid receptor	Homo sapiens (human)	Ki	6.4000	0.0000	0.5978	9.9300	AID1692689
Kappa-type opioid receptor	Homo sapiens (human)	Ki	2.3000	0.0000	0.3624	10.0000	AID1692683
Cholinesterase	Equus caballus (horse)	IC50 (µMol)	0.6700	0.0000	2.2214	9.4000	AID1773260
N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)	IC50 (µMol)	100.0000	0.7000	0.7000	0.7000	AID1625159
Cytochrome P450 1B1	Homo sapiens (human)	Ki	3.6300	0.0030	0.9741	7.4600	AID1692709
Heat sensitive channel TRPV3	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.7500	0.7500	0.7500	0.7500	AID1681222
Sigma intracellular receptor 2	Homo sapiens (human)	Ki	3.4000	0.0001	0.8360	4.6005	AID1692687
Transient receptor potential cation channel subfamily A member 1	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.4500	0.4500	3.4243	7.5000	AID1681216
Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)	IC50 (µMol)	3.7000	0.0002	0.6060	10.0000	AID1681228
Transient receptor potential cation channel subfamily M member 8	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.8000	0.0580	2.6504	8.3000	AID1681215
Transient receptor potential cation channel subfamily V member 4	Rattus norvegicus (Norway rat)	IC50 (µMol)	5.9000	0.0370	1.4541	5.9000	AID1681219
Transient receptor potential cation channel subfamily V member 2	Rattus norvegicus (Norway rat)	IC50 (µMol)	1.1000	0.0370	1.9345	8.6000	AID1681225
Diacylglycerol lipase-alpha	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0010	1.0538	5.0119	AID1625150
Histamine H3 receptor	Homo sapiens (human)	Ki	3.1000	0.0001	0.3399	8.5110	AID1692685
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
5-hydroxytryptamine receptor 1A	Homo sapiens (human)	EC50 (µMol)	8.0000	0.0001	0.2571	8.0000	AID1692634
5-hydroxytryptamine receptor 2A	Rattus norvegicus (Norway rat)	EC50 (µMol)	32.0000	0.0001	0.4929	4.0000	AID1692635
Caspase-1	Homo sapiens (human)	Kd	0.0188	0.0188	0.0188	0.0188	AID1780736
Cannabinoid receptor 2	Homo sapiens (human)	EC50 (µMol)	0.1791	0.0003	0.1517	3.2800	AID1847100; AID1847103; AID1847106; AID1847108; AID1847114; AID1847121; AID1847127; AID1847131; AID1847133; AID1847137; AID1847139; AID1847145; AID1847151; AID1847158; AID1847162; AID1847164; AID1847168; AID1847169; AID1847171; AID1847177; AID1847183; AID1847189; AID1847193
Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)	EC50 (µMol)	25.0000	0.0000	0.9922	10.0000	AID1657599
Heat sensitive channel TRPV3	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.5100	0.5100	0.5100	0.5100	AID1681223
Transient receptor potential cation channel subfamily A member 1	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.2880	0.0600	2.2223	8.4000	AID1681217; AID482146
Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)	EC50 (µMol)	4.1000	0.0005	1.0674	6.3096	AID1681229
Transient receptor potential cation channel subfamily V member 4	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.9000	0.0300	0.3315	0.9000	AID1681220
Transient receptor potential cation channel subfamily V member 2	Rattus norvegicus (Norway rat)	EC50 (µMol)	1.2000	0.0300	0.4507	1.7000	AID1681226
G-protein coupled receptor 55	Homo sapiens (human)	EC50 (µMol)	0.4450	0.0020	0.6662	2.0100	AID482752
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cannabinoid receptor 1	Homo sapiens (human)	Log Ki	0.0036	0.0003	0.0019	0.0036	AID49325
Cannabinoid receptor 2	Homo sapiens (human)	Log Ki	0.0035	0.0005	0.0020	0.0035	AID49851
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
lactate metabolic process	L-lactate dehydrogenase A chain	Homo sapiens (human)
pyruvate metabolic process	L-lactate dehydrogenase A chain	Homo sapiens (human)
glycolytic process	L-lactate dehydrogenase A chain	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
cellular response to organic cyclic compound	Cytochrome P450 1A1	Homo sapiens (human)
response to hypoxia	Cytochrome P450 1A1	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 1A1	Homo sapiens (human)
fatty acid metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
steroid biosynthetic process	Cytochrome P450 1A1	Homo sapiens (human)
porphyrin-containing compound metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
amine metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
response to nematode	Cytochrome P450 1A1	Homo sapiens (human)
response to herbicide	Cytochrome P450 1A1	Homo sapiens (human)
ethylene metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
flavonoid metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
response to iron(III) ion	Cytochrome P450 1A1	Homo sapiens (human)
insecticide metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
dibenzo-p-dioxin catabolic process	Cytochrome P450 1A1	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 1A1	Homo sapiens (human)
response to food	Cytochrome P450 1A1	Homo sapiens (human)
response to lipopolysaccharide	Cytochrome P450 1A1	Homo sapiens (human)
response to vitamin A	Cytochrome P450 1A1	Homo sapiens (human)
response to immobilization stress	Cytochrome P450 1A1	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 1A1	Homo sapiens (human)
9-cis-retinoic acid biosynthetic process	Cytochrome P450 1A1	Homo sapiens (human)
camera-type eye development	Cytochrome P450 1A1	Homo sapiens (human)
nitric oxide metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
response to arsenic-containing substance	Cytochrome P450 1A1	Homo sapiens (human)
digestive tract development	Cytochrome P450 1A1	Homo sapiens (human)
tissue remodeling	Cytochrome P450 1A1	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Cytochrome P450 1A1	Homo sapiens (human)
response to hyperoxia	Cytochrome P450 1A1	Homo sapiens (human)
maternal process involved in parturition	Cytochrome P450 1A1	Homo sapiens (human)
hepatocyte differentiation	Cytochrome P450 1A1	Homo sapiens (human)
cellular response to copper ion	Cytochrome P450 1A1	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 1A1	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	Cytochrome P450 1A1	Homo sapiens (human)
response to 3-methylcholanthrene	Cytochrome P450 1A1	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
porphyrin-containing compound metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
toxin biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
post-embryonic development	Cytochrome P450 1A2	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
regulation of gene expression	Cytochrome P450 1A2	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lung development	Cytochrome P450 1A2	Homo sapiens (human)
methylation	Cytochrome P450 1A2	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
cellular respiration	Cytochrome P450 1A2	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 1A2	Homo sapiens (human)
cellular response to cadmium ion	Cytochrome P450 1A2	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
behavioral fear response	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
gamma-aminobutyric acid signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
positive regulation of cell population proliferation	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of serotonin secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of vasoconstriction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
exploration behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of dopamine metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of hormone secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2A6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2A6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2A6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2A6	Homo sapiens (human)
coumarin catabolic process	Cytochrome P450 2A6	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2A6	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
MAPK cascade	Alpha-2B adrenergic receptor	Homo sapiens (human)
angiogenesis	Alpha-2B adrenergic receptor	Homo sapiens (human)
regulation of vascular associated smooth muscle contraction	Alpha-2B adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-2B adrenergic receptor	Homo sapiens (human)
female pregnancy	Alpha-2B adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2B adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2B adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2B adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2B adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of neuron differentiation	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of blood pressure	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of uterine smooth muscle contraction	Alpha-2B adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
regulation of smooth muscle contraction	Alpha-2C adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-2C adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2C adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of neuron differentiation	Alpha-2C adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2B6	Homo sapiens (human)
cellular ketone metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2B6	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A5	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A5	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A5	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A5	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A5	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A5	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A5	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A5	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A5	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A5	Homo sapiens (human)
positive regulation of acute inflammatory response to antigenic stimulus	Cannabinoid receptor 1	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Cannabinoid receptor 1	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Cannabinoid receptor 1	Homo sapiens (human)
spermatogenesis	Cannabinoid receptor 1	Homo sapiens (human)
axonal fasciculation	Cannabinoid receptor 1	Homo sapiens (human)
response to nutrient	Cannabinoid receptor 1	Homo sapiens (human)
memory	Cannabinoid receptor 1	Homo sapiens (human)
positive regulation of neuron projection development	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of serotonin secretion	Cannabinoid receptor 1	Homo sapiens (human)
positive regulation of fever generation	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of fatty acid beta-oxidation	Cannabinoid receptor 1	Homo sapiens (human)
regulation of synaptic transmission, GABAergic	Cannabinoid receptor 1	Homo sapiens (human)
response to lipopolysaccharide	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of mast cell activation	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of dopamine secretion	Cannabinoid receptor 1	Homo sapiens (human)
response to nicotine	Cannabinoid receptor 1	Homo sapiens (human)
cannabinoid signaling pathway	Cannabinoid receptor 1	Homo sapiens (human)
response to cocaine	Cannabinoid receptor 1	Homo sapiens (human)
glucose homeostasis	Cannabinoid receptor 1	Homo sapiens (human)
positive regulation of apoptotic process	Cannabinoid receptor 1	Homo sapiens (human)
response to ethanol	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of action potential	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of blood pressure	Cannabinoid receptor 1	Homo sapiens (human)
positive regulation of blood pressure	Cannabinoid receptor 1	Homo sapiens (human)
regulation of insulin secretion	Cannabinoid receptor 1	Homo sapiens (human)
regulation of synaptic transmission, glutamatergic	Cannabinoid receptor 1	Homo sapiens (human)
maternal process involved in female pregnancy	Cannabinoid receptor 1	Homo sapiens (human)
regulation of feeding behavior	Cannabinoid receptor 1	Homo sapiens (human)
regulation of penile erection	Cannabinoid receptor 1	Homo sapiens (human)
retrograde trans-synaptic signaling by endocannabinoid	Cannabinoid receptor 1	Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentration	Cannabinoid receptor 1	Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmission	Cannabinoid receptor 1	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Cannabinoid receptor 1	Homo sapiens (human)
regulation of metabolic process	Cannabinoid receptor 1	Homo sapiens (human)
temperature homeostasis	D(1A) dopamine receptor	Homo sapiens (human)
conditioned taste aversion	D(1A) dopamine receptor	Homo sapiens (human)
behavioral fear response	D(1A) dopamine receptor	Homo sapiens (human)
regulation of protein phosphorylation	D(1A) dopamine receptor	Homo sapiens (human)
synaptic transmission, dopaminergic	D(1A) dopamine receptor	Homo sapiens (human)
response to amphetamine	D(1A) dopamine receptor	Homo sapiens (human)
protein import into nucleus	D(1A) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	D(1A) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	D(1A) dopamine receptor	Homo sapiens (human)
activation of adenylate cyclase activity	D(1A) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathway	D(1A) dopamine receptor	Homo sapiens (human)
synapse assembly	D(1A) dopamine receptor	Homo sapiens (human)
memory	D(1A) dopamine receptor	Homo sapiens (human)
mating behavior	D(1A) dopamine receptor	Homo sapiens (human)
grooming behavior	D(1A) dopamine receptor	Homo sapiens (human)
adult walking behavior	D(1A) dopamine receptor	Homo sapiens (human)
visual learning	D(1A) dopamine receptor	Homo sapiens (human)
response to xenobiotic stimulus	D(1A) dopamine receptor	Homo sapiens (human)
astrocyte development	D(1A) dopamine receptor	Homo sapiens (human)
dopamine transport	D(1A) dopamine receptor	Homo sapiens (human)
transmission of nerve impulse	D(1A) dopamine receptor	Homo sapiens (human)
neuronal action potential	D(1A) dopamine receptor	Homo sapiens (human)
dentate gyrus development	D(1A) dopamine receptor	Homo sapiens (human)
striatum development	D(1A) dopamine receptor	Homo sapiens (human)
cerebral cortex GABAergic interneuron migration	D(1A) dopamine receptor	Homo sapiens (human)
positive regulation of cell migration	D(1A) dopamine receptor	Homo sapiens (human)
peristalsis	D(1A) dopamine receptor	Homo sapiens (human)
operant conditioning	D(1A) dopamine receptor	Homo sapiens (human)
synaptic transmission, glutamatergic	D(1A) dopamine receptor	Homo sapiens (human)
regulation of dopamine metabolic process	D(1A) dopamine receptor	Homo sapiens (human)
vasodilation	D(1A) dopamine receptor	Homo sapiens (human)
dopamine metabolic process	D(1A) dopamine receptor	Homo sapiens (human)
maternal behavior	D(1A) dopamine receptor	Homo sapiens (human)
positive regulation of potassium ion transport	D(1A) dopamine receptor	Homo sapiens (human)
glucose import	D(1A) dopamine receptor	Homo sapiens (human)
habituation	D(1A) dopamine receptor	Homo sapiens (human)
sensitization	D(1A) dopamine receptor	Homo sapiens (human)
behavioral response to cocaine	D(1A) dopamine receptor	Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol	D(1A) dopamine receptor	Homo sapiens (human)
regulation of dopamine uptake involved in synaptic transmission	D(1A) dopamine receptor	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	D(1A) dopamine receptor	Homo sapiens (human)
prepulse inhibition	D(1A) dopamine receptor	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(1A) dopamine receptor	Homo sapiens (human)
long-term synaptic potentiation	D(1A) dopamine receptor	Homo sapiens (human)
long-term synaptic depression	D(1A) dopamine receptor	Homo sapiens (human)
cellular response to catecholamine stimulus	D(1A) dopamine receptor	Homo sapiens (human)
modification of postsynaptic structure	D(1A) dopamine receptor	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	D(1A) dopamine receptor	Homo sapiens (human)
positive regulation of neuron migration	D(1A) dopamine receptor	Homo sapiens (human)
positive regulation of MAPK cascade	D(1A) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	D(1A) dopamine receptor	Homo sapiens (human)
dopamine receptor signaling pathway	D(1A) dopamine receptor	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A7	Homo sapiens (human)
steroid biosynthetic process	Cytochrome P450 3A7	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A7	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A7	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A7	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A7	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A7	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A7	Homo sapiens (human)
behavioral fear response	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
intracellular calcium ion homeostasis	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
locomotory behavior	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
feeding behavior	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
cGMP-mediated signaling	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of nervous system process	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of appetite	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of corticotropin-releasing hormone secretion	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of fat cell differentiation	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of calcium-mediated signaling	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
release of sequestered calcium ion into cytosol	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
cellular response to organic substance	Caspase-1	Homo sapiens (human)
pattern recognition receptor signaling pathway	Caspase-1	Homo sapiens (human)
proteolysis	Caspase-1	Homo sapiens (human)
apoptotic process	Caspase-1	Homo sapiens (human)
signal transduction	Caspase-1	Homo sapiens (human)
osmosensory signaling pathway	Caspase-1	Homo sapiens (human)
protein autoprocessing	Caspase-1	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Caspase-1	Homo sapiens (human)
positive regulation of interleukin-18 production	Caspase-1	Homo sapiens (human)
defense response to bacterium	Caspase-1	Homo sapiens (human)
regulation of apoptotic process	Caspase-1	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Caspase-1	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	Caspase-1	Homo sapiens (human)
icosanoid biosynthetic process	Caspase-1	Homo sapiens (human)
regulation of inflammatory response	Caspase-1	Homo sapiens (human)
positive regulation of inflammatory response	Caspase-1	Homo sapiens (human)
protein maturation	Caspase-1	Homo sapiens (human)
defense response to virus	Caspase-1	Homo sapiens (human)
pyroptosis	Caspase-1	Homo sapiens (human)
cellular response to lipopolysaccharide	Caspase-1	Homo sapiens (human)
cellular response to mechanical stimulus	Caspase-1	Homo sapiens (human)
cellular response to type II interferon	Caspase-1	Homo sapiens (human)
cytokine precursor processing	Caspase-1	Homo sapiens (human)
signaling receptor ligand precursor processing	Caspase-1	Homo sapiens (human)
AIM2 inflammasome complex assembly	Caspase-1	Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathway	Caspase-1	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
response to amphetamine	Cannabinoid receptor 2	Homo sapiens (human)
inflammatory response	Cannabinoid receptor 2	Homo sapiens (human)
immune response	Cannabinoid receptor 2	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Cannabinoid receptor 2	Homo sapiens (human)
leukocyte chemotaxis	Cannabinoid receptor 2	Homo sapiens (human)
negative regulation of synaptic transmission, GABAergic	Cannabinoid receptor 2	Homo sapiens (human)
response to lipopolysaccharide	Cannabinoid receptor 2	Homo sapiens (human)
negative regulation of mast cell activation	Cannabinoid receptor 2	Homo sapiens (human)
cannabinoid signaling pathway	Cannabinoid receptor 2	Homo sapiens (human)
negative regulation of action potential	Cannabinoid receptor 2	Homo sapiens (human)
regulation of metabolic process	Cannabinoid receptor 2	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Cannabinoid receptor 2	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Mu-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
sensory perception	Mu-type opioid receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Mu-type opioid receptor	Homo sapiens (human)
sensory perception of pain	Mu-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
behavioral response to ethanol	Mu-type opioid receptor	Homo sapiens (human)
positive regulation of neurogenesis	Mu-type opioid receptor	Homo sapiens (human)
negative regulation of Wnt protein secretion	Mu-type opioid receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Mu-type opioid receptor	Homo sapiens (human)
calcium ion transmembrane transport	Mu-type opioid receptor	Homo sapiens (human)
cellular response to morphine	Mu-type opioid receptor	Homo sapiens (human)
regulation of cellular response to stress	Mu-type opioid receptor	Homo sapiens (human)
regulation of NMDA receptor activity	Mu-type opioid receptor	Homo sapiens (human)
neuropeptide signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
negative regulation of gene expression	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of cholesterol efflux	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
long-chain fatty acid transport	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of osteoblast differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of smooth muscle cell proliferation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of receptor signaling pathway via STAT	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of low-density lipoprotein receptor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of signaling receptor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of gene expression	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of BMP signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of MAP kinase activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of adiponectin secretion	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of miRNA transcription	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stress	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healing	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
placenta development	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
lipid metabolic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
signal transduction	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
response to nutrient	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
regulation of blood pressure	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of gene expression	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of gene expression	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
macrophage derived foam cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of cholesterol storage	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of lipid storage	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of sequestering of triglyceride	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of angiogenesis	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
monocyte differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
BMP signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
epithelial cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cellular response to insulin stimulus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
response to lipid	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
peroxisome proliferator activated receptor signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
glucose homeostasis	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
regulation of circadian rhythm	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
mRNA transcription by RNA polymerase II	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
lipoprotein transport	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of blood vessel endothelial cell migration	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
innate immune response	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cell fate commitment	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of fat cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of DNA-templated transcription	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of DNA-templated transcription	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
retinoic acid receptor signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cell maturation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
rhythmic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
white fat cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
lipid homeostasis	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of type II interferon-mediated signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of SMAD protein signal transduction	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
regulation of cholesterol transporter activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cellular response to hypoxia	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of mitochondrial fission	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
regulation of cellular response to insulin stimulus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of extracellular matrix assembly	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of miRNA transcription	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of miRNA transcription	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of adipose tissue development	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of vascular endothelial cell proliferation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of fatty acid metabolic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
fatty acid metabolic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of inflammatory response	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
hormone-mediated signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
immune response	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Delta-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
adult locomotory behavior	Delta-type opioid receptor	Homo sapiens (human)
negative regulation of gene expression	Delta-type opioid receptor	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Delta-type opioid receptor	Homo sapiens (human)
positive regulation of CREB transcription factor activity	Delta-type opioid receptor	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Delta-type opioid receptor	Homo sapiens (human)
response to nicotine	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
eating behavior	Delta-type opioid receptor	Homo sapiens (human)
regulation of mitochondrial membrane potential	Delta-type opioid receptor	Homo sapiens (human)
regulation of calcium ion transport	Delta-type opioid receptor	Homo sapiens (human)
cellular response to growth factor stimulus	Delta-type opioid receptor	Homo sapiens (human)
cellular response to hypoxia	Delta-type opioid receptor	Homo sapiens (human)
cellular response to toxic substance	Delta-type opioid receptor	Homo sapiens (human)
neuropeptide signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
immune response	Kappa-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
chemical synaptic transmission	Kappa-type opioid receptor	Homo sapiens (human)
sensory perception	Kappa-type opioid receptor	Homo sapiens (human)
locomotory behavior	Kappa-type opioid receptor	Homo sapiens (human)
sensory perception of pain	Kappa-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
response to insulin	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of dopamine secretion	Kappa-type opioid receptor	Homo sapiens (human)
negative regulation of luteinizing hormone secretion	Kappa-type opioid receptor	Homo sapiens (human)
response to nicotine	Kappa-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
maternal behavior	Kappa-type opioid receptor	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
L-lactate dehydrogenase activity	L-lactate dehydrogenase A chain	Homo sapiens (human)
protein binding	L-lactate dehydrogenase A chain	Homo sapiens (human)
identical protein binding	L-lactate dehydrogenase A chain	Homo sapiens (human)
cadherin binding	L-lactate dehydrogenase A chain	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 1A1	Homo sapiens (human)
iron ion binding	Cytochrome P450 1A1	Homo sapiens (human)
protein binding	Cytochrome P450 1A1	Homo sapiens (human)
arachidonic acid monooxygenase activity	Cytochrome P450 1A1	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 1A1	Homo sapiens (human)
oxidoreductase activity, acting on diphenols and related substances as donors	Cytochrome P450 1A1	Homo sapiens (human)
flavonoid 3'-monooxygenase activity	Cytochrome P450 1A1	Homo sapiens (human)
oxygen binding	Cytochrome P450 1A1	Homo sapiens (human)
enzyme binding	Cytochrome P450 1A1	Homo sapiens (human)
heme binding	Cytochrome P450 1A1	Homo sapiens (human)
Hsp70 protein binding	Cytochrome P450 1A1	Homo sapiens (human)
demethylase activity	Cytochrome P450 1A1	Homo sapiens (human)
Hsp90 protein binding	Cytochrome P450 1A1	Homo sapiens (human)
aromatase activity	Cytochrome P450 1A1	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 1A1	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 1A1	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 1A1	Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activity	Cytochrome P450 1A1	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Cytochrome P450 1A1	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 1A1	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 1A2	Homo sapiens (human)
iron ion binding	Cytochrome P450 1A2	Homo sapiens (human)
protein binding	Cytochrome P450 1A2	Homo sapiens (human)
electron transfer activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 1A2	Homo sapiens (human)
enzyme binding	Cytochrome P450 1A2	Homo sapiens (human)
heme binding	Cytochrome P450 1A2	Homo sapiens (human)
demethylase activity	Cytochrome P450 1A2	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 1A2	Homo sapiens (human)
aromatase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Cytochrome P450 1A2	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
receptor-receptor interaction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2A6	Homo sapiens (human)
coumarin 7-hydroxylase activity	Cytochrome P450 2A6	Homo sapiens (human)
enzyme binding	Cytochrome P450 2A6	Homo sapiens (human)
heme binding	Cytochrome P450 2A6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2A6	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2A6	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2B adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2B adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2B adrenergic receptor	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-alpha-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
heme binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-beta-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2B6	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A5	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A5	Homo sapiens (human)
protein binding	Cytochrome P450 3A5	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A5	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A5	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A5	Homo sapiens (human)
heme binding	Cytochrome P450 3A5	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A5	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A5	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A5	Homo sapiens (human)
cannabinoid receptor activity	Cannabinoid receptor 1	Homo sapiens (human)
protein binding	Cannabinoid receptor 1	Homo sapiens (human)
identical protein binding	Cannabinoid receptor 1	Homo sapiens (human)
G protein-coupled receptor activity	Cannabinoid receptor 1	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gs	D(1A) dopamine receptor	Homo sapiens (human)
G-protein alpha-subunit binding	D(1A) dopamine receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity	D(1A) dopamine receptor	Homo sapiens (human)
protein binding	D(1A) dopamine receptor	Homo sapiens (human)
heterotrimeric G-protein binding	D(1A) dopamine receptor	Homo sapiens (human)
dopamine binding	D(1A) dopamine receptor	Homo sapiens (human)
arrestin family protein binding	D(1A) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(1A) dopamine receptor	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A7	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A7	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A7	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A7	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A7	Homo sapiens (human)
heme binding	Cytochrome P450 3A7	Homo sapiens (human)
all-trans retinoic acid 18-hydroxylase activity	Cytochrome P450 3A7	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A7	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A7	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A7	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A7	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
endopeptidase activity	Caspase-1	Homo sapiens (human)
cysteine-type endopeptidase activity	Caspase-1	Homo sapiens (human)
protein binding	Caspase-1	Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic process	Caspase-1	Homo sapiens (human)
kinase binding	Caspase-1	Homo sapiens (human)
cytokine binding	Caspase-1	Homo sapiens (human)
identical protein binding	Caspase-1	Homo sapiens (human)
CARD domain binding	Caspase-1	Homo sapiens (human)
caspase binding	Caspase-1	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
protein binding	Cannabinoid receptor 2	Homo sapiens (human)
cannabinoid receptor activity	Cannabinoid receptor 2	Homo sapiens (human)
G-protein alpha-subunit binding	Mu-type opioid receptor	Homo sapiens (human)
G protein-coupled receptor activity	Mu-type opioid receptor	Homo sapiens (human)
beta-endorphin receptor activity	Mu-type opioid receptor	Homo sapiens (human)
voltage-gated calcium channel activity	Mu-type opioid receptor	Homo sapiens (human)
protein binding	Mu-type opioid receptor	Homo sapiens (human)
morphine receptor activity	Mu-type opioid receptor	Homo sapiens (human)
G-protein beta-subunit binding	Mu-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Mu-type opioid receptor	Homo sapiens (human)
transcription cis-regulatory region binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
transcription coregulator binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
nucleic acid binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
chromatin binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
double-stranded DNA binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA-binding transcription factor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
nuclear receptor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
prostaglandin receptor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
protein binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
zinc ion binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
enzyme binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
peptide binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
identical protein binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
sequence-specific DNA binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
nuclear retinoid X receptor binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
arachidonic acid binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA binding domain binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
LBD domain binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
alpha-actinin binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
R-SMAD binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
E-box binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
STAT family protein binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA-binding transcription factor binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
G protein-coupled opioid receptor activity	Delta-type opioid receptor	Homo sapiens (human)
protein binding	Delta-type opioid receptor	Homo sapiens (human)
receptor serine/threonine kinase binding	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled enkephalin receptor activity	Delta-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor activity	Kappa-type opioid receptor	Homo sapiens (human)
protein binding	Kappa-type opioid receptor	Homo sapiens (human)
receptor serine/threonine kinase binding	Kappa-type opioid receptor	Homo sapiens (human)
dynorphin receptor activity	Kappa-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Kappa-type opioid receptor	Homo sapiens (human)
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
N-acylsphingosine amidohydrolase activity	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
fatty acid amide hydrolase activity	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
N-(long-chain-acyl)ethanolamine deacylase activity	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
ceramidase activity	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
DNA-binding transcription factor binding	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 1B1	Homo sapiens (human)
iron ion binding	Cytochrome P450 1B1	Homo sapiens (human)
protein binding	Cytochrome P450 1B1	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 1B1	Homo sapiens (human)
heme binding	Cytochrome P450 1B1	Homo sapiens (human)
aromatase activity	Cytochrome P450 1B1	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 1B1	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Cytochrome P450 1B1	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen	Cytochrome P450 1B1	Homo sapiens (human)
protein binding	Sigma intracellular receptor 2	Homo sapiens (human)
oxysterol binding	Sigma intracellular receptor 2	Homo sapiens (human)
cholesterol binding	Sigma intracellular receptor 2	Homo sapiens (human)
transmembrane signaling receptor activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
extracellular ligand-gated monoatomic ion channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
voltage-gated calcium channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calcium channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
protein binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calmodulin binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
ATP binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
intracellularly gated calcium channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
chloride channel regulator activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
phosphatidylinositol binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
identical protein binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
metal ion binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
phosphoprotein binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
temperature-gated ion channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
G protein-coupled receptor activity	G-protein coupled receptor 55	Homo sapiens (human)
cannabinoid receptor activity	G-protein coupled receptor 55	Homo sapiens (human)
protein binding	Diacylglycerol lipase-alpha	Homo sapiens (human)
metal ion binding	Diacylglycerol lipase-alpha	Homo sapiens (human)
acylglycerol lipase activity	Diacylglycerol lipase-alpha	Homo sapiens (human)
lipoprotein lipase activity	Diacylglycerol lipase-alpha	Homo sapiens (human)
histamine receptor activity	Histamine H3 receptor	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Histamine H3 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	L-lactate dehydrogenase A chain	Homo sapiens (human)
cytosol	L-lactate dehydrogenase A chain	Homo sapiens (human)
membrane	L-lactate dehydrogenase A chain	Homo sapiens (human)
extracellular exosome	L-lactate dehydrogenase A chain	Homo sapiens (human)
oxidoreductase complex	L-lactate dehydrogenase A chain	Homo sapiens (human)
mitochondrion	L-lactate dehydrogenase A chain	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
mitochondrial inner membrane	Cytochrome P450 1A1	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 1A1	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A1	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2A6	Homo sapiens (human)
cytoplasmic microtubule	Cytochrome P450 2A6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2A6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2A6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytosol	Alpha-2B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2B adrenergic receptor	Homo sapiens (human)
cell surface	Alpha-2B adrenergic receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Alpha-2B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2B adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-2C adrenergic receptor	Homo sapiens (human)
endosome	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2B6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2B6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2B6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A5	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A5	Homo sapiens (human)
mitochondrial outer membrane	Cannabinoid receptor 1	Homo sapiens (human)
plasma membrane	Cannabinoid receptor 1	Homo sapiens (human)
actin cytoskeleton	Cannabinoid receptor 1	Homo sapiens (human)
growth cone	Cannabinoid receptor 1	Homo sapiens (human)
presynaptic membrane	Cannabinoid receptor 1	Homo sapiens (human)
membrane raft	Cannabinoid receptor 1	Homo sapiens (human)
glutamatergic synapse	Cannabinoid receptor 1	Homo sapiens (human)
GABA-ergic synapse	Cannabinoid receptor 1	Homo sapiens (human)
plasma membrane	Cannabinoid receptor 1	Homo sapiens (human)
cytoplasm	Cannabinoid receptor 1	Homo sapiens (human)
nucleus	D(1A) dopamine receptor	Homo sapiens (human)
endoplasmic reticulum membrane	D(1A) dopamine receptor	Homo sapiens (human)
plasma membrane	D(1A) dopamine receptor	Homo sapiens (human)
cilium	D(1A) dopamine receptor	Homo sapiens (human)
presynaptic membrane	D(1A) dopamine receptor	Homo sapiens (human)
dendritic spine	D(1A) dopamine receptor	Homo sapiens (human)
postsynaptic membrane	D(1A) dopamine receptor	Homo sapiens (human)
ciliary membrane	D(1A) dopamine receptor	Homo sapiens (human)
non-motile cilium	D(1A) dopamine receptor	Homo sapiens (human)
glutamatergic synapse	D(1A) dopamine receptor	Homo sapiens (human)
GABA-ergic synapse	D(1A) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor complex	D(1A) dopamine receptor	Homo sapiens (human)
plasma membrane	D(1A) dopamine receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A7	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
cytoplasm	Caspase-1	Homo sapiens (human)
cytosol	Caspase-1	Homo sapiens (human)
nucleolus	Caspase-1	Homo sapiens (human)
cytoplasm	Caspase-1	Homo sapiens (human)
cytosol	Caspase-1	Homo sapiens (human)
microtubule	Caspase-1	Homo sapiens (human)
plasma membrane	Caspase-1	Homo sapiens (human)
canonical inflammasome complex	Caspase-1	Homo sapiens (human)
NLRP1 inflammasome complex	Caspase-1	Homo sapiens (human)
NLRP3 inflammasome complex	Caspase-1	Homo sapiens (human)
AIM2 inflammasome complex	Caspase-1	Homo sapiens (human)
protein-containing complex	Caspase-1	Homo sapiens (human)
IPAF inflammasome complex	Caspase-1	Homo sapiens (human)
protease inhibitor complex	Caspase-1	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cannabinoid receptor 2	Homo sapiens (human)
dendrite	Cannabinoid receptor 2	Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membrane	Cannabinoid receptor 2	Homo sapiens (human)
perikaryon	Cannabinoid receptor 2	Homo sapiens (human)
endoplasmic reticulum	Cannabinoid receptor 2	Homo sapiens (human)
plasma membrane	Cannabinoid receptor 2	Homo sapiens (human)
cytoplasm	Cannabinoid receptor 2	Homo sapiens (human)
endosome	Mu-type opioid receptor	Homo sapiens (human)
endoplasmic reticulum	Mu-type opioid receptor	Homo sapiens (human)
Golgi apparatus	Mu-type opioid receptor	Homo sapiens (human)
plasma membrane	Mu-type opioid receptor	Homo sapiens (human)
axon	Mu-type opioid receptor	Homo sapiens (human)
dendrite	Mu-type opioid receptor	Homo sapiens (human)
perikaryon	Mu-type opioid receptor	Homo sapiens (human)
synapse	Mu-type opioid receptor	Homo sapiens (human)
plasma membrane	Mu-type opioid receptor	Homo sapiens (human)
neuron projection	Mu-type opioid receptor	Homo sapiens (human)
nucleus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
nucleus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
nucleoplasm	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cytosol	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
intracellular membrane-bounded organelle	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
RNA polymerase II transcription regulator complex	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
chromatin	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
receptor complex	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
plasma membrane	Delta-type opioid receptor	Homo sapiens (human)
synaptic vesicle membrane	Delta-type opioid receptor	Homo sapiens (human)
dendrite membrane	Delta-type opioid receptor	Homo sapiens (human)
presynaptic membrane	Delta-type opioid receptor	Homo sapiens (human)
axon terminus	Delta-type opioid receptor	Homo sapiens (human)
spine apparatus	Delta-type opioid receptor	Homo sapiens (human)
postsynaptic density membrane	Delta-type opioid receptor	Homo sapiens (human)
neuronal dense core vesicle	Delta-type opioid receptor	Homo sapiens (human)
plasma membrane	Delta-type opioid receptor	Homo sapiens (human)
neuron projection	Delta-type opioid receptor	Homo sapiens (human)
nucleoplasm	Kappa-type opioid receptor	Homo sapiens (human)
mitochondrion	Kappa-type opioid receptor	Homo sapiens (human)
cytosol	Kappa-type opioid receptor	Homo sapiens (human)
plasma membrane	Kappa-type opioid receptor	Homo sapiens (human)
membrane	Kappa-type opioid receptor	Homo sapiens (human)
sarcoplasmic reticulum	Kappa-type opioid receptor	Homo sapiens (human)
T-tubule	Kappa-type opioid receptor	Homo sapiens (human)
dendrite	Kappa-type opioid receptor	Homo sapiens (human)
synaptic vesicle membrane	Kappa-type opioid receptor	Homo sapiens (human)
presynaptic membrane	Kappa-type opioid receptor	Homo sapiens (human)
perikaryon	Kappa-type opioid receptor	Homo sapiens (human)
axon terminus	Kappa-type opioid receptor	Homo sapiens (human)
postsynaptic membrane	Kappa-type opioid receptor	Homo sapiens (human)
plasma membrane	Kappa-type opioid receptor	Homo sapiens (human)
neuron projection	Kappa-type opioid receptor	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
cytoplasm	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
lysosome	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
membrane	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
lysosomal lumen	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
extracellular exosome	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
mitochondrion	Cytochrome P450 1B1	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 1B1	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1B1	Homo sapiens (human)
endoplasmic reticulum	Sigma intracellular receptor 2	Homo sapiens (human)
lysosome	Sigma intracellular receptor 2	Homo sapiens (human)
endoplasmic reticulum	Sigma intracellular receptor 2	Homo sapiens (human)
rough endoplasmic reticulum	Sigma intracellular receptor 2	Homo sapiens (human)
plasma membrane	Sigma intracellular receptor 2	Homo sapiens (human)
rough endoplasmic reticulum membrane	Sigma intracellular receptor 2	Homo sapiens (human)
nuclear membrane	Sigma intracellular receptor 2	Homo sapiens (human)
plasma membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
external side of plasma membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
dendritic spine membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
neuronal cell body	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
postsynaptic membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
plasma membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
plasma membrane	G-protein coupled receptor 55	Homo sapiens (human)
plasma membrane	G-protein coupled receptor 55	Homo sapiens (human)
plasma membrane	Diacylglycerol lipase-alpha	Homo sapiens (human)
early endosome membrane	Diacylglycerol lipase-alpha	Homo sapiens (human)
dendrite membrane	Diacylglycerol lipase-alpha	Homo sapiens (human)
dendritic spine membrane	Diacylglycerol lipase-alpha	Homo sapiens (human)
varicosity	Diacylglycerol lipase-alpha	Homo sapiens (human)
postsynaptic density membrane	Diacylglycerol lipase-alpha	Homo sapiens (human)
dendrite membrane	Diacylglycerol lipase-alpha	Homo sapiens (human)
cytoplasm	Diacylglycerol lipase-alpha	Homo sapiens (human)
postsynaptic membrane	Diacylglycerol lipase-alpha	Homo sapiens (human)
plasma membrane	Histamine H3 receptor	Homo sapiens (human)
presynapse	Histamine H3 receptor	Homo sapiens (human)
plasma membrane	Histamine H3 receptor	Homo sapiens (human)
synapse	Histamine H3 receptor	Homo sapiens (human)
dendrite	Histamine H3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (366)

Assay ID	Title	Year	Journal	Article
AID1692729	Anti-seizure activity in Lennox-Gastaut patient assessed as median percent reduction in seizure frequency at 20 mg/kg administered daily for 14 weeks (Rvb = 17%)	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692668	Inhibition of D2 dopamine receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID132300	The difference between the preinjection and postinjection (60 min) temperatures in mice was evaluated at a dose 100 mg/kg	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Hashish: synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of delta 9-tetrahydrocannabinol.
AID1847167	Partial agonist activity at wild type CB2 receptor (unknown origin) expressed in HEK293T assessed as increase in picometer shifts of reflected light wavelengths in presence of JWH-133 by DMR assay relative to control	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1847162	Partial agonist activity at wild type CB2 receptor (unknown origin) expressed in HEK293T assessed as increase in picometer shifts of reflected light wavelengths by DMR assay	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1692675	Inhibition of D1 dopamine receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692712	Half-life in human at 10 mg/kg, po BID administered for 6 weeks measured weekly for 15 weeks by GC/MS analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692660	Inhibition of muscarinic acetylcholine receptor M2 (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1303157	Displacement of [3H]CP 55940 from human recombinant CB1 receptor expressed in CHO cell membranes at 10 uM after 120 mins by scintillation counting analysis	2016	ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4	Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.
AID482748	Displacement of [3H]CP-55940 from human cannabinoid CB1 receptor expressed in CHO cells	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	Emerging targets in osteoporosis disease modification.
AID1692731	Drug degradation in simulated gastric fluid at 40 mg incubated for 2 hrs by UPLC-MS analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1625146	Displacement of [3H]-CP55940 from recombinant human CB1 receptor expressed in Sf9 cell membranes co-expressing Galphai3beta1gamma2 measured after 90 mins by scintillation counting method	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1847133	Partial agonist activity at wild type CB2 receptor (unknown origin) expressed in HEK293T assessed as increase in ERK1/2 phosphorylation incubated for 7 mins in presence of JWH-133 by AlphaScreenSureFire method	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1303156	Therapeutic index, ratio of TC50 for rat hippocampal neurons to EC50 for protection against ammonium acetate induced toxicity in rat hippocampal neurons after 5 hrs by carboxyfluorescein diacetate based fluorimetric analysis	2016	ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4	Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.
AID1193125	Induction of rat TRPV3 expressed in HEK293 cells assessed as increase of Ca2+ level relative to ionomycin	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
AID1780730	Downregulation of IL-1beta mRNA expression in H2O2- stimulated human HaCaT cells at 10 uM incubated for 6 hrs by SPE based fluorescence amplification assay relative to control	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1692690	Critical aggregation concentration of compound by dynamic light scattering	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847171	Partial agonist activity at CBR2 V1133.32M mutant (unknown origin) expressed in HEK293T assessed as increase in picometer shifts of reflected light wavelengths in presence of JWH-133 by DMR assay	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1692709	Competitive inhibition of human recombinant CYP1B1 using 7-Ethoxyresorufin as substrate by Lineweaver-Burk plot analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847130	Partial agonist activity at CBR2 S2857.39L mutant (unknown origin) stably expressed in HEK293T assessed as decrease in forskolin induced cAMP level preincubated for 15 mins followed by forskolin addition incubated for 15 mins in presence of JWH-133 by HTR	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1660158	Inhibition of NLRP3 inflammasome activation in LPS-stimulated human THP1 cells assessed as reduction in IL-1beta secretion at 10 uM incubated for 1 hr followed by nigericin addition and measured after 1 hr by ELISA relative to control	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1692671	Inhibition of histamine H2 receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847127	Partial agonist activity at CBR2 S2857.39L mutant (unknown origin) stably expressed in HEK293T assessed as decrease in forskolin induced cAMP level preincubated for 15 mins followed by forskolin addition incubated for 15 mins in presence of JWH-133 by HTR	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1863994	Protective index, ratio of TD50 for toxicity in CD-1 seizure mouse model assessed as effect on motor coordination administered ip measured after 0.5 hrs for 3 mins by rotarod test to ED50 for antiseizure activity against ScPTZ-induced seizure in ip dosed
AID1681222	Antagonist activity at rat TRPV3 expressed in HEK293 cells assessed as inhibition of thymol-induced Ca2+ response preincubated for 5 mins followed by thymol addition by Fluo-4AM dye based fluorescence assay	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Cannabitwinol, a Dimeric Phytocannabinoid from Hemp,
AID1847168	Positive allosteric modulation of JWH-133-induced agonist activity at wild type CB2 receptor (unknown origin) stably expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP levels preincubated for 15 mins followed by forskolin addit	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1762670	Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability incubated for 24 hrs in presence of DHA by crystal violet dye based assay	2021	Bioorganic & medicinal chemistry, 06-01, Volume: 39	Cannabidiol-dihydroartemisinin conjugates for ameliorating neuroinflammation with reduced cytotoxicity.
AID1762668	Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability incubated for 24 hrs by crystal violet dye based assay	2021	Bioorganic & medicinal chemistry, 06-01, Volume: 39	Cannabidiol-dihydroartemisinin conjugates for ameliorating neuroinflammation with reduced cytotoxicity.
AID362542	Antibacterial activity against macrolide-resistant Staphylococcus aureus RN4220 after 18 hrs	2008	Journal of natural products, Aug, Volume: 71, Issue:8	Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID1780731	Inhibition of caspase-1 activity in H2O2-stimulated human HaCaT cells assessed as reduction in enzyme activity at 10 uM using YUAD-Pna as a substrate measured after 2 hrs by colorimetric assay relative to control	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1692658	Inhibition of PBR (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692685	Inhibition of histamine H3 receptor (unknown origin)	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1863986	Toxicity in CD-1 seizure mouse model assessed as effect on motor coordination administered ip measured after 1 hrs for 3 mins by rotarod test
AID1303162	Apparent permeability from apical to basolateral side in MDCK cells expressing MDR1	2016	ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4	Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.
AID1625162	Inhibition of [14C]-AEA uptake in rat RBL2H3 cells by scintillation counting method	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1692707	Competitive inhibition of human recombinant CYP1A1 using 7-Ethoxyresorufin as substrate by Lineweaver-Burk plot analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692697	Cmax in human plasma at 3.5 +/- 5.5 mg, INH	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1681229	Agonist activity at human TRPV1 stably transfected in HEK293 cells assessed as increase in calcium influx in presence of ionomycin by Fluo-4-AM dye based spectrofluorimetric method	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Cannabitwinol, a Dimeric Phytocannabinoid from Hemp,
AID1773264	Permeability of the compound at 100 ug/ml incubated for 18 hrs by PAMPA	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.
AID133447	Compound was evaluated for the maximum possible effect in tail-flick test in mice at dose 50 mg/kg; Not tested	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Hashish: synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of delta 9-tetrahydrocannabinol.
AID1660156	Inhibition of NLRP3 inflammasome activation in LPS-stimulated human THP1 cells assessed as reduction in IL-1beta secretion at 0.1 uM incubated for 1 hr followed by nigericin addition and measured after 1 hr by ELISA relative to control	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1692682	Inhibition of mu-type opioid receptor (unknown origin)	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847172	Partial agonist activity at CBR2 V1133.32M mutant (unknown origin) expressed in HEK293T assessed as increase in picometer shifts of reflected light wavelengths by DMR assay relative to control	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1193126	Induction of rat TRPV3 expressed in HEK293 cells assessed as increase of Ca2+ level	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
AID1847183	Partial agonist activity at CBR2 A2827.36M mutant (unknown origin) expressed in HEK293T assessed as increase in picometer shifts of reflected light wavelengths in presence of JWH-133 by DMR assay	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1847103	Partial agonist activity at wild type CB2 receptor (unknown origin) stably expressed in HEK293T assessed as decrease in forskolin induced cAMP level preincubated for 15 mins followed by forskolin addition incubated for 15 mins in presence of JWH-133 by HT	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1524907	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1692664	Inhibition of D3 dopamine receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692676	Inhibition of histamine H3 receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1681219	Antagonist activity at rat TRPV4 expressed in HEK293 cells assessed as inhibition of GSK1016790A-induced Ca2+ response preincubated for 5 mins followed by GSK1016790A addition by Fluo-4AM dye based fluorescence assay	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Cannabitwinol, a Dimeric Phytocannabinoid from Hemp,
AID1625155	Inhibition of MAGL in African green monkey COS cell homogenates at 50 uM using [3H]-arachidonoylglycerol as substrate measured after 20 mins by scintillation counting method relative to control	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1524901	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1780722	Cytoprotective activity against H2O2-induced oxidative stress in human HaCaT cells assessed as change in cellular ROS level at 10 uM incubated for 6 hrs followed by H2O2 stimulation measured after 24 hrs by DCF-DA dye based fluorescence analysis (Rvb = 8.	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1692679	Inhibition of alpha2C receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID362543	Antibacterial activity against tetracycline-resistant Staphylococcus aureus XU212 after 18 hrs	2008	Journal of natural products, Aug, Volume: 71, Issue:8	Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID1692726	Mixed type inhibition of human recombinant CYP3A7 expressed in baculovirus-infected insect cells using diltiazem as substrate incubated for 30 mins followed by NADPH-generating system addition by Michaelis-Menten plot analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692693	Cmax in human plasma at 14+/- 15 mg, po	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692722	Mixed type inhibition of human recombinant CYP2C19 using (S)-mephenytoin as substrate preincubated for 5 mins followed by NADPH-generating system addition measured after 40 mins by Lineweaver-Burk plot analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692727	Mixed type inhibition of CYP17 in Sprague-Dawley rat testis microsomes assessed as reduction in 17alpha-Hydroxylase activity in presence of NADPH-generating system incubated for 2 mins by Lineweaver-Burk plot analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID482749	Displacement of [3H]CP-55940 from human cannabinoid CB2 receptor expressed in CHO cells	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	Emerging targets in osteoporosis disease modification.
AID1625157	Inhibition of FAAH in rat brain membranes at 50 uM using [14C]-AEA as substrate measured after 30 mins by scintillation counting method relative to control	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1660161	Modulation of P2X7 receptor in nigericin-stimulated human THP1 cells assessed as intracellular potassium efflux at 10 uM incubated for 30 mins followed by 1 uM nigericin challenge and measured after 30 mins by Green-2 AM dye based flow cytometric analysis	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1692716	Elimination rate constant in human at 20 mg using aerosol spray measured for 6 weeks	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1863977	Antiseizure activity against electrical stimulus induced seizure in ip dosed CD-1 mouse model assessed as reduction in hindlimb tonic extension pretreated for 1 hr by maximal electroshock seizure test
AID1692674	Inhibition of kappa-type opioid receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1193113	Reduction of lecithin content in Niemann-Pick patient fibroblast at 30 uM	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
AID1692657	Inhibition of rat brain BZP at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847101	Partial agonist activity at wild type CB2 receptor (unknown origin) stably expressed in HEK293T assessed as decrease in forskolin induced cAMP level preincubated for 15 mins followed by forskolin addition incubated for 15 mins by HTRF assay relative to co	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1780737	Binding affinity to recombinant human caspase-1 assessed as association constant measured after 60 sec by SPR method	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1692672	Inhibition of 5-HT2C (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692684	Inhibition of D1 dopamine receptor (unknown origin)	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1660150	Cytotoxicity against human THP1 cells assessed as cell viability at 100 uM after 24 hrs by CellTiter-Glo luminescent cell viability assay relative to control	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1847165	Partial agonist activity at wild type CB2 receptor (unknown origin) expressed in HEK293T assessed as increase in picometer shifts of reflected light wavelengths by DMR assay relative to control	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1692659	Inhibition of alpha1D receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1524912	Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1692717	Elimination rate constant in human at 20 mg using nebulizer measured for 6 weeks	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1625156	Inhibition of FAAH in rat brain membranes using [14C]-AEA as substrate measured after 30 mins by scintillation counting method	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1692713	Apparent oral clearance in human at 5 to 20 mg using oromucosal-spray formulation by GC-MS analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID49491	Binding affinity for Cannabinoid receptor 1 by the ability to displace radiolabeled CP-55940 from purified rat forebrain synaptosomes	2002	Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24	Novel 1',1'-chain substituted Delta(8)-tetrahydrocannabinols.
AID1863998	Antiseizure activity against electrical stimulus induced seizure in ip dosed CD-1 mouse model assessed as normal behavior within 10 seconds after stimulation at 6 Hz and 44 mA for 3 secs pretreated for 1 hr by psychomotor seizure test
AID1127484	Selectivity ratio of Ki for human CB1 receptor to Ki for human CB2 receptor	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID260287	Displacement of [3H]HU243 from CB1 receptor in Sabra rat brain	2006	Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3	New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity.
AID1303151	Neuroprotective activity in rat hippocampal neurons assessed as protection against ethanol induced cell death by measuring neuronal viability after 5 hrs by carboxyfluorescein diacetate dye based fluorimetric analysis	2016	ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4	Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.
AID1692705	Elimination half-life in human at 10 mg, po using PTL401 formulation measured upto 24 hrs by LC-MS/MS assay	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847145	Partial agonist activity at CBR2 V361.35M mutant (unknown origin) expressed in HEK293T assessed as increase in ERK1/2 phosphorylation incubated for 7 mins in presence of JWH-133 by AlphaScreenSureFire method	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1762669	Antiinflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced nitric oxide production incubated for 24 hrs in presence of DHA by 2, 3-diaminonaphthalene based assay	2021	Bioorganic & medicinal chemistry, 06-01, Volume: 39	Cannabidiol-dihydroartemisinin conjugates for ameliorating neuroinflammation with reduced cytotoxicity.
AID362544	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 25923 after 18 hrs	2008	Journal of natural products, Aug, Volume: 71, Issue:8	Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID1780733	Anti-pyroptosis activity in human HaCaT cells assessed as reduction in H2O2-induced LDH production at 1 uM incubated for 6 hrs followed by H2O2 stimulation measured after 24 hrs by LDH assay relative to control	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1681217	Agonist activity at rat TRPA1 stably transfected in HEK293 cells assessed as increase in calcium influx in presence of allylisothiocyanate by Fluo-4-AM dye based spectrofluorimetric method	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Cannabitwinol, a Dimeric Phytocannabinoid from Hemp,
AID1692706	Elimination half-life in human at 10 mg using oromucosal-spray formulation measured upto 24 hrs by LC-MS/MS assay	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692689	Inhibition of delta-type opioid receptor receptor (unknown origin)	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1660155	Antiinflammatory activity in human THP1 cells assessed as reduction in LPS-induced IL-1beta secretion at 0.1 to 10 uM incubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID482746	Induction of bone formation in GPR55 knockout male mouse assessed as increase in tibia mass volume	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	Emerging targets in osteoporosis disease modification.
AID1692691	Protein binding in human plasma incubated for 20 to 24 hrs	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1780717	Effect on cell cycle distribution in human HaCaT cells assessed as accumulation of cells at S phase at 10 uM pretreated for 6 hrs followed by H2O2 challenge for 24 hrs by propidium iodide staining based flow cytometry analysis (Rvb= 28.1%)	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1847106	Partial agonist activity at CBR2 V1133.32M mutant (unknown origin) stably expressed in HEK293T assessed as decrease in forskolin induced cAMP level preincubated for 15 mins followed by forskolin addition incubated for 15 mins by HTRF assay	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1692695	Cmax in human plasma at 525 +/- 340 mg, po	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692635	Displacement of [3H] ketanserin from rat 5-HT2aR expressed in mouse NIH/3T3 cells incubated for 30 mins by liquid scintillation counting method	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692651	Inhibition of 5-HT2B (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID49852	Binding affinity for Cannabinoid receptor 2 by the ability to displace radiolabeled CP-55940 from mouse spleen synaptosomes	2002	Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24	Novel 1',1'-chain substituted Delta(8)-tetrahydrocannabinols.
AID362541	Antibacterial activity against methicillin-resistant Staphylococcus aureus SA1199B after 18 hrs	2008	Journal of natural products, Aug, Volume: 71, Issue:8	Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID1692728	Toxicity in pig assessed as mean arterial blood pressure drop at 50 mg/kg, iv administered for 15 mins by pulse oximetry relative to baseline	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692654	Inhibition of alpha1B receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847136	Partial agonist activity at wild type CB2 receptor (unknown origin) expressed in HEK293T assessed as increase in ERK1/2 phosphorylation incubated for 7 mins in presence of JWH-133 by AlphaScreenSureFire method relative to control	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1252767	Cytotoxicity against cdkn2a/TRPV1 doubly deficient PDGFB amplified mouse neurosphere glioma cells using bis-AAF-R110 as substrate at 10 uM preincubated for 24 hrs followed by substrate addition measured after 2 hrs by fluorescence analysis	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Wittig derivatization of sesquiterpenoid polygodial leads to cytostatic agents with activity against drug resistant cancer cells and capable of pyrrolylation of primary amines.
AID1681221	Agonist activity at rat TRPV4 stably transfected in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based spectrofluorimetric method relative to ionomycin	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Cannabitwinol, a Dimeric Phytocannabinoid from Hemp,
AID1780734	Anti-pyroptosis activity in human HaCaT cells assessed as reduction in H2O2-induced LDH production at 10 uM incubated for 6 hrs followed by H2O2 stimulation measured after 24 hrs by LDH assay relative to control	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1692636	Displacement of [3H]CP-55,940 from human CB1 receptor expressed in CHO cells incubated for 1 hr by liquid scintillation spectrometry	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1625150	Inhibition of recombinant human DAGLalpha expressed in COS7 cells using [14C]-oleoyl-2-arachidonoyl-glycerol as substrate measured after 20 mins by beta-counting method	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1847131	Partial agonist activity at wild type CB2 receptor (unknown origin) expressed in HEK293T assessed as increase in ERK1/2 phosphorylation incubated for 7 mins by AlphaScreenSureFire method	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID243998	Inhibitory potency against fatty acid amide hydrolase activity in mouse brain microsomes in presence of 58 uM anandamide at 160 uM	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
AID167511	Number of rabbits convulsed at 15 mg/kg, iv out of 7 rabbits tested	1982	Journal of medicinal chemistry, May, Volume: 25, Issue:5	Use of a potential rabbit model for structure--behavioral activity studies of cannabinoids.
AID1193123	Antiinflammatory activity in human glial cells assessed as reduction of LPS-induced nitrate expression at 1 uM	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
AID1252765	Cytotoxicity against cdkn2a-deficient EGFRvIII amplified mouse neurosphere glioma cells using bis-AAF-R110 as substrate at 10 uM preincubated for 24 hrs followed by substrate addition measured after 2 hrs by fluorescence analysis	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Wittig derivatization of sesquiterpenoid polygodial leads to cytostatic agents with activity against drug resistant cancer cells and capable of pyrrolylation of primary amines.
AID1660149	Cytotoxicity against human THP1 cells assessed as cell viability at 10 uM after 24 hrs by CellTiter-Glo luminescent cell viability assay relative to control	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1193120	Reduction of IL-1beta release in C57BL/6J mouse hippocampus inoculated with human amyloid beta (1 to 42) at 10 ug/kg, ip after 10 days by ELISA	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
AID1847152	Positive allosteric modulation of JWH-133-induced agonist activity at wild type CB2 receptor (unknown origin) stably expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP levels preincubated for 15 mins followed by forskolin addit	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1692719	Mixed type inhibition of human recombinant CYP2B6 expressed in baculovirus-infected insect cells using coumarin as substrate preincubated for 5 mins followed by NADPH-generating system addition by Lineweaver-Burk plot analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1524908	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1660159	Inhibition of NLRP3 inflammasome activation in LPS-stimulated human THP1 cells assessed as IL-1beta secretion at 10 uM incubated for 1 hr followed by nigericin addition and measured after 1 hr by ELISA relative to control	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1303161	Efflux ratio of permeability from basolateral to apical over apical to basolateral side in human Caco cells	2016	ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4	Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.
AID1692647	Inhibition of alpha1A receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID132313	The difference between the preinjection and postinjection (60 min) temperatures in mice was evaluated at a dose 75 mg/kg	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Hashish: synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of delta 9-tetrahydrocannabinol.
AID1780735	Antiapoptotic activity in human HaCaT cells assessed as reduction in apoptotic cells at 10 uM incubated for 6 hrs followed by H2O2 stimulation measured after 24 hrs by Mitotracker red/annexin V double staining based flow cytometry analysis (Rvb= 12.1%)	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1692663	Inhibition of beta-2 adrenergic receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1524904	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1847105	Partial agonist activity at wild type CB2 receptor (unknown origin) stably expressed in HEK293T assessed as decrease in forskolin induced cAMP level preincubated for 15 mins followed by forskolin addition incubated for 15 mins in presence of JWH-133 by HT	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1524905	Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID49325	Binding affinity towards cloned human Cannabinoid receptor 1	2000	Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12	A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors.
AID1692673	Inhibition of mu-type opioid receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID482752	Binding affinity to GPR55	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	Emerging targets in osteoporosis disease modification.
AID130160	Compound was evaluated for the percent antagonism in tail-flick test in mice at dose 40 mg/kg	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Hashish: synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of delta 9-tetrahydrocannabinol.
AID1692694	Tmax in human plasma at 525 +/- 340 mg, po	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1681230	Agonist activity at human TRPV1 stably transfected in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based spectrofluorimetric method relative to ionomycin	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Cannabitwinol, a Dimeric Phytocannabinoid from Hemp,
AID362546	Antibacterial activity against epidemic methicillin-resistant Staphylococcus aureus 16 after 18 hrs	2008	Journal of natural products, Aug, Volume: 71, Issue:8	Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID167517	Number of rabbits convulsed at 20 mg/kg, iv out of 6 rabbits tested	1982	Journal of medicinal chemistry, May, Volume: 25, Issue:5	Use of a potential rabbit model for structure--behavioral activity studies of cannabinoids.
AID1524911	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1692669	Inhibition of histamine H1 receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1681216	Antagonist activity at rat TRPA1 expressed in HEK293 cells assessed as inhibition of allylisothiocyanate-induced Ca2+ response preincubated for 5 mins followed by allylisothiocyanate addition by Fluo-4AM dye based fluorescence assay	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Cannabitwinol, a Dimeric Phytocannabinoid from Hemp,
AID1847553	Metabolic stability in rat liver microsomes assessed as intrinsic clearance	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.
AID1782665	Inhibition of human LDHB assessed as reduction in lactate production using pyruvate as substrate at 10 uM in presence of NADH by spectrophotometric analysis relative to control	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabichromene and Δ
AID1692661	Inhibition of 5-HT1B (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID260282	Ability to suppress nitric acid production by LPS-activated peritoneal macrophages form C57BL/6 mice at 4 ug/ml	2006	Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3	New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity.
AID1193122	Antiinflammatory activity in human glial cells assessed as reduction of LPS-induced iNOS expression at 1 uM	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
AID130147	Spontaneous activity in mice at a dose 40 mg/kg	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Hashish: synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of delta 9-tetrahydrocannabinol.
AID1681227	Agonist activity at rat TRPV2 stably transfected in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based spectrofluorimetric method relative to ionomycin	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Cannabitwinol, a Dimeric Phytocannabinoid from Hemp,
AID1681224	Agonist activity at rat TRPV3 stably transfected in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based spectrofluorimetric method relative to ionomycin	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Cannabitwinol, a Dimeric Phytocannabinoid from Hemp,
AID1681226	Agonist activity at rat TRPV2 stably transfected in HEK293 cells assessed as increase in calcium influx in presence of ionomycin by Fluo-4-AM dye based spectrofluorimetric method	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Cannabitwinol, a Dimeric Phytocannabinoid from Hemp,
AID1660148	Cytotoxicity against human THP1 cells assessed as cell viability at 1 uM after 24 hrs by CellTiter-Glo luminescent cell viability assay relative to control	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1524914	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1780736	Binding affinity to recombinant human caspase-1 assessed as dissociation constant measured after 90 sec by SPR method	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1625147	Displacement of [3H]-CP55940 from recombinant human CB2 receptor expressed in Sf9 cell membranes co-expressing Galphai3beta1gamma2 measured after 90 mins by scintillation counting method	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1847148	Partial agonist activity at CBR2 V361.35M mutant (unknown origin) expressed in HEK293T assessed as increase in ERK1/2 phosphorylation incubated for 7 mins in presence of JWH-133 by AlphaScreenSureFire method relative to control	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1830992	Inhibition of Beta-hematin in Plasmodium falciparum cells assessed as hemozoin formation after 32 hrs by NP40 detergent-mediated assay	2021	Bioorganic & medicinal chemistry letters, 12-15, Volume: 54	THC shows activity against cultured Plasmodium falciparum.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1681215	Antagonist activity at rat TRPM8 expressed in HEK293 cells assessed as inhibition of icilin-induced Ca2+ response preincubated for 5 mins followed by icilin addition by Fluo-4AM dye based fluorescence assay	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Cannabitwinol, a Dimeric Phytocannabinoid from Hemp,
AID482753	Antiosteoporotic activity in mouse assessed as decrease in bone resorption-associated serum CTX-1 level at 10 mg/kg administered 3 times a week for 8 weeks	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	Emerging targets in osteoporosis disease modification.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1649358	Anti-seizure activity in ip dosed CF1 mouse assessed as attenuation of psychomotor seizures at stimulus intensities of 42 mA at pre-treated at 1 hr before test by 6 Hz limbic seizure test relative to control
AID1847177	Partial agonist activity at CBR2 V361.35M mutant (unknown origin) expressed in HEK293T assessed as increase in picometer shifts of reflected light wavelengths in presence of JWH-133 by DMR assay	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1847117	Partial agonist activity at CBR2 V361.35M mutant (unknown origin) stably expressed in HEK293T assessed as decrease in forskolin induced cAMP level preincubated for 15 mins followed by forskolin addition incubated for 15 mins in presence of JWH-133 by HTRF	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1692653	Inhibition of DRD4 (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1657599	Agonist activity at GAL4-tagged PPARgamma (unknown origin) transiently expressed in HEK293T cells co-transfected with GAL4-tagged luc incubated for 6 hrs by dual luciferase reporter gene assay	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	The Oxidation of Phytocannabinoids to Cannabinoquinoids.
AID1692637	Displacement of [3H]CP-55,940 from human CB2 receptor expressed in CHO cells incubated for 1 hr by liquid scintillation spectrometry	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1193117	Reduction of iNOS protein expression in C57BL/6J mouse hippocampus inoculated with human amyloid beta (1 to 42) at 10 ug/kg, ip after 10 days by immunofluorescence analysis	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
AID1847158	Partial agonist activity at CBR2 S2857.39L mutant (unknown origin) expressed in HEK293T assessed as increase in ERK1/2 phosphorylation incubated for 7 mins in presence of JWH-133 by AlphaScreenSureFire method	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1692632	Inhibition of 5-HT7A (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID165405	Capability to induce convulsions in tetrahydrocannabinol-seizure susceptible (THC-SS) rabbit	1982	Journal of medicinal chemistry, May, Volume: 25, Issue:5	Use of a potential rabbit model for structure--behavioral activity studies of cannabinoids.
AID1692639	Inhibition of H4 receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692662	Inhibition of DAT (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1681228	Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as inhibition of capsaicin-induced Ca2+ response preincubated for 5 mins followed by capsaicin addition by Fluo-4AM dye based fluorescence assay	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Cannabitwinol, a Dimeric Phytocannabinoid from Hemp,
AID1773252	Cytotoxicity against human L02 cells assessed as cell viability at 50 uM incubated for 24 hrs by MTT assay	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.
AID1847109	Partial agonist activity at CBR2 V1133.32M mutant (unknown origin) stably expressed in HEK293T assessed as decrease in forskolin induced cAMP level preincubated for 15 mins followed by forskolin addition incubated for 15 mins by HTRF assay relative to con	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1780727	Antioxidant activity in human HaCaT cells assessed as reduction in mitochondria-derived ROS production by measuring mean fluorescence intensity at 10 uM preincubated for 6 hrs followed by H2O2 stimulation at 400 uM measured after 24 hrs by mitoSOX stainin	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID482146	Agonist activity at rat TRPA1 channel expressed in HEK293 cells assessed as increase in intracellular calcium influx	2010	Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14	Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
AID227699	Virtual screen for compounds with anticonvulsant activity	2003	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16	Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID1692634	Displacement of [3H]8-OH-DPAT from human 5-HT1a receptor expressed in CHO cells incubated for 30 mins by liquid scintillation counting method	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1780713	Cytotoxicity against human HaCaT cells assessed as cell viability at 1 to 10 uM incubated for 24 hrs followed by H2O2 stimulation by celltiter-glo assay relative to control	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1625163	Inhibition of [14C]-AEA uptake in rat RBL2H3 cells at 25 uM by scintillation counting method relative to control	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1692701	Apparent oral volume of distribution in human at 5 to 20 mg using oromucosal-spray formulation administered for 9 days cotreated with THC by GC-MS analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847169	Partial agonist activity at CBR2 V1133.32M mutant (unknown origin) expressed in HEK293T assessed as increase in picometer shifts of reflected light wavelengths by DMR assay	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1692714	Apparent oral clearance in human in fed state at 5 to 20 mg using oromucosal-spray formulation cotreated with THC by GC-MS analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID260280	Ability to suppress the production of reactive oxygen intermediates by activated RAW 264.7 macrophages from BALB/c mice at 4 ug/ml	2006	Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3	New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity.
AID1660154	Antiinflammatory activity in LPS-induced human THP1 cells assessed as IL-1beta secretion at 10 uM incubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA (Rvb = 51.2 pg/mL)	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1692710	Half-life in human at 20 mg, iv measured after 0.05 to 72 hrs by gas chromatograph mass spectrometry	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1863993	Protective index, ratio of TD50 for toxicity in CD-1 seizure mouse model assessed as effect on motor coordination administered ip measured after 0.5 hrs for 3 mins by rotarod test to ED50 for antiseizure activity against electrical stimulus induced seizur
AID1692628	Plasma concentration in human at 100 mg/kg, po	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692633	Inhibition of 5-HT2A (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847137	Partial agonist activity at CBR2 V1133.32M mutant (unknown origin) expressed in HEK293T assessed as increase in ERK1/2 phosphorylation incubated for 7 mins by AlphaScreenSureFire method	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID260283	Ability to suppress nitric acid production by LPS-activated peritoneal macrophages form C57BL/6 mice at 8 ug/ml	2006	Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3	New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity.
AID1780715	Effect on cell cycle distribution in human HaCaT cells assessed as <2N cells at 10 uM pretreated for 6 hrs followed by H2O2 challenge for 24 hrs by propidium iodide staining based flow cytometry analysis (Rvb= 1.88%)	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1864000	Protective index, ratio of TD50 for toxicity in CD-1 seizure mouse model assessed as effect on motor coordination administered ip measured after 0.5 hrs for 3 mins by rotarod test to ED50 for antiseizure activity against electrical stimulus induced seizur
AID1303152	Neuroprotective activity in rat hippocampal neurons assessed as protection against ethanol induced cell death after 5 hrs by propidium iodide staining based fluorimetric analysis	2016	ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4	Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.
AID260281	Ability to suppress the production of reactive oxygen intermediates by activated RAW 264.7 macrophages from BALB/c mice at 8 ug/ml	2006	Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3	New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity.
AID1692715	Elimination rate constant in human using oromucosal-spray measured for 6 weeks	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692700	Volume of distribution in human at 20 mg, iv measured after 0.05 to 72 hrs by gas chromatograph mass spectrometry	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1780732	Inhibition of IL-1beta expression in H2O2- stimulated human HaCaT cells at 10 uM incubated for 6 hrs followed by H2O2 stimulation measured after 24 hrs by ELISA relative to control	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1773260	Inhibition of equine serum BuChE using butyrylthiocholine iodide as substrate preincubated with enzyme for 20 mins followed by substrate addition and measured after 20 mins by Ellman's method	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.
AID1692678	Inhibition of sigma2 receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847139	Partial agonist activity at CBR2 V1133.32M mutant (unknown origin) expressed in HEK293T assessed as increase in ERK1/2 phosphorylation incubated for 7 mins in presence of JWH-133 by AlphaScreenSureFire method	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1782666	Non-competitive inhibition of human LDHA assessed as reduction in lactate production using pyruvate as substrate in presence of NADH by Lineweaver-Burk plot analysis	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabichromene and Δ
AID1692681	Inhibition of 5-HT2C (unknown origin)	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692677	Inhibition of alpha2B receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID482747	Induction of bone formation in GPR55 knockout male mouse assessed as increase in femur mass volume	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	Emerging targets in osteoporosis disease modification.
AID1193124	Antiinflammatory activity in human glial cells assessed as reduction of LPS-induced S100B expression at 1 uM	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
AID1692704	Elimination half-life in human at 20 mg using aerosol spray measured for 6 weeks	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1303155	Toxicity in rat hippocampal neurons assessed as neuronal viability after 5 hrs by carboxyfluorescein diacetate dye based fluorimetric analysis	2016	ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4	Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.
AID1692680	Inhibition of delta-type opioid receptor receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1193116	Reduction of sphingomyelin content in human fibroblast at 30 uM	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
AID1780725	Antioxidant activity in human HaCaT cells assessed as reduction in mean fluorescence intensity at 10 uM preincubated for 6 hrs followed by H2O2 stimulation at 600 uM measured after 24 hrs by cellROS staining based flow cytometry analysis	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID132309	The difference between the preinjection and postinjection (60 min) temperatures in mice was evaluated at a dose 50 mg/kg	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Hashish: synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of delta 9-tetrahydrocannabinol.
AID1863983	Antiseizure activity against ScPTZ-induced seizure in ip dosed CD-1 mouse model assessed as clonic seizures pretreated for 1 hr and measured after 30 mins by subcutaneous pentylenetetrazole test
AID1773253	Cytotoxicity against human HepG2 cells assessed as cell viability at 25 uM incubated for 24 hrs by MTT assay	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.
AID1692699	Bioavailability in dog at 180 mg	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1773266	Neuroprotective activity against H2O2-induced cytotoxicity in rat PC-12 cells assessed as cell viability at 25 uM pretreated for 3 hrs followed by H2O2 stimulation and measured after 24 hrs by MTT assay (Rvb = 38.7%)	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.
AID1692641	Inhibition of sigma 1 receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1303158	Displacement of [3H]WIN 55212-2 from human recombinant CB2 receptor expressed in CHO cell membranes at 10 uM after 120 mins by scintillation counting analysis	2016	ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4	Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.
AID1453018	Competitive inhibition of human liver microsomes CYP1A1 expressed in supersomes coexpressing NADPH-CYP reductase using 7-Ethoxyresorufin as substrate measured every 5 mins for 30 mins in presence of NADPH by fluorescence assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Inhibitors of cytochrome P450 (CYP) 1B1.
AID1692640	Inhibition of M3 receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692718	Non-competitive inhibition of human recombinant CYP2A6 expressed in baculovirus-infected insect cells using coumarin as substrate preincubated for 5 mins followed by NADPH-generating system addition by Lineweaver-Burk plot analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1625151	Inhibition of recombinant human DAGLalpha expressed in COS7 cells at 50 uM using [14C]-oleoyl-2-arachidonoyl-glycerol as substrate measured after 20 mins by beta-counting method relative to control	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1692646	Inhibition of 5-HT3 receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1193121	Antiinflammatory activity in Swiss OF1 mouse assessed as reduction of LPS-induced TNF-alpha expression at 10 mg/kg, ip by immunoblotting analysis	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
AID1773263	n-Octanol/PBS partition coefficient, logP of the compound incubated for 48 hrs at pH 7.4 by shake flask method	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.
AID1692724	Competitive inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using diltiazem as substrate incubated for 15 mins followed by NADPH-generating system addition by Michaelis-Menten plot analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1780719	Effect on cell cycle distribution in human HaCaT cells assessed as >4N cells at 10 uMpretreated for 6 hrs followed by H2O2 challenge for 24 hrs by propidium iodide staining based flow cytometry analysis (Rvb= 11.1%)	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1524913	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1830990	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54	2021	Bioorganic & medicinal chemistry letters, 12-15, Volume: 54	THC shows activity against cultured Plasmodium falciparum.
AID1590134	Reduction in anandamide production in athymic CD-1 nude mouse xenografted with human U87 cells at 0.5 mg/mouse/day administered peritumorally for 5 days by RP-HPLC with fluorimetric detection method relative to control	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Eicosanoid mediation of cannabinoid actions.
AID1847114	Partial agonist activity at CBR2 V361.35M mutant (unknown origin) stably expressed in HEK293T assessed as decrease in forskolin induced cAMP level preincubated for 15 mins followed by forskolin addition incubated for 15 mins in presence of JWH-133 by HTRF	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1847161	Partial agonist activity at CBR2 S2857.39L mutant (unknown origin) expressed in HEK293T assessed as increase in ERK1/2 phosphorylation incubated for 7 mins in presence of JWH-133 by AlphaScreenSureFire method relative to control	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1692702	Maximum drug concentration in Swiss mouse brain at 120 mg/kg, po measured up to 24 hrs by HPLC analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847140	Partial agonist activity at CBR2 V1133.32M mutant (unknown origin) expressed in HEK293T assessed as increase in ERK1/2 phosphorylation incubated for 7 mins by AlphaScreenSureFire method relative to control	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1863992	Protective index, ratio of TD50 for toxicity in CD-1 seizure mouse model assessed as effect on motor coordination administered ip measured after 0.5 hrs for 3 mins by rotarod test to ED50 for antiseizure activity against electrical stimulus induced seizur
AID1847155	Partial agonist activity at CBR2 A2827.36M mutant (unknown origin) expressed in HEK293T assessed as increase in ERK1/2 phosphorylation incubated for 7 mins in presence of JWH-133 by AlphaScreenSureFire method relative to control	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1524902	Cytotoxicity against human OVCAR cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1193119	Reduction of NO release in C57BL/6J mouse hippocampus inoculated with human amyloid beta (1 to 42) at 10 ug/kg, ip after 7 days	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
AID1660166	Modulation of intracellular calcium release in LPS-stimulated human THP1 cells at 1 to 100 uM incubated for 1 hr followed by nigericin challenge and measured after 1 hr by Fluo-3dye based flow cytometric analysis	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1830991	Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1	2021	Bioorganic & medicinal chemistry letters, 12-15, Volume: 54	THC shows activity against cultured Plasmodium falciparum.
AID1692723	Inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate incubated for 10 mins in presence of NADPH generating by Lineweaver-Burk plot analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1303160	Apparent permeability from apical to basolateral side in human Caco cells	2016	ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4	Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.
AID1847151	Partial agonist activity at CBR2 A2827.36M mutant (unknown origin) expressed in HEK293T assessed as increase in ERK1/2 phosphorylation incubated for 7 mins in presence of JWH-133 by AlphaScreenSureFire method	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1625161	Inhibition of recombinant human NAAA expressed in HEK293 cells at 50 uM using [14C]-N-palmitoylethanolamine as substrate measured after 30 mins by beta-counting method relative to control	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1847100	Partial agonist activity at wild type CB2 receptor (unknown origin) stably expressed in HEK293T assessed as decrease in forskolin induced cAMP level preincubated for 15 mins followed by forskolin addition incubated for 15 mins by HTRF assay	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1193114	Reduction of sphingomyelin content in Niemann-Pick patient fibroblast at 30 uM	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
AID1692687	Inhibition of sigma2 receptor (unknown origin)	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847186	Partial agonist activity at CBR2 A2827.36M mutant (unknown origin) expressed in HEK293T assessed as increase in picometer shifts of reflected light wavelengths in presence of JWH-133 by DMR assay relative to control	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1660160	Inhibition of TNF-alpha secretion in LPS-stimulated human THP1 cells assessed as TNF-alpha level at 10 uM incubated for 1 hr followed by nigericin addition and measured after 1 hr by ELISA (Rvb = 957.6 pg/mL)	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1649367	Toxicity in CF1 mouse assessed as induction of motor impairment during acute (1 hr) observation period by rotarod assay
AID1524903	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1847121	Partial agonist activity at CBR2 A2827.36M mutant (unknown origin) stably expressed in HEK293T assessed as decrease in forskolin induced cAMP level preincubated for 15 mins followed by forskolin addition incubated for 15 mins in presence of JWH-133 by HTR	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1863980	Anti-seizure activity against electrical stimulus induced seizure in ip dosed CD-1 mouse model assessed as normal behavior within 10 seconds after stimulation at 6 Hz and 32 mA for 3 secs pretreated for 1 hr by psychomotor seizure test
AID1692686	Inhibition of alpha2B receptor (unknown origin)	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847108	Partial agonist activity at CBR2 V1133.32M mutant (unknown origin) stably expressed in HEK293T assessed as decrease in forskolin induced cAMP level preincubated for 15 mins followed by forskolin addition incubated for 15 mins in presence of JWH-133 by HTR	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1847189	Partial agonist activity at CBR2 S2857.39L mutant (unknown origin) expressed in HEK293T assessed as increase in picometer shifts of reflected light wavelengths in presence of JWH-133 by DMR assay	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1780738	Binding affinity to recombinant human caspase-1 assessed as dissociation constant at equilibrium measured after 30 sec by SPR method	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1847192	Partial agonist activity at CBR2 S2857.39L mutant (unknown origin) expressed in HEK293T assessed as increase in picometer shifts of reflected light wavelengths in presence of JWH-133 by DMR assay relative to control	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1762667	Antiinflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced nitric oxide production incubated for 24 hrs by 2, 3-diaminonaphthalene based assay	2021	Bioorganic & medicinal chemistry, 06-01, Volume: 39	Cannabidiol-dihydroartemisinin conjugates for ameliorating neuroinflammation with reduced cytotoxicity.
AID1590133	Reduction in LTB4 production in athymic CD-1 nude mouse xenografted with human U87 cells at 0.5 mg/mouse/day administered peritumorally for 5 days by RP-HPLC analysis relative to control	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Eicosanoid mediation of cannabinoid actions.
AID260286	Ability to suppress TNFalpha production by LPS-activated peritoneal macrophages form C57BL/6 mice at 8 ug/ml	2006	Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3	New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity.
AID1692665	Inhibition of 5-HT1A (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID132306	The difference between the preinjection and postinjection (60 min) temperatures in mice was evaluated at a dose 40 mg/kg	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Hashish: synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of delta 9-tetrahydrocannabinol.
AID1847549	Metabolic stability in human liver microsomes assessed as half life	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.
AID1681225	Antagonist activity at rat TRPV2 expressed in HEK293 cells assessed as inhibition of LPC-induced Ca2+ response preincubated for 5 mins followed by LPC addition by Fluo-4AM dye based fluorescence assay	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Cannabitwinol, a Dimeric Phytocannabinoid from Hemp,
AID1847124	Partial agonist activity at CBR2 A2827.36M mutant (unknown origin) stably expressed in HEK293T assessed as decrease in forskolin induced cAMP level preincubated for 15 mins followed by forskolin addition incubated for 15 mins in presence of JWH-133 by HTR	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1127483	Binding affinity to human CB2 receptor	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID1692642	Inhibition of alpha2A receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692650	Inhibition of NET receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1660152	Antiinflammatory activity in LPS-induced human THP1 cells assessed as IL-1beta secretion at 0.1 uM incubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA (Rvb = 51.2 pg/mL)	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1692656	Inhibition of GABAA receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692692	Tmax in human plasma at 14+/- 15 mg, po	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1681220	Agonist activity at rat TRPV4 stably transfected in HEK293 cells assessed as increase in calcium influx in presence of ionomycin by Fluo-4-AM dye based spectrofluorimetric method	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Cannabitwinol, a Dimeric Phytocannabinoid from Hemp,
AID1681218	Agonist activity at rat TRPA1 stably transfected in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based spectrofluorimetric method relative to allylisothiocyanate	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Cannabitwinol, a Dimeric Phytocannabinoid from Hemp,
AID1692725	Competitive inhibition of human recombinant CYP3A5 expressed in baculovirus-infected insect cells using diltiazem as substrate incubated for 15 mins followed by NADPH-generating system addition by Michaelis-Menten plot analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847193	Negative allosteric modulation of JWH-133-induced agonist activity at wild type CB2 receptor (unknown origin) stably expressed in HEK293T cells assessed as decrease in cAMP levels preincubated for 15 mins followed by forskolin addition incubated for 15 mi	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1303153	Neuroprotective activity in rat hippocampal neurons assessed as protection against ammonium acetate induced cell death by measuring neuronal viability after 5 hrs by carboxyfluorescein diacetate dye based fluorimetric analysis	2016	ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4	Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.
AID1660157	Inhibition of NLRP3 inflammasome activation in LPS-stimulated human THP1 cells assessed as reduction in IL-1beta secretion at 1 uM incubated for 1 hr followed by nigericin addition and measured after 1 hr by ELISA relative to control	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1692721	Competitive inhibition of CYP2C11 in rat liver microsomes	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847551	Metabolic stability in mouse liver microsomes assessed as half life	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.
AID1780728	Antioxidant activity in human HaCaT cells assessed as reduction in mitochondria-derived ROS production by measuring mean fluorescence intensity at 10 uM preincubated for 6 hrs followed by H2O2 stimulation at 600 uM measured after 24 hrs by mitoSOX stainin	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1847552	Metabolic stability in human liver microsomes assessed as intrinsic clearance	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.
AID1692643	Inhibition of D5 dopamine receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1660164	Modulation of P2X7 receptor in LPS-stimulated human THP1 cells assessed as LPS-nigericin-stimulated intracellular potassium efflux at 1 uM incubated for 1 hr followed by nigericin challenge and measured after 1 hr by Green-2 AM dye based flow cytometric a	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1780723	Antioxidant activity in human HaCaT cells assessed as reduction in mean fluorescence intensity at 10 uM preincubated for 6 hrs followed by H2O2 stimulation at 200 uM measured after 24 hrs by cellROS staining based flow cytometry analysis	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1867003	Activation of Nrf2 transcriptional activity in human HaCaT-ARE-Luc cells at 1 to 25 uM incubated for 6 hrs by luciferase activity assay
AID1692683	Inhibition of kappa-type opioid receptor (unknown origin)	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1773262	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated with enzyme for 20 mins followed by substrate addition and measured after 20 mins by Ellman's method	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.
AID1692655	Inhibition of muscarinic acetylcholine receptor M5 (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1127482	Binding affinity to human CB1 receptor	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID1847142	Partial agonist activity at CBR2 V1133.32M mutant (unknown origin) expressed in HEK293T assessed as increase in ERK1/2 phosphorylation incubated for 7 mins in presence of JWH-133 by AlphaScreenSureFire method relative to control	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1692720	Competitive inhibition of CYP2C9 in pooled human liver microsomes using S-warfarin as substrate preincubated for 5 mins followed by NADPH-generating system addition and measured after 20 mins by Lineweaver-Burk plot analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1524910	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1692649	Inhibition of beta-3 adrenergic receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1780716	Effect on cell cycle distribution in human HaCaT cells assessed as 2N cells at 10 uM pretreated for 6 hrs followed by H2O2 challenge for 24 hrs by propidium iodide staining based flow cytometry analysis (Rvb= 17.9%)	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1692688	Inhibition of alpha2C receptor (unknown origin)	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID624672	Mechanism based inhibition of mouse cytochrome P450 CYP3A11	2005	Current drug metabolism, Oct, Volume: 6, Issue:5	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1692732	Drug degradation in simulated gastric fluid at 40 mg assessed as formation of d9-tetrahydrocannabinol incubated for 2 hrs by UPLC-MS analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1780724	Antioxidant activity in human HaCaT cells assessed as reduction in mean fluorescence intensity at 10 uM preincubated for 6 hrs followed by H2O2 stimulation at 400 uM measured after 24 hrs by cellROS staining based flow cytometry analysis	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1193127	Inhibition of human neutrophil migration incubated for 30 mins prior to fMLP challenge by boyden chamber assay	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
AID1303163	Efflux ratio of permeability from basolateral to apical over apical to basolateral side in MDCK cells expressing MDR1	2016	ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4	Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.
AID1193115	Reduction of lecithin content in human fibroblast at 30 uM	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
AID1626211	Binding affinity to human serum albumin at 40 uM by surface plasmon resonance method	2016	Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14	Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.
AID1847180	Partial agonist activity at CBR2 V361.35M mutant (unknown origin) expressed in HEK293T assessed as increase in picometer shifts of reflected light wavelengths in presence of JWH-133 by DMR assay relative to control	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1692696	Tmax in human plasma at 3.5 +/- 5.5 mg, INH	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1303159	Kinetic aqueous solubility of the compound at pH 7.4	2016	ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4	Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.
AID1303164	Displacement of [3H]-HU-243 from CB1 receptor in Sabra rat brain synaptosomes after 90 mins	2016	ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4	Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.
AID1692703	Cmax in mouse brain at 10 mg/kg, sc measured after 1 to 3 hrs by HPLC analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847164	Partial agonist activity at wild type CB2 receptor (unknown origin) expressed in HEK293T assessed as increase in picometer shifts of reflected light wavelengths in presence of JWH-133 by DMR assay	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1773259	Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM incubated for 2 hrs by microplate reader method	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.
AID1847134	Partial agonist activity at wild type CB2 receptor (unknown origin) expressed in HEK293T assessed as increase in ERK1/2 phosphorylation incubated for 7 mins by AlphaScreenSureFire method relative to control	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1692698	Bioavailability in human at 3.5 +/- 5.5 mg, INH measured after 0.05 to 72 hrs by gas chromatograph mass spectrometry	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1660147	Cytotoxicity against human THP1 cells assessed as cell viability at 0.1 uM after 24 hrs by CellTiter-Glo luminescent cell viability assay relative to control	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1780721	Cytoprotective activity against H2O2-induced oxidative stress in human HaCaT cells assessed as change in cellular ROS level at 1 uM incubated for 6 hrs followed by H2O2 stimulation measured after 24 hrs by DCF-DA dye based fluorescence analysis (Rvb = 8.2	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1692666	Inhibition of 5-HT5A (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847111	Partial agonist activity at CBR2 V1133.32M mutant (unknown origin) stably expressed in HEK293T assessed as decrease in forskolin induced cAMP level preincubated for 15 mins followed by forskolin addition incubated for 15 mins in presence of JWH-133 by HTR	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID362545	Antibacterial activity against epidemic methicillin-resistant Staphylococcus aureus 15 after 18 hrs	2008	Journal of natural products, Aug, Volume: 71, Issue:8	Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID1692652	Inhibition of 5-HT6 (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1660163	Modulation of P2X7 receptor in nigericin-stimulated human THP1 cells assessed as intracellular potassium efflux at 10 uM incubated for 30 mins followed by 10 uM nigericin challenge and measured after 30 mins by Green-2 AM dye based flow cytometric analysi	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1660153	Antiinflammatory activity in LPS-induced human THP1 cells assessed as IL-1beta secretion at 1 uM incubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA (Rvb = 51.2 pg/mL)	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1692670	Inhibition of SERT (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1625153	Inhibition of MAGL in African green monkey COS cell homogenates using [3H]-arachidonoylglycerol as substrate measured after 20 mins by scintillation counting method	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1692644	Inhibition of 5-HT1E receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1780718	Effect on cell cycle distribution in human HaCaT cells assessed as 4N cells at 10 uM pretreated for 6 hrs followed by H2O2 challenge for 24 hrs by propidium iodide staining based flow cytometry analysis (Rvb= 41.0%)	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1626212	Binding affinity to PDEA modified AGP (unknown origin) at 40 uM by surface plasmon resonance method	2016	Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14	Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.
AID1660165	Modulation of P2X7 receptor in LPS-stimulated human THP1 cells assessed as LPS-nigericin-stimulated intracellular potassium efflux at 10 uM incubated for 1 hr followed by nigericin challenge and measured after 1 hr by Green-2 AM dye based flow cytometric	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1625159	Inhibition of recombinant human NAAA expressed in HEK293 cells using [14C]-N-palmitoylethanolamine as substrate measured after 30 mins by beta-counting method	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1681223	Agonist activity at rat TRPV3 stably transfected in HEK293 cells assessed as increase in calcium influx in presence of ionomycin by Fluo-4-AM dye based spectrofluorimetric method	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Cannabitwinol, a Dimeric Phytocannabinoid from Hemp,
AID1660151	Cytotoxicity against human THP1 cells assessed as cell viability at 0.1 to 100 uM after 24 hrs in presence of LPS by CellTiter-Glo luminescent cell viability assay relative to control	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1780726	Antioxidant activity in human HaCaT cells assessed as reduction in mitochondria-derived ROS production by measuring mean fluorescence intensity at 10 uM preincubated for 6 hrs followed by H2O2 stimulation at 200 uM measured after 24 hrs by mitoSOX stainin	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1692730	Drug conversion in artificial gastric juice assessed as formation of d9-tetrahydrocannabinol at 250 ug incubated for 20 hrs by GC-MS analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1847174	Partial agonist activity at CBR2 V1133.32M mutant (unknown origin) expressed in HEK293T assessed as increase in picometer shifts of reflected light wavelengths in presence of JWH-133 by DMR assay relative to control	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID482754	Antiosteoporotic activity in mouse assessed as increase in bone volume at 10 mg/kg administered 3 times a week for 8 weeks	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	Emerging targets in osteoporosis disease modification.
AID1780714	Cytoprotective activity against H2O2-induced oxidative stress in human HaCaT cells assessed as increase in cell viability at 10 uM incubated for 24 hrs followed by H2O2 stimulation by celltiter-glo assay relative to control	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1847550	Metabolic stability in rat liver microsomes assessed as half life	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.
AID1692708	Competitive inhibition of human recombinant CYP1A2 using 7-Ethoxyresorufin as substrate by Lineweaver-Burk plot analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID49851	Binding affinity towards cloned human cannabinoid receptor 2	2000	Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12	A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors.
AID1303154	Neuroprotective activity in rat hippocampal neurons assessed as protection against ammonium acetate induced cell death after 5 hrs by propidium iodide staining based fluorimetric analysis	2016	ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4	Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.
AID1524906	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1692645	Inhibition of beta1 adrenergic receptor (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1692711	Half-life in human at 20 mg via smoking measured after 0.05 to 72 hrs by gas chromatograph mass spectrometry	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1660162	Modulation of P2X7 receptor in nigericin-stimulated human THP1 cells assessed as intracellular potassium efflux at 10 uM incubated for 30 mins followed by 5 uM nigericin challenge and measured after 30 mins by Green-2 AM dye based flow cytometric analysis	2020	Journal of natural products, 06-26, Volume: 83, Issue:6	Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes.
AID1780729	Downregulation of caspase-1 mRNA expression in H2O2- stimulated human HaCaT cells at 10 uM incubated for 6 hrs by SPE based fluorescence amplification assay relative to control	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1524915	Inhibition of Wnt/beta-catenin signaling pathway in human HepG2 cells assessed as reduction in TCF-dependent beta-catenin mediated transcription incubated for 24 hrs by Topflash reporter assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1692667	Inhibition of muscarinic acetylcholine receptor M1 (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1780720	Effect on cell cycle distribution in human HaCaT cells assessed as accumulation of cells in G2-M phase at 10 uM pretreated for 6 hrs followed by H2O2 challenge for 24 hrs by propidium iodide staining based flow cytometry analysis relative to control	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1β Axis.
AID1193118	Reduction of IL-1beta protein expression in C57BL/6J mouse hippocampus inoculated with human amyloid beta (1 to 42) at 10 ug/kg, ip after 10 days by immunofluorescence analysis	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
AID1617308	Anticonvulsant activity against hyperthermia-induced seizure in ip administered Scn1aRX/+ mouse model of Dravet syndrome assessed as effective dose causing increase in generalized tonic-clonic seizure temperature threshold measured by RET-3 rectal probe	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID133446	Compound was evaluated for the maximum possible effect in tail-flick test in mice at dose 40 mg/kg	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Hashish: synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of delta 9-tetrahydrocannabinol.
AID1847554	Metabolic stability in mouse liver microsomes assessed as intrinsic clearance	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.
AID1692638	Inhibition of muscarinic acetylcholine receptor M4 (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1252763	Cytotoxicity against cdkn2a-deficient mouse neurosphere glioma cells at 10 uM after 24 hrs	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Wittig derivatization of sesquiterpenoid polygodial leads to cytostatic agents with activity against drug resistant cancer cells and capable of pyrrolylation of primary amines.
AID1524909	Cytotoxicity against human OVCAR cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1692648	Inhibition of 5-HT1D (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1346701	Human CB1 receptor (Cannabinoid receptors)	2015	British journal of pharmacology, Oct, Volume: 172, Issue:20	Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor.
AID1345070	Human GPR55 (GPR18, GPR55 and GPR119)	2010	Pharmacological reviews, Dec, Volume: 62, Issue:4	International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.
AID1345070	Human GPR55 (GPR18, GPR55 and GPR119)	2007	British journal of pharmacology, Dec, Volume: 152, Issue:7	The orphan receptor GPR55 is a novel cannabinoid receptor.
AID1346561	Human TRPV2 (Transient Receptor Potential channels)	2008	The Journal of neuroscience : the official journal of the Society for Neuroscience, Jun-11, Volume: 28, Issue:24	TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons.
AID1346564	Rat TRPV2 (Transient Receptor Potential channels)	2008	The Journal of neuroscience : the official journal of the Society for Neuroscience, Jun-11, Volume: 28, Issue:24	TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons.
AID1346814	Human GPR18 (GPR18, GPR55 and GPR119)	2012	British journal of pharmacology, Apr, Volume: 165, Issue:8	Δ(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells.
AID1347414	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1802031	FABP1 Fluorescent Ligand Displacement Assay from Article 10.1021/acs.biochem.6b00446: \\FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.\\	2016	Biochemistry, 09-20, Volume: 55, Issue:37	FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	205 (6.45)	18.7374
1990's	62 (1.95)	18.2507
2000's	203 (6.39)	29.6817
2010's	1091 (34.33)	24.3611
2020's	1617 (50.88)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	321 (9.79%)	5.53%
Reviews	624 (19.03%)	6.00%
Case Studies	73 (2.23%)	4.05%
Observational	40 (1.22%)	0.25%
Other	2,221 (67.73%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (260)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Safety and Efficacy of Cannabidiol (CBD) for Symptoms of Post-Traumatic Stress Disorder (PTSD) in Adults Using Liquid StructureTM Formulation (NantheiaTM ATL5). [NCT05269459]	Phase 2	180 participants (Anticipated)	Interventional	2022-12-01	Recruiting
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of CBD TPM Capsules in Adults for Use in the Reduction of Insomnia Severity [NCT05840822]	Phase 3	540 participants (Anticipated)	Interventional	2023-06-30	Not yet recruiting
Effects of Cannabidiol in Alcohol Use Disorder [NCT03252756]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2019-09-01	Completed
Cannabidiol as Treatment Intervention for Opioid Relapse [NCT01311778]	Phase 1	18 participants (Actual)	Interventional	2010-02-28	Completed
Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial [NCT05822362]	Phase 2	236 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Tolerability and Efficacy of Hemp-Derived CBD for the Treatment of Alcohol Use Disorder [NCT04873453]	Phase 2	45 participants (Actual)	Interventional	2021-08-30	Completed
Randomized Placebo-controlled Trial to Determine the Biological Signature of Cannabidiol as a Treatment for Social Anxiety Disorder (R61) [NCT05571592]	Phase 2	60 participants (Anticipated)	Interventional	2023-01-26	Recruiting
Placebo-Controlled, Triple-Blind, Randomized Crossover Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD) [NCT02759185]	Phase 2	80 participants (Actual)	Interventional	2017-01-02	Completed
An Open-label Extension Trial to Investigate the Long-term Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome [NCT04252586]	Phase 3	21 participants (Actual)	Interventional	2020-02-28	Terminated(stopped due to Study was terminated due to COVID-19 pandemic and recruitment challenges in the parent study (GWND18064 - NCT03848832).)
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Crossover, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients [NCT04056442]	Phase 2	28 participants (Anticipated)	Interventional	2019-07-07	Recruiting
A Randomized Placebo-controlled Trial of Cannabidiol to Treat Severe Behavioral Problems in Children and Adolescents With Intellectual Disability [NCT04821856]	Phase 2	140 participants (Anticipated)	Interventional	2021-05-11	Recruiting
A Pilot Human Laboratory Study of Cannabidiol in Alcohol Use Disorder [NCT03904849]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2019-10-01	Withdrawn(stopped due to This study was intended to produce pilot data for a center grant component that will no longer be conducted.)
Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder [NCT03102918]	Phase 1	10 participants (Actual)	Interventional	2016-02-20	Completed
University of Alabama at Birmingham (UAB) Adult CBD Program [NCT02700412]	Phase 1	80 participants (Actual)	Interventional	2015-04-30	Completed
Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease [NCT02392780]	Phase 2	10 participants (Anticipated)	Interventional	2015-04-30	Not yet recruiting
The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol [NCT03164512]	Phase 1	19 participants (Actual)	Interventional	2018-06-01	Completed
Mechanisms of Cannabidiol (CBD) in Persons With Multiple Sclerosis (MS): the Role of Sleep and Pain Phenotype [NCT05269628]	Phase 2	166 participants (Anticipated)	Interventional	2022-03-25	Recruiting
Cannabidiol Modulation of ∆-9-THC's Psychotomimetic Effects in Healthy Humans [NCT01180374]	Early Phase 1	27 participants (Actual)	Interventional	2010-02-01	Completed
The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children [NCT02815540]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2017-02-16	Terminated(stopped due to Investigator no longer at institution, and difficult recruitment; study will not resume)
The Role of the Endocannabinoid System in Sweet Taste Intensity and Liking [NCT02112292]		10 participants (Actual)	Interventional	2014-04-30	Completed
Effects of Cannabidiol and Tetrahydrocannabinol on the Microbiome, Endocannabinoids, and Neuroinflammation in HIV [NCT05514899]	Phase 2	100 participants (Anticipated)	Interventional	2023-07-15	Recruiting
Cannabidiol Effects on Learning and Anxiety [NCT05283382]	Early Phase 1	160 participants (Anticipated)	Interventional	2024-02-01	Not yet recruiting
Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study [NCT02083874]	Phase 2	5 participants (Anticipated)	Interventional	2014-03-31	Active, not recruiting
Phase I, Single Center, Open-label Study of Cannabidiol in Patients With Heart Failure in AHA/ACC Stages A-C [NCT03634189]	Phase 1	20 participants (Anticipated)	Interventional	2021-03-01	Not yet recruiting
Effectiveness of Cannabidiol vs. Narcotics for Post Operative Pain Control in Elective Shoulder Arthroscopic Surgery [NCT05240755]	Early Phase 1	50 participants (Anticipated)	Interventional	2022-07-01	Recruiting
Impact of Cannabidiol-Rich Hemp Extract Oil on Reconsolidation Disruption of Naturalistic Interoceptive Aversive Memory in Humans [NCT04726475]	Phase 1/Phase 2	96 participants (Anticipated)	Interventional	2022-01-31	Recruiting
Shifting Brain Excitation-Inhibition Balance Through the Endocannabinoid System in Men With Autism Spectrum Disorder (ASD) and in Healthy Controls [NCT03537950]		38 participants (Actual)	Interventional	2016-08-22	Active, not recruiting
Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis [NCT03883360]	Phase 2	0 participants (Actual)	Interventional	2050-01-31	Withdrawn(stopped due to not funded)
Topical Cannabidiol (CBD) for the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Randomized Placebo-Controlled Pilot Trial [NCT05388058]	Phase 2	30 participants (Actual)	Interventional	2022-06-09	Active, not recruiting
PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product [NCT03984565]	Phase 2	56 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
Cannabidiol as an Adjunctive to Prolonged Exposure for the Treatment of PTSD [NCT03518801]	Phase 2	136 participants (Anticipated)	Interventional	2019-03-01	Recruiting
Physician Expanded Access to Investigational New Drug Cannabidiol for the Treatment of Drug Resistant Epilepsy [NCT02461706]		0 participants	Expanded Access		No longer available
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of [NCT03196934]		0 participants	Expanded Access		Available
CBD Treatment in Hand Osteoarthritis and Psoriatic Arthritis. A Randomized, Double-blind Placebo Controlled Study [NCT03693833]	Phase 2	136 participants (Actual)	Interventional	2018-11-28	Completed
Interaction Between Cannabidiol, Meal Ingestion, and Liver Function [NCT04971837]		26 participants (Actual)	Interventional	2021-05-20	Completed
Randomized Double-Blind, Placebo-Controlled Parallel Multi-Center Study to Assess the Efficacy of Cannabidiol (BRCX014) Combined With Standard-Of-Care Treatment in Subjects With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies [NCT03607643]	Phase 1/Phase 2	160 participants (Anticipated)	Interventional	2019-01-15	Not yet recruiting
Observational, Prospective, Multicenter Study of Epidyolex® (Cannabidiol CBD 100 mg/ml) Oral Solution, as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) [NCT05485831]		70 participants (Anticipated)	Observational	2024-03-01	Not yet recruiting
A Four-week, Multicentre, Double-blinded, Randomised, Active- and Placebo- Controlled, Parallel-group Trial Investigating Efficacy and Safety of Cannabidiol in Acute, Early-stage Schizophrenic Patients [NCT02088060]	Phase 2	150 participants (Anticipated)	Interventional	2014-03-31	Active, not recruiting
Cannabidiol for the Treatment of Pediatric Epilepsy (Expanded Access/Compassionate Use Protocol) [NCT02556008]		0 participants	Expanded Access		No longer available
A 2-part Study to Investigate the Dose-ranging Pharmacokinetics and Tolerability, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With [NCT02286986]	Phase 1	26 participants (Actual)	Interventional	2014-09-18	Completed
An Open Label Extension Study to Investigate the Safety of Cannabidiol (GWP42003-P; CBD) in Children and Adults With Inadequately Controlled Dravet or Lennox-Gastaut Syndromes. [NCT02224573]	Phase 3	681 participants (Actual)	Interventional	2015-06-11	Completed
[NCT02255292]	Phase 2	60 participants (Anticipated)	Interventional	2014-11-30	Not yet recruiting
Alcohol Use Disorder and Cannabis: Testing Novel Harm Reduction Strategies [NCT05613608]	Phase 2/Phase 3	180 participants (Anticipated)	Interventional	2023-04-30	Recruiting
A Phase 2, Open-label, Dose-finding Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients With Treatment-Resistant Childhood Absence Seizures [NCT03336242]	Phase 2	20 participants (Actual)	Interventional	2017-12-29	Terminated(stopped due to More patients in Cohort 1 than Cohort 2 demonstrated a clinically meaningful reduction of seizure count. Given this, enrollment of Cohort 3 was discontinued.)
Effects of Cannabidiol (CBD) Oral Solution in Patients Undergoing Bilateral Total Knee Arthroplasty: a Randomized, Controlled, Parallel, Triple Blind, Pilot Study [NCT04749628]	Phase 4	36 participants (Anticipated)	Interventional	2022-11-02	Recruiting
A Randomized Placebo-Controlled Evaluation of the Safety of Oral Cannabidiol in a Clinically Relevant Model of Opioid Withdrawal [NCT04238754]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2020-11-01	Completed
Randomized, Double Blind, Placebo-Controlled Trial to Evaluate the Safety and Tolerability of Cannabidiol (CBD) in Moderate to Severe Rheumatoid Arthritis [NCT04911127]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2021-10-05	Recruiting
A Double-blind, Randomized Placebo-controlled Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epileptic Crisis in Children and Adolescents [NCT02783092]	Phase 3	126 participants (Anticipated)	Interventional	2019-01-09	Active, not recruiting
Enhancing Recovery in Early Schizophrenia - a Multi-center, Two-arm, Double-blind, Randomized Phase II Trial Investigating Cannabidiol vs. Placebo as an add-on to an Individualized Antipsychotic Treatment [NCT02926859]	Phase 2	180 participants (Anticipated)	Interventional	2017-04-08	Recruiting
Open-label Pilot Study to Assess the Efficacy and Safety of Cannabidiol Oral Solution as an Adjunctive Treatment for Children and Young Adults With Rare Disease-associated Severe Epilepsy [NCT05803434]	Phase 2	30 participants (Anticipated)	Interventional	2023-06-01	Not yet recruiting
Cannabidiol for Reducing Drinking in Alcohol Use Disorder and Modifying the Effects of Alcohol on the Brain and the Liver: a Phase 2 Clinical Trial.-The CARAMEL Study [NCT05159830]	Phase 2	76 participants (Anticipated)	Interventional	2023-09-01	Not yet recruiting
Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study [NCT03549819]	Phase 3	50 participants (Anticipated)	Interventional	2021-12-15	Recruiting
Cannabidiol (CBD) in Patients With Mild to Moderate Symptoms of Coronavirus 2019: A Randomized, Double-blind, Placebo-controlled Clinical Trial [NCT04467918]	Phase 2/Phase 3	100 participants (Anticipated)	Interventional	2020-07-06	Active, not recruiting
Effects of D-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Human Episodic Memory Function [NCT02291562]		20 participants (Actual)	Interventional	2014-07-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults With Fragile X Syndrome - RECONNECT [NCT04977986]	Phase 3	204 participants (Anticipated)	Interventional	2021-09-13	Recruiting
Pilot Trial of Cannabidiol (CBD) for Sleep Problems in People With HIV [NCT05097651]	Phase 2	16 participants (Anticipated)	Interventional	2023-04-01	Recruiting
Processing of Salient Emotional Stimuli as a Function of Tetrahydrocannabinol (THC) and Cannabidiol (CBD) [NCT02291536]		20 participants (Actual)	Interventional	2014-02-28	Completed
Hemp-derived Cannabidiol for the Treatment of Cannabis Use Disorder: A Double-blind Placebo-controlled Randomized Trial [NCT06107062]	Phase 2	165 participants (Anticipated)	Interventional	2024-03-01	Not yet recruiting
Exploring the Effects of Acute Cannabidiol Administration on Blood Alcohol Level and Intoxication in Adult Human Subjects [NCT06105138]		36 participants (Actual)	Interventional	2021-03-09	Completed
Oral Cannabidiol Capsule Usage as an Adjunct Therapy for Crohn's Disease: a Randomized, Placebo-controlled Study [NCT03467620]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2018-07-31	Withdrawn(stopped due to Inadequate funding)
A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol (CBD; GWP42003-P) in Infants With Infantile Spasms Following an Initial Open-label Pilot Study [NCT02954887]	Phase 3	9 participants (Actual)	Interventional	2017-05-12	Completed
A Single-arm, Open-label Feasibility Pilot of Cannabidiol as an Adjunct to Sublingual Buprenorphine on Cue-induced Cravings Among Individuals With Opioid Use Disorder [NCT04192370]	Phase 2	8 participants (Actual)	Interventional	2020-08-03	Completed
Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids on the Endocannabinoid System and Brain Function [NCT02492074]	Phase 1	60 participants (Anticipated)	Interventional	2020-06-30	Not yet recruiting
Extended Use of Cannabidiol for the Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation [NCT02478424]	Phase 2	10 participants (Anticipated)	Interventional	2015-07-31	Not yet recruiting
Neuroimaging and CBD for Opiod Use Disorder [NCT04567784]	Phase 2	160 participants (Anticipated)	Interventional	2020-11-12	Recruiting
Crossover Trial of Cannabidiol (CBD) Versus Placebo for Psychiatric Presentations in Adults With Autism Spectrum Disorder [NCT05015439]	Phase 1	40 participants (Anticipated)	Interventional	2023-04-20	Recruiting
Cannabidiol Effects on Chronic Periodontitis: Monocentric, Randomized, Interventional and Placebo-controlled Study [NCT05498012]	Phase 1/Phase 2	90 participants (Actual)	Interventional	2020-11-05	Completed
A Randomized, Controlled Trial of Cannabis in Bipolar Disorder Patients and Healthy Volunteers Evaluating Cognition and Endocannabinoid Levels [NCT04231643]	Early Phase 1	144 participants (Anticipated)	Interventional	2021-09-01	Recruiting
Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids on the Endocannabinoid System, Cognition and Neuronal Oscillations [NCT02487381]	Phase 1	60 participants (Anticipated)	Interventional	2015-04-30	Completed
A Randomized, Double Blind, Placebo-controlled Crossover Study of Tolerability and Efficacy of Cannabidiol (CBD) on Tremor in Parkinson's Disease [NCT02818777]	Phase 2	13 participants (Actual)	Interventional	2016-10-31	Completed
A Double-blind, Randomized, Placebo-controlled Clinical Trial of Adjunctive Cannabidiol for Bipolar Depression [NCT03310593]	Phase 2/Phase 3	36 participants (Actual)	Interventional	2017-11-01	Terminated(stopped due to It was interrupted due to the coronavirus pandemic outbreak.)
Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study With Approved Antipsychotics in Vivo [NCT02051387]	Phase 1	74 participants (Actual)	Interventional	2013-01-31	Completed
Modulation of ∆9-tetrahydrocannabinol Acute Psychoactive Effects by Ranging Doses of Cannabidiol in Healthy, Occasional Cannabis Users: a Controlled, Triple Blind, Randomized, Cross-over Study [NCT06099379]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2023-11-15	Not yet recruiting
Do Adolescents and Adults Differ in Their Acute Subjective, Behavioural and Neural Responses to Cannabis, With and Without Cannabidiol? [NCT04851392]		48 participants (Actual)	Interventional	2019-03-11	Completed
A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Carpal Tunnel Syndrome [NCT06108349]	Phase 2	20 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
An Open-Label Exploratory Investigation of Cognitive Outcomes With Cannabidiol Oral Solution (EPIDIOLEX®; GWP42003-P) [NCT04133480]	Phase 4	0 participants (Actual)	Interventional	2020-10-31	Withdrawn(stopped due to The decision to withdraw the study was based on pandemic-related concerns of conducting a Phase IV study requiring multiple clinic visits when medication is commercially available. The study was withdrawn before any participants were recruited.)
Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder: A Pilot Study [NCT05132699]	Phase 1/Phase 2	22 participants (Actual)	Interventional	2022-04-04	Completed
Sublingual Cannabidiol for Anxiety [NCT02548559]	Phase 2	97 participants (Anticipated)	Interventional	2018-08-14	Recruiting
Sublingual Cannabidiol Oil Extract for Prevention of Postoperative Nausea and Vomiting in Elective Gynaecological Patients at the University Hospital of the West Indies (UHWI) [NCT06137027]	Early Phase 1	120 participants (Anticipated)	Interventional	2023-09-21	Recruiting
Sex Differences in the Interface Between Cannabis Use and Stress Among Emerging Adults [NCT05885542]	Phase 1/Phase 2	148 participants (Anticipated)	Interventional	2023-11-01	Recruiting
Cannabidiol as a New Treatment for Cocaine Addiction [NCT02559167]	Phase 2	79 participants (Actual)	Interventional	2016-07-01	Completed
Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain [NCT03891264]	Phase 4	7 participants (Actual)	Interventional	2019-11-13	Terminated(stopped due to Funding obtained to do a larger placebo-controlled trial)
A Double-Blind, Crossover Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism [NCT04517799]	Phase 2/Phase 3	42 participants (Actual)	Interventional	2020-06-01	Active, not recruiting
Characterization of the Analgesic Effects of Oral CBD in Healthy, Normal Volunteers [NCT02751359]	Phase 1/Phase 2	18 participants (Actual)	Interventional	2016-07-31	Completed
Prospective Evaluation of Cannabidiol (CBD) on Anxiety: A Pilot Study [NCT04267679]	Phase 2	0 participants (Actual)	Interventional	2020-03-01	Withdrawn(stopped due to Stopped due to COVID-19 pandemic.)
Cannabidiol (CBD) for the Management of Emergency Dental Pain [NCT04642404]	Phase 1/Phase 2	64 participants (Actual)	Interventional	2021-03-01	Completed
A Phase 2, Double-blind, Randomized, Placebo-controlled Pharmacokinetic Trial in 2 Parallel Groups to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and GWP42003-P in Patients With Epilepsy [NCT02607891]	Phase 2	35 participants (Actual)	Interventional	2016-11-09	Completed
An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Participants With Tuberous Sclerosis Complex (Age 1 Month to < 2 Years of Age), Dravet Syndrome (1 Year to < 2 Yea [NCT04485104]	Phase 3	27 participants (Anticipated)	Interventional	2021-05-19	Recruiting
Randomized, Double-blind Phase II Study of a Single Dose of Cannabidiol (CBD) for Acute Anticipatory Anxiety in Advanced Breast Cancer [NCT04482244]	Phase 2	50 participants (Anticipated)	Interventional	2022-01-19	Recruiting
Impact of CardiolRx on Myocardial Recovery in Acute Myocarditis. A Double-blind, Placebo-controlled Trial [NCT05180240]	Phase 2	100 participants (Anticipated)	Interventional	2022-06-22	Recruiting
Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee [NCT04992624]	Phase 2	200 participants (Anticipated)	Interventional	2022-02-22	Recruiting
A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome [NCT03848832]	Phase 3	29 participants (Actual)	Interventional	2019-07-29	Terminated(stopped due to The study was terminated due to enrollment challenges and the COVID-19 pandemic.)
An Open-Label, Randomized, Single-Dose, Two-Sequence, Two-Treatment, Four-Period, Crossover Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience. [NCT02325011]	Phase 1	14 participants (Actual)	Interventional	2014-11-30	Completed
Surgery With Alternative Pain Management (SWAP): Analgesic Effects of Cannabidiol for Simple Tooth Extractions in Dental Patients [NCT04271917]	Phase 3	68 participants (Actual)	Interventional	2020-02-24	Completed
Epidiolex® For The Treatment Of Anxiety Comorbidity in Refractory Pediatric Epilepsy [NCT05324449]	Phase 4	20 participants (Anticipated)	Interventional	2022-04-05	Recruiting
The Effects of Topical Cannabidiol Cream on Post-exercise Recovery [NCT05044936]	Early Phase 1	0 participants (Actual)	Interventional	2023-05-15	Withdrawn(stopped due to The researchers were not able to acquire funding to initiate the study. Also, the study was not approved by the local IRB which requested a FDA new drug application.)
The Effect of Medical Cannabidiol on Lean Body Mass in Patients Receiving Oxaliplatin or Paclitaxel Based Chemotherapy [NCT04585841]	Phase 1	32 participants (Actual)	Interventional	2020-12-01	Completed
Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia [NCT00588731]	Phase 2	41 participants (Actual)	Interventional	2009-02-28	Completed
Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES). [NCT04721691]	Phase 1	34 participants (Anticipated)	Interventional	2021-03-10	Recruiting
CBD Cannabis Extract: Pharmacokinetic Studies [NCT04280289]	Early Phase 1	10 participants (Anticipated)	Interventional	2020-12-01	Not yet recruiting
An Exploratory, Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder [NCT04745026]	Phase 2	160 participants (Anticipated)	Interventional	2021-05-31	Active, not recruiting
A Randomised Controlled Trial of Cannabidiol (CBD) for the Treatment of Alcohol Withdrawal [NCT04205682]	Early Phase 1	52 participants (Anticipated)	Interventional	2020-01-31	Not yet recruiting
Evaluation of the Antipsychotic Efficacy of the Phytocannabinoid Cannabidiol in Treating Acute Schizophrenic Psychosis. A Double-Blind, Controlled Clinical Trial [NCT00628290]	Phase 2	42 participants (Anticipated)	Interventional	2002-10-31	Completed
A Phase 2, Double-blind, Randomized, Placebo-controlled Pharmacokinetic Trial in 2 Parallel Groups to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and GWP42003-P in Patients With Epilepsy [NCT02607904]	Phase 2	30 participants (Actual)	Interventional	2016-12-15	Completed
Evaluation of Cannabidiol for Reduction of Brain Neuroinflammation [NCT05066308]	Phase 2	80 participants (Anticipated)	Interventional	2022-01-04	Recruiting
A Prospective Multi-Center Single-Arm Clinical Trial on Cognitive Effect of Cannabidiol (CBD-OS®) on Dravet Syndrome and Lennox-Gastaut Syndrome [NCT04611438]	Phase 3	107 participants (Anticipated)	Interventional	2020-03-30	Recruiting
Safety and Efficacy of Oral Cannabidiol for GVHD Prophylaxis in Allogeneic Stem Cell Transplantation [NCT01385124]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2012-09-30	Recruiting
Exploring the Mechanisms Underlying the Analgesic Properties of Cannabidiol Using Magnetic Resonance Spectroscopy [NCT04044729]	Early Phase 1	52 participants (Anticipated)	Interventional	2020-03-16	Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Multiple Crossover N-of-1 Study Design of the Use of Medicinal Cannabis Oil-Based Extracts for Symptom Management in Cancer Patients [NCT03948074]	Phase 2	150 participants (Anticipated)	Interventional	2021-02-01	Recruiting
Sex Differences in Neural Response to Cannabidiol [NCT04777643]	Early Phase 1	19 participants (Actual)	Interventional	2022-06-07	Completed
A Controlled-Dose Study Using A One Time Low Dose Cannabidiol Tablet For The Treatment of Mild to Moderate Musculoskeletal Pain [NCT04193631]	Phase 1	16 participants (Actual)	Interventional	2019-12-07	Completed
Physiological and Appetitive Effects of Four Weeks of 60 mg/Day CBD Supplementation in an Adult Population [NCT05774574]		30 participants (Anticipated)	Interventional	2023-01-20	Recruiting
A Phase IIa/b, Randomised, Double-blind, Placebo-controlled, Single-site, Parallel Group Clinical Trial to Examine Cannabidiol (CBD) as a Pharmacological Treatment for Cannabis Dependence. [NCT02044809]	Phase 2	82 participants (Actual)	Interventional	2014-03-31	Completed
A Randomized, Open-Label Trial on the Effects of Cannabidiol Isolate on Menstrual-Related Symptoms [NCT05679830]	Phase 2	33 participants (Actual)	Interventional	2020-09-23	Completed
Use of Cannabidiol for the Treatment of Inflammatory Bowel Disease [NCT01037322]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2010-01-31	Completed
Effectiveness of a Combined Therapy With Paravertebral Oxygen-ozone Injections and Topical Patch Containing Cannabidiol and β-Caryophyllene for Treatment of Neck Pain: a Prospective, Randomized, Controlled Trial. [NCT06099171]	Phase 3	52 participants (Anticipated)	Interventional	2024-02-01	Not yet recruiting
A Phase 4, Interventional, Multicenter, Open-Label, Single-Arm Study to Assess Behavioral and Other Co-occurring Outcomes Following Treatment With EPID(I/Y)OLEX as Add-on Therapy in Participants (Aged 1 to 65 Years Old) With Seizures Associated With Tuber [NCT05864846]	Phase 4	75 participants (Anticipated)	Interventional	2023-06-29	Recruiting
Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome: A Phase II Trial [NCT04447846]	Phase 2	11 participants (Actual)	Interventional	2019-10-14	Completed
Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use [NCT04105231]	Phase 2	130 participants (Anticipated)	Interventional	2021-06-01	Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome [NCT02844933]	Phase 2	7 participants (Actual)	Interventional	2018-05-09	Terminated(stopped due to Insys Therapeutics filed Chapter 11 and terminated all studies.)
Cannabidiol Treatment for Severe and Critical COVID-19 Pulmonary Infection [NCT04731116]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2021-01-10	Recruiting
The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial [NCT04613102]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2020-08-01	Withdrawn(stopped due to The study protocol should to be updated (major updates), following the second Health Canada review /requests. The study has been withdrawn form the REB review and will not be performed at SickKids.)
Comparative Analysis of the Effectiveness of the Use of Nimesulide and CBD Oil in Patients With Pain in the Preauricular Region Due to the Pain-dysfunctional Syndrome of the Temporomandibular Joint. [NCT04609748]	Phase 2	30 participants (Anticipated)	Interventional	2021-01-27	Recruiting
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study, Evaluating the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution in Subjects With Social Anxiety Disorder [NCT05600114]	Phase 2	225 participants (Anticipated)	Interventional	2022-10-27	Active, not recruiting
A Phase I/II, Randomized, Double-blind, Placebo-controlled, Single-center Study of the Effects of Cannabidiol (CBD) on Opioid Plasma Levels in Participants With Chronic Radiculopathic Pain Syndromes Maintained on Chronic Opioid Therapy (COT) [NCT04760613]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2022-02-03	Completed
A Phase II, Blinded, Randomised, Placebo Controlled Clinical Trial to Determine the Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis [NCT05942911]	Phase 2	128 participants (Anticipated)	Interventional	2023-11-22	Recruiting
The Effects of Topical Cannabidiol on Paramedian Forehead Flap Scar Healing: A Split Scar Study [NCT05650697]	Early Phase 1	10 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
A Multicenter, Open-Label, Flexible Dose Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients With Treatment-Resistant Childhood Absence Seizures [NCT03355300]	Phase 2	11 participants (Actual)	Interventional	2018-02-20	Terminated(stopped due to Insys Therapeutics filed Chapter 11 and terminated all studies.)
Investigation of the Pharmacokinetic Profile of CBD [NCT05023070]	Phase 1	24 participants (Anticipated)	Interventional	2021-07-22	Active, not recruiting
Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder [NCT05457465]	Phase 2	25 participants (Anticipated)	Interventional	2023-06-01	Recruiting
Effects of Cannabidiol (CBD) on the Brain [NCT04831294]		15 participants (Actual)	Interventional	2021-07-15	Active, not recruiting
Evaluation of Potential Central Glucoregulatory Compounds to Treat/Ameliorate the Symptoms of Schizophrenia: a Proof-of-concept Study in Healthy Volunteers. [NCT00916201]	Phase 1	86 participants (Anticipated)	Interventional	2020-06-30	Not yet recruiting
A Randomised Controlled Phase II Trial of Temozolomide With or Without Cannabinoids in Patients With Recurrent Glioblastoma [NCT05629702]	Phase 2	234 participants (Anticipated)	Interventional	2023-02-03	Recruiting
CBD-induced Biomarkers of Inflammation Reduction in People Living With HIV at the Single Cell Level [NCT05209867]	Phase 4	4 participants (Actual)	Interventional	2022-05-01	Completed
Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation in Patients With Severe Alcohol Use Disorder: A Phase II Trial [NCT05860699]	Phase 2	210 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
Chronic Effects of Effective Oral Cannabidiol Delivery on 24-hour Ambulatory Blood Pressure and Vascular Outcomes in Treated and Untreated Hypertension: A Randomized, Placebo-controlled and Crossover Study [NCT05346562]	Phase 1	70 participants (Actual)	Interventional	2022-04-08	Completed
Influence of Cannabidiol on Glucose Tolerance and The Gut Microbiota [NCT05285449]		30 participants (Actual)	Interventional	2022-02-09	Active, not recruiting
Effects of Cannabidiol on Memory Reconsolidation and Trauma-Related Symptoms: A Randomized Clinical Trial [NCT05892276]		120 participants (Anticipated)	Interventional	2024-08-31	Suspended(stopped due to The UT IRB determined that CBD oil is being used as a drug as defined by the FDA. Therefore, an IND must be obtained for the use of CBD oil in this research study in accordance with FDA regulations, 21 CFR 312.)
Open-Label, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome [NCT05149898]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2020-03-03	Completed
Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia [NCT02932605]		32 participants (Actual)	Interventional	2017-11-03	Completed
Comparative Randomized Clinical Trial of the Efficacy of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment and APOE ε4 Carriers [NCT05022186]	Phase 4	90 participants (Anticipated)	Interventional	2021-04-01	Recruiting
Effect of Local Cannabidiol on Clinical and Inflammatory Outcomes in Periodontal Maintenance Patients. [NCT05646459]	Phase 1	0 participants (Actual)	Interventional	2019-06-30	Withdrawn(stopped due to Study was unable to obtain IRB approval because CBD was not legal in Nebraska at that time.)
A Randomised, Partially-blind, Placebo-controlled, Pilot, Dose-ranging Study To Assess The Effect Of Cannabidiol (CBD) On Liver Fat Levels In Subjects With Fatty Liver Disease. [NCT01284634]	Phase 2	25 participants (Actual)	Interventional	2011-05-03	Completed
Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus [NCT05490511]	Phase 1	72 participants (Anticipated)	Interventional	2022-10-31	Recruiting
A Randomized, Double-blind, Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients [NCT05753007]	Phase 2	36 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder [NCT03787628]	Phase 2	60 participants (Anticipated)	Interventional	2022-05-19	Recruiting
A Randomized Controlled Pilot Study of the Use of Cannabidiol in the Management of Endometriosis Pain [NCT04527003]	Phase 3	36 participants (Anticipated)	Interventional	2020-12-04	Recruiting
A Randomized, Double-blind, Placebo-controlled, Multisite, Phase 3 Study to Investigate the Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P) in Children and Adolescents With Epilepsy With Myoclonic-Atonic Seizures [NCT05288283]	Phase 3	3 participants (Actual)	Interventional	2022-10-31	Terminated(stopped due to The study was terminated due to a business decision.)
A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease [NCT03582137]	Phase 2	74 participants (Actual)	Interventional	2018-09-17	Completed
Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC): Effectiveness, Side Effects and Neurobiological Changes [NCT03215940]	Early Phase 1	75 participants (Anticipated)	Interventional	2018-02-01	Recruiting
Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study [NCT04605393]		36 participants (Actual)	Interventional	2021-01-01	Completed
Efficacy of Cannabidiol in Treatment of Pain Due to Symptomatic Osteoarthritis of the Knee: A Randomized, Double-blind, Placebo-controlled Clinical Trial [NCT04607603]	Phase 4	86 participants (Actual)	Interventional	2020-10-13	Completed
Observational Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy to Assess the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant [NCT06113237]		50 participants (Anticipated)	Observational	2024-01-31	Not yet recruiting
Cannabidiol Adjunctive Therapy for Acute Bipolar Depression: A Randomized Double-Blind, Placebo Controlled Trial [NCT05867849]	Phase 3	360 participants (Anticipated)	Interventional	2023-10-15	Recruiting
Neurobehavioral Effects of Cannabidiol in Youth Alcohol Use Disorder [NCT05317546]	Phase 2	50 participants (Anticipated)	Interventional	2022-10-01	Recruiting
Safety and Efficacy of CBD (Epidiolex) in Idiopathic Generalized Epilepsy With Typical Absence Seizures [NCT04899050]	Phase 4	14 participants (Actual)	Interventional	2021-07-30	Completed
Cannabidiol and Oral Contraceptive Pills: Exploring a Drug-Drug Interaction [NCT04396730]	Phase 4	9 participants (Actual)	Interventional	2020-04-08	Completed
A Randomised, Double Blind, Placebo Controlled, Parallel Group, Pilot Study of 1:1 and 20:1 Ratio of Formulated GWP42003 : GWP42004 Plus GWP42003 and GWP42004 Alone in the Treatment of Dyslipidaemia in Subjects With Type 2 Diabetes [NCT01217112]	Phase 2	62 participants (Actual)	Interventional	2010-10-31	Completed
Laboratory Study of the Influence of Oral Cannabidiol on the Subjective, Reinforcing and Cardiovascular Effects of Smoked Marijuana [NCT01844687]	Phase 2	50 participants (Actual)	Interventional	2013-05-31	Completed
Cannabidiol (CBD) Cannabis Extract Oral Solution for Drug Resistant Pediatric Epilepsy (Expanded Access Use) [NCT03676049]		0 participants	Expanded Access		Available
Cannabidiol and Autonomic Function in Individuals at Rest [NCT04731779]	Early Phase 1	18 participants (Actual)	Interventional	2021-08-30	Completed
A Phase I/Ib Study on the Safety of Epidiolex in Patients With Prostate Cancer With Rising PSA After Localized Therapy With Either Surgery or Radiation [NCT04428203]	Phase 1	21 participants (Actual)	Interventional	2020-08-03	Completed
Efficacy of Inhaled Cannabis Versus Placebo for the Acute Treatment of Migraine: a Randomized, Double-blind, Placebo-controlled, Crossover Trial [NCT04360044]	Phase 2	92 participants (Actual)	Interventional	2020-11-20	Completed
Cannabidiol on reward-and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder: A Double-blind, Placebo-controlled, Cross-over Trial [NCT04982029]	Phase 2	15 participants (Actual)	Interventional	2022-04-14	Completed
An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study [NCT04978428]	Phase 2	15 participants (Anticipated)	Interventional	2022-04-14	Recruiting
An Assessment of the Drug Interaction Potential Between Oral Cannabidiol (Epidiolex®) and the CES1 Substrate Methylphenidate in Healthy Volunteers [NCT04603391]	Phase 4	12 participants (Actual)	Interventional	2021-02-25	Completed
Endocannabinoid System Engagement to Reduce Anxiety Reactivity With Cannabidiol in Social Anxiety Disorder (R61 Project) [NCT05823753]	Phase 2	60 participants (Anticipated)	Interventional	2023-04-19	Recruiting
A Phase II Trial of Cannabidiol for Prevention of Chemotherapy-induced Peripheral Neuropathy in Patients Receiving Oxaliplatin or Paclitaxel Based Chemotherapy [NCT04582591]	Phase 2	54 participants (Actual)	Interventional	2021-03-03	Active, not recruiting
A Placebo-Controlled Randomized Cross-Over Clinical Trial on the Antipsychotic Properties of the Endocannabinoid Modulator Cannabidiol [NCT00309413]	Phase 2	29 participants (Actual)	Interventional	2006-03-31	Completed
A Double Blind, Randomized, Cross Over, Placebo Controlled Phase 2 Clinical Trial to Asses Neuroprotection by Cannabinoids in Huntington's Disease [NCT01502046]	Phase 2	25 participants (Actual)	Interventional	2011-09-30	Completed
The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: A Pilot Study [NCT05836857]		100 participants (Anticipated)	Observational	2023-01-30	Recruiting
Are Natural Killer Cells Novel Mediators of the Effects of Cannabidiol on Physical Fitness, Mental Health and Well-Being, Sleep Quantity, Sleep Quantity and Immune Function? [NCT04881539]		50 participants (Actual)	Interventional	2021-05-15	Completed
Cannabidiol Effects on Cardiovascular System and Exercise Responses [NCT05232123]	Early Phase 1	60 participants (Anticipated)	Interventional	2023-07-31	Suspended(stopped due to waiting on funding)
Sativex Associated With Behavioral-relapse Prevention Strategy as Treatment for Cannabis Dependence [NCT01747850]	Phase 2	45 participants (Actual)	Interventional	2013-03-31	Completed
Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation [NCT05032807]	Phase 1	14 participants (Actual)	Interventional	2022-07-01	Completed
The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC) [NCT04349930]	Phase 1	0 participants (Actual)	Interventional	2021-01-31	Withdrawn(stopped due to Need to obtain IND approval.)
Long-term Follow-up of a Multicentre, Non-interventional, Prospective Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting [NCT05772429]		150 participants (Anticipated)	Observational	2023-04-17	Recruiting
The Effect of Cannabidiol in Learning and Memory of Adults [NCT06074172]	Phase 2	57 participants (Actual)	Interventional	2020-03-14	Completed
A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy [NCT05672342]	Early Phase 1	120 participants (Anticipated)	Interventional	2023-12-06	Not yet recruiting
The Role of Cannabidiol in Regulating Meal Time Anxiety in Anorexia Nervous: Safety, Tolerability and Pharmacokinetics [NCT04878627]	Early Phase 1	40 participants (Anticipated)	Interventional	2022-01-20	Recruiting
A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Dravet Syndrom [NCT02318563]	Phase 3	0 participants (Actual)	Interventional	2017-12-30	Withdrawn(stopped due to Sponsor elected not to continue with study.)
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol (GWP42003-P) [NCT02565108]	Phase 2	20 participants (Actual)	Interventional	2016-01-20	Completed
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol (GWP42003-P) [NCT02564952]	Phase 2	18 participants (Actual)	Interventional	2016-03-11	Completed
A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures [NCT02544750]	Phase 3	199 participants (Actual)	Interventional	2016-08-31	Completed
Randomized, Double Blind Clinical Trial to Study the Effect of Cannabidiol (CBD) 133mg + Cannabigerol (CBG) 66mg + Tetrahydrocannabinol (THC) 4mg a Day as Adjunctive Therapy in the Treatment of Chronic Migraine - CAMTREA TRIAL [NCT04989413]	Phase 4	110 participants (Anticipated)	Interventional	2022-10-18	Recruiting
Marijuana in Combination With Opioids for Pain and Symptom Control in Hospice Patients [NCT03233633]	Phase 1	66 participants (Actual)	Interventional	2017-05-10	Completed
A Phase 2a Open Label, Single Arm Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis [NCT04129489]	Phase 2	2 participants (Actual)	Interventional	2019-02-07	Terminated(stopped due to low recruitment)
The Use of Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis. A Double-Blind, Randomized Control Study [NCT05020028]	Phase 2/Phase 3	100 participants (Anticipated)	Interventional	2022-06-22	Recruiting
Cannabis Use, Cognition, and the Endocannabinoid System in HIV [NCT04883255]	Early Phase 1	138 participants (Anticipated)	Interventional	2023-05-03	Recruiting
A Phase 1/2 Study to Assess the Pharmacokinetics and Safety of Multiple Doses of Pharmaceutical Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Seizure Disorders [NCT02324673]	Phase 1/Phase 2	61 participants (Actual)	Interventional	2015-04-13	Completed
Characterisation of Relative Bioavailability of GLA-015 in Comparison With an Oily Cannabidiol Solution (NRF 22.10) - a Multiple Dose, Randomised, 2-period Crossover-trial With Twice Daily Administration in Healthy Adult Male and Female Subjects [NCT04790136]	Phase 1	18 participants (Actual)	Interventional	2021-03-17	Completed
Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy [NCT02660255]		0 participants	Expanded Access		Approved for marketing
Effects of Fixed or Self-Titrated Dosages of Sativex on Cannabis Users [NCT01748799]		16 participants (Actual)	Interventional	2013-02-28	Completed
Evaluation of a Specific Transdermal Cannabidiol Product for Chronic Musculoskeletal Joint Pain. [NCT05002114]	Phase 1	0 participants (Actual)	Interventional	2023-01-31	Withdrawn(stopped due to there were issues with the primary study material that prohibited continuation at this time)
Cannabidiol Treatment in Patients With Early Psychosis [NCT02504151]	Phase 2	18 participants (Actual)	Interventional	2016-01-28	Completed
A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures [NCT02544763]	Phase 3	224 participants (Actual)	Interventional	2016-04-06	Completed
Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation [NCT01596075]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2012-07-31	Recruiting
The CANabidiol Use for RElief of Short Term Insomnia (CAN-REST). A Randomised, Double-Blind, Placebo-Controlled Clinical Study [NCT05253417]	Phase 2	208 participants (Actual)	Interventional	2022-05-01	Completed
A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol (CBD; GWP42003-P) in Infants With Infantile Spasms Following an Initial Open-label Pilot Study [NCT02953548]	Phase 3	9 participants (Actual)	Interventional	2017-04-24	Completed
Evaluation of Hemp-Derived Botanical Dietary Supplementation to Promote Healthy Brain Function During Recovery From Brain Injury [NCT03826368]		0 participants (Actual)	Observational	2020-04-13	Withdrawn(stopped due to Lack of initial funding after approval of study)
An Open-Label Trial to Assess the Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Combination With Cannabidiol, as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome or Lennox-Gastaut Syndrome [NCT03467113]	Phase 1	9 participants (Actual)	Interventional	2018-01-19	Completed
A Double-blind, Randomised, Placebo-controlled, Parallel Group Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder [NCT02006628]	Phase 2	88 participants (Actual)	Interventional	2014-02-25	Completed
Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome [NCT02332655]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2014-12-31	Completed
A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution [NCT05044819]	Phase 4	150 participants (Anticipated)	Interventional	2021-07-07	Recruiting
A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome [NCT03614663]	Phase 2/Phase 3	212 participants (Actual)	Interventional	2018-06-12	Completed
Cannabidiol for Treating PTSD Symptoms and Neurocognitive Impairment in PTSD and PTSD Comorbid With TBI: A Placebo-controlled RCT With Neural-circuit Centered Precision Medicine Prediction of Response. [NCT04550377]	Phase 2	120 participants (Anticipated)	Interventional	2021-05-26	Recruiting
Cannabidiol as a Treatment for Alcohol Use Disorder Comorbid With Posttraumatic Stress Disorder [NCT03248167]	Phase 1/Phase 2	95 participants (Actual)	Interventional	2019-09-16	Completed
Reducing Pain and Opioid Use With CBD [NCT05299944]	Phase 2	150 participants (Anticipated)	Interventional	2022-03-08	Recruiting
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults. [NCT02224560]	Phase 3	225 participants (Actual)	Interventional	2015-06-08	Completed
Effects of Cannabidiol on Responses to Emotional Stimuli [NCT02902081]		38 participants (Actual)	Interventional	2013-02-28	Completed
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia [NCT03941288]	Phase 2	111 participants (Actual)	Interventional	2019-09-04	Completed
Cannabidiol Pharmacotherapy for Co-occurring Opioid Use Disorder and Chronic Pain [NCT04587791]	Early Phase 1	40 participants (Anticipated)	Interventional	2021-12-08	Recruiting
A Controlled Study of the Effect of Cannabis on Visual Functions in Healthy Subjects and in Retinitis Pigmentosa Patients [NCT03078309]	Early Phase 1	50 participants (Anticipated)	Interventional	2018-09-01	Recruiting
Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial [NCT04729179]	Phase 3	200 participants (Anticipated)	Interventional	2021-03-01	Recruiting
An Open Label, Multi-Center Study to Investigate the Safety of Cannabinoid (GWP42003-P) in Children With Medication Resistant Epilepsy [NCT02397863]		0 participants	Expanded Access	2014-12-31	Available
A Phase 2 Study to Assess the Efficacy and Safety of Cannabidiol Oral Solution for the Treatment of Refractory Infantile Spasms [NCT02551731]	Phase 2	9 participants (Actual)	Interventional	2016-01-27	Terminated(stopped due to Sponsor elected not to continue with study)
The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis [NCT03172741]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2017-01-31	Withdrawn(stopped due to Did not pursue study)
University of Alabama at Birmingham (UAB) Pediatric CBD Program [NCT02695537]	Phase 1	89 participants (Actual)	Interventional	2015-04-30	Completed
A Multicenter, Open-Label Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome [NCT03458416]	Phase 2	2 participants (Actual)	Interventional	2018-09-06	Terminated(stopped due to Insys Therapeutics filed Chapter 11 and terminated all studies.)
Bioequivalence Assessment of Cannabidiol (CBD) Administrated in Oral Formulations [NCT03877991]	Early Phase 1	12 participants (Actual)	Interventional	2019-05-02	Completed
Cannabidiol as Treatment Intervention for Opioid Relapse [NCT01605539]	Phase 2	10 participants (Actual)	Interventional	2012-05-31	Completed
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution as Adjunctive Therapy With Vigabatrin as Initial Therapy in Patients With Infantile Spasms [NCT03421496]	Phase 3	2 participants (Actual)	Interventional	2018-09-05	Terminated(stopped due to The study was terminated due to slow enrollment and failure to identify adequate patients that met entry criteria.)
Population Pharmacokinetics of Antiepileptic in Pediatrics [NCT03196466]		1,000 participants (Anticipated)	Observational	2017-06-19	Recruiting
Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoid Combination (Δ9 -Tetrahydrocannabinol (THC) and Cannabidiol (CBD) In 1:1 Ratio) [NCT01893424]	Phase 1	12 participants (Actual)	Interventional	2013-08-31	Completed
A Double Blind, Randomized, Placebo Controlled, Parallel Group Dose-range Exploration Study of Sativex® in Relieving Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy. [NCT00530764]	Phase 2	360 participants (Actual)	Interventional	2007-11-30	Completed
Investigating the Effects of Cannabidiol on Social Anxiety Disorder [NCT05649059]	Phase 4	50 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
A Double-Blind, Cross-Over, Placebo- Controlled Efficacy and Tolerability Study of Oral Cannabidiol (CBD) and Tetrahydrocannabinol (THC) for Essential Tremor (ET). [NCT03805750]	Phase 1/Phase 2	7 participants (Actual)	Interventional	2019-01-22	Completed
The Pharmacokinetics of Oral Tetrahydrocannabinol and Cannabidiol Across the Spectrum of Glomerular Filtration Rate: a PharmacoKinetic Study [NCT05742724]	Phase 1	24 participants (Anticipated)	Interventional	2023-01-11	Recruiting
Effect of Cannabidiol Oil on Postoperative Pain After Ureteroscopy for Urinary Calculi [NCT04387617]	Phase 2/Phase 3	90 participants (Actual)	Interventional	2021-02-15	Completed
A Phase 1/2, Safety, Tolerability, and Dose-Finding Study of Cannabidiol for Drug-Resistant Epilepsies [NCT03014440]		0 participants	Expanded Access		No longer available
Cannabidiol Effects on Fear Extinction in Social Phobia [NCT06123702]	Early Phase 1	20 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
Anxiety Symptoms in Relation to Use of Hemp-Derived, Full Spectrum Cannabidiol (CBD): a Cohort Study [NCT05023759]		30 participants (Actual)	Observational	2020-06-01	Completed
Why Antiprogestrone (Mifepristone) and Cyp 26 Inhibitor Must be Combined With Tamoxifen or ( Tamoxifen and Retinoic Acid) for Treating Early Breast Cancer [NCT05016349]	Phase 3	160 participants (Anticipated)	Interventional	2021-08-31	Not yet recruiting
CAnnabidiol Study in Children With Autism Spectrum DisordEr (CASCADE): A Double-Blind, Placebo-Controlled Study to Investigate Efficacy and Safety of Cannabidiol in Children and Adolescents With Autism [NCT04520685]	Phase 2	70 participants (Anticipated)	Interventional	2021-12-15	Recruiting
An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome [NCT03802799]	Phase 2/Phase 3	450 participants (Anticipated)	Interventional	2018-11-09	Enrolling by invitation
Effectiveness of Cannabidiol vs. Narcotics for Post Operative Pain Control in Elective Knee Arthroscopic Surgery [NCT05934500]	Early Phase 1	100 participants (Anticipated)	Interventional	2023-10-15	Not yet recruiting
Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm - a Prospective Double-masked Cross-over Study [NCT04423341]	Phase 2/Phase 3	12 participants (Actual)	Interventional	2020-05-20	Completed
Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial [NCT05632627]	Phase 2	120 participants (Anticipated)	Interventional	2023-04-11	Recruiting
Cannabidiol and Vascular Reactivity to Skin Sensory Nerve Stimulation [NCT05456113]		48 participants (Anticipated)	Interventional	2024-12-01	Enrolling by invitation
Cannabidiol in the Treatment of Opioid Use Disorder [NCT05269706]	Phase 2	200 participants (Actual)	Interventional	2022-05-18	Active, not recruiting
A Retrospective Cohort Study to Evaluate the Effects of Cannabidiol (CBD)-Containing Test Products on Anxiety Among Women in the U.S. [NCT05108220]		1,350 participants (Actual)	Observational	2020-10-15	Completed
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of [NCT02318602]	Phase 3	52 participants (Actual)	Interventional	2016-01-08	Completed
Oral Cannabidiol for Tobacco Cessation [NCT05445804]	Phase 1	50 participants (Anticipated)	Interventional	2022-11-01	Recruiting
Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa [NCT05651607]	Phase 2	10 participants (Anticipated)	Interventional	2023-07-06	Recruiting
Cannabidiol as a Medication for Neuropsychiatric and Other Medical Conditions - an in Vivo Innovative Drug Delivery Study [NCT03471559]	Phase 1	8 participants (Actual)	Interventional	2018-12-10	Terminated(stopped due to Two step study, step two was not feasible based on results from phase one.)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults. [NCT02224690]	Phase 3	171 participants (Actual)	Interventional	2015-04-28	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Lennox-Gastaut [NCT02318537]	Phase 3	0 participants (Actual)	Interventional	2017-12-30	Withdrawn(stopped due to Sponsor elected not to continue with study.)
CBD/THC Solution as a Pharmacological Strategy for Patients With Fibromyalgia. Single-center, Double-blind, Randomized, Placebo-controlled Clinical Trial Protocol (FibroCann) [NCT05283161]	Phase 2/Phase 3	40 participants (Anticipated)	Interventional	2022-04-15	Not yet recruiting
Reducing the Harmful Effects of Cannabis Use: Finding the Optimal CBD:THC Ratio [NCT05170217]		46 participants (Actual)	Interventional	2017-11-08	Completed
The Efficacy and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol Dependence: An Exploratory Pilot Study [NCT05387148]	Phase 2	20 participants (Anticipated)	Interventional	2022-06-30	Recruiting
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis: Understanding the Mechanism and Mediators of Action [NCT04411225]	Phase 3	120 participants (Anticipated)	Interventional	2021-07-01	Recruiting
The Effects of Cannabidiol on the Driving Ability of Healthy Adults: a Clinical Trial [NCT04590495]	Phase 2	40 participants (Actual)	Interventional	2021-04-01	Completed
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome. [NCT02224703]	Phase 3	199 participants (Actual)	Interventional	2015-04-13	Completed
A Double Blind, Placebo-controlled, Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome [NCT02091206]	Phase 2	34 participants (Actual)	Interventional	2014-10-22	Completed
Phase 2 Trial of Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias [NCT04754399]	Phase 2	40 participants (Actual)	Interventional	2021-04-16	Completed
The Effects of Cannabinoids on Vascular and Cognitive Function in Young and Old Healthy Adults. [NCT03295903]	Early Phase 1	24 participants (Anticipated)	Interventional	2018-01-01	Active, not recruiting
Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling (Bonsai Study) wIth COVID-19: a Randomised Controlled Trial [NCT04504877]	Phase 2/Phase 3	120 participants (Actual)	Interventional	2020-06-16	Completed
A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome [NCT02091375]	Phase 3	120 participants (Actual)	Interventional	2015-03-30	Completed
Study to Evaluate the Efficacy and Safety of CardiolRx™ in Patients With COVID-19 and Cardiovascular Disease or Risk Factors A Double-blind, Placebo-controlled Trial [NCT04615949]	Phase 2/Phase 3	90 participants (Actual)	Interventional	2021-04-30	Terminated(stopped due to The changing nature of COVID-19 including a more vaccinated population, increasing natural population immunity, milder variants and other related factors has meant that it is no longer realistic to recruit the patients in a reasonable time frame.)
A Randomised, Double-blind, Placebo-controlled Parallel Group, Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis [NCT01562314]	Phase 2	60 participants (Actual)	Interventional	2012-05-09	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00530764 (9) [back to overview]	Change in Brief Pain Inventory - Short Form (BPI-SF)
NCT00530764 (9) [back to overview]	Change in Patient Assessment of Constipation Quality of Life (PAC-QoL)
NCT00530764 (9) [back to overview]	Change in Montgomery Asberg Depression Rating Scale (MADRS)
NCT00530764 (9) [back to overview]	Change in Mean Daily NRS Pain Score (Worst Pain).
NCT00530764 (9) [back to overview]	Change in Cumulative Average Pain Response Curves
NCT00530764 (9) [back to overview]	Change in Mean Daily NRS Pain Score (Average Pain).
NCT00530764 (9) [back to overview]	Change in Patient Global Impression of Change - PGIC
NCT00530764 (9) [back to overview]	Number of Patients With at Least 30% Improvement in Numerical Rating Scale (NRS) Average Pain Score From Baseline
NCT00530764 (9) [back to overview]	Change in Sleep Disruption NRS
NCT00588731 (2) [back to overview]	Overall Cognition as Measured on the MATRICS Battery
NCT00588731 (2) [back to overview]	Verbal Short Term Memory
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Internal Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Serum High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Insulin Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test)
NCT01217112 (44) [back to overview]	The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Glucose Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test [OGTT])
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Waist-to-hip Ratio After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Waist Measurement After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Visceral Abdominal Fat After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Very Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Triglyceride Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Total Subcutaneous Fat After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Total Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Total Internal Fat After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	Adverse Events as a Measure of Patient Safety
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Total Fat After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Serum Apolipoprotein B Concentration After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Total Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Serum Apolipoprotein B : Apolipoprotein A Ratio After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Serum Apolipoprotein A Concentration After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Body Mass Index After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Total Abdominal Fat After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean % Liver Fat After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Abdominal Adiposity After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Appetite 0-10 Numerical Rating Scale Score After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Beck Depression Inventory-II (BDI-II) Score at the End of 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Body Weight After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean C-peptide Concentration After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Fasting Glucose Concentration After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Fasting Insulin Concentration After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Fructosamine Concentration After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Glycated Haemoglobin Concentration After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Insulin Sensitivity Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean High Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Hip Measurement After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Insulin Resistance Measured by Homeostasis Model Assessment 2 (HOMA2-IR) After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Insulin B Cell Function Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Subcutaneous Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Subcutaneous Abdominal Fat After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Serum Triglyceride Concentration After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Serum Total Cholesterol Concentration After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Serum Non-Esterified Fatty Acid Concentration After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Serum Low Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment
NCT01217112 (44) [back to overview]	The Change From Baseline in Mean Serum High Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment
NCT01284634 (6) [back to overview]	Change From Baseline To The EOT In Mean Serum Triglyceride Levels
NCT01284634 (6) [back to overview]	Percent Change From Baseline To The End Of Treatment (EOT) In Mean Liver Triglyceride Levels
NCT01284634 (6) [back to overview]	Change From Baseline To The EOT In Mean Serum HDL: Low Density Lipoprotein (LDL)-Cholesterol (C) Ratio
NCT01284634 (6) [back to overview]	Change From Baseline To The EOT In Mean Serum High Density Lipoprotein (HDL)-Cholesterol(C) Levels
NCT01284634 (6) [back to overview]	Change From Baseline To The EOT In Mean Serum Total Cholesterol Levels
NCT01284634 (6) [back to overview]	Change From Baseline To The EOT In Mean Serum Low-Density Lipoprotein (LDL)-C Levels
NCT01562314 (18) [back to overview]	Number Of Participants Who Reported An Improvement In The Subject Global Impression Of Change (SGIC) Questionnaire At EOT
NCT01562314 (18) [back to overview]	Change From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Stool Frequency NRS - PP Analysis
NCT01562314 (18) [back to overview]	Number Of Participants Who Reported An Improvement In The SGIC Questionnaire At EOT - PP Analysis
NCT01562314 (18) [back to overview]	Change From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Stool Frequency Numerical Rating Scale (NRS)
NCT01562314 (18) [back to overview]	Number Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT
NCT01562314 (18) [back to overview]	Number Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT - PP Analysis
NCT01562314 (18) [back to overview]	Change From Baseline To EOT In Levels Of Fecal Calprotectin
NCT01562314 (18) [back to overview]	Change From Baseline To EOT In Levels Of Fecal Calprotectin- PP Analysis
NCT01562314 (18) [back to overview]	Change From Baseline To EOT In The IBDQ Total Score - PP Analysis
NCT01562314 (18) [back to overview]	Change From Baseline To EOT In The Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score
NCT01562314 (18) [back to overview]	Change From Baseline To EOT In The Mayo Partial Score
NCT01562314 (18) [back to overview]	Change From Baseline To EOT In The Mayo Partial Score - PP Analysis Set
NCT01562314 (18) [back to overview]	Change From Baseline To EOT In The Mayo Total Score
NCT01562314 (18) [back to overview]	Change From Baseline To EOT In The Mayo Total Score - PP Analysis
NCT01562314 (18) [back to overview]	Change From Baseline To EOT In The PGAS Score
NCT01562314 (18) [back to overview]	Change From Baseline To EOT In The PGAS Score - PP Analysis
NCT01562314 (18) [back to overview]	Change From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Rectal Bleeding NRS
NCT01562314 (18) [back to overview]	Change From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Rectal Bleeding NRS - PP Analysis
NCT01605539 (9) [back to overview]	Visual Analog Scale for Anxiety (VASA)
NCT01605539 (9) [back to overview]	The Positive and Negative Affect Schedule (PANAS) - Positive Affect Schedule (PAS) Data
NCT01605539 (9) [back to overview]	The Positive and Negative Affect Schedule (PANAS) - Negative Affect Schedule (NAS) Data
NCT01605539 (9) [back to overview]	Changes in Out-of-Clinic Craving (From Pre-Dose to Approximately 6 Hours Post-Dose for Test Visits I and II; and From Pre-Dose Test Visit I to Pre-Cue Test Visit IV) - Via the Heroin Craving Questionnaire (HCQ)
NCT01605539 (9) [back to overview]	Changes in Cue-Induced In-Clinic Craving (From Baseline to Post-cue or Post-neutral - Via the Visual Analog Scale for Craving (VASC)
NCT01605539 (9) [back to overview]	Vital Signs - Blood Pressure
NCT01605539 (9) [back to overview]	Vital Signs - Heart Rate
NCT01605539 (9) [back to overview]	Vital Signs - Respiratory Rate
NCT01605539 (9) [back to overview]	Vital Signs - Temperature
NCT01747850 (5) [back to overview]	Withdrawal
NCT01747850 (5) [back to overview]	Cannabis Use (in Days)
NCT01747850 (5) [back to overview]	Tolerability
NCT01747850 (5) [back to overview]	Cannabis Use (Grams)
NCT01747850 (5) [back to overview]	Cannabis Craving
NCT01748799 (3) [back to overview]	Cannabis Withdrawal
NCT01748799 (3) [back to overview]	Feasibility
NCT01748799 (3) [back to overview]	Tolerability of Sativex in Persons That Are Cannabis Dependent
NCT01844687 (7) [back to overview]	Plasma Concentration of CBD
NCT01844687 (7) [back to overview]	Mood Scale - Subscale 'Feeling High'
NCT01844687 (7) [back to overview]	Marijuana Rating Form - Strength
NCT01844687 (7) [back to overview]	Number of Optional Puffs of MJ Cigarette Taken
NCT01844687 (7) [back to overview]	Marijuana Rating Form - Like
NCT01844687 (7) [back to overview]	Optional Additional Puffs of MJ Cigarette
NCT01844687 (7) [back to overview]	Heart Rate
NCT02006628 (8) [back to overview]	Change From Baseline To The End Of Treatment (Day 43) In The Clinical Global Impression Severity Scale (CGI-S)
NCT02006628 (8) [back to overview]	Change From Baseline To The End Of Treatment (Day 43) In The Scale For The Assessment Of Negative Symptoms (SANS)
NCT02006628 (8) [back to overview]	Clinical Global Impression Improvement Scale (CGI-I) Values At Day 8 And End Of Treatment (Day 43)
NCT02006628 (8) [back to overview]	Change From Baseline To End Of Treatment (Day 43) In Positive And Negative Syndrome Scale (PANSS) Total Score
NCT02006628 (8) [back to overview]	Change From Baseline To The End Of Treatment (Day 43) In Brief Assessment Of Cognition In Schizophrenia (BACS) Score
NCT02006628 (8) [back to overview]	Change From Baseline To The End Of Treatment (Day 43) In PANSS 'G' Score
NCT02006628 (8) [back to overview]	Change From Baseline To The End Of Treatment (Day 43) In PANSS 'N' Score
NCT02006628 (8) [back to overview]	Change From Baseline To The End Of Treatment (Day 43) In PANSS 'P' Score
NCT02091206 (3) [back to overview]	Area Under The Concentration-Time Curve Calculated To The Last Observable Concentration At Time T (AUC0-t) For CBD And Its Metabolites At Days 1 And 22
NCT02091206 (3) [back to overview]	Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs)
NCT02091206 (3) [back to overview]	Mean Percentage Change From Baseline To End Of Treatment In Plasma Clobazam (CLB) And N-Desmethylclobazam (N-CLB) Concentrations
NCT02091375 (11) [back to overview]	Number Of Participants With Inpatient Hospitalizations Due To Epilepsy
NCT02091375 (11) [back to overview]	Change From Baseline In Sleep Disruption 0 To 10 Numerical Rating Scale (0 to 10 NRS) Score
NCT02091375 (11) [back to overview]	Change From Baseline In Quality Of Life In Childhood Epilepsy (QOLCE) Score
NCT02091375 (11) [back to overview]	Change From Baseline In Epworth Sleepiness Scale (ESS) Score
NCT02091375 (11) [back to overview]	Number Of Participants With A ≥50% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period
NCT02091375 (11) [back to overview]	Caregiver Global Impression Of Change In Seizure Duration (CGICSD)
NCT02091375 (11) [back to overview]	Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score
NCT02091375 (11) [back to overview]	Percentage Change From Baseline In Non-Convulsive Seizure Frequency During The Treatment Period
NCT02091375 (11) [back to overview]	Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period
NCT02091375 (11) [back to overview]	Number Of Participants Using Rescue Medication
NCT02091375 (11) [back to overview]	Number of Participants With A ≥25%, ≥75% Or 100% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period
NCT02224560 (4) [back to overview]	Number Of Participants With A ≥50% Reduction From Baseline In Drop Seizure Frequency During The Treatment Period
NCT02224560 (4) [back to overview]	Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period
NCT02224560 (4) [back to overview]	Subject/Caregiver Global Impression Of Change (S/CGIC) Assessment
NCT02224560 (4) [back to overview]	Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Purdue Pegboard Fine Motor Speed (Both Hands Z Score)
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Purdue Pegboard Fine Motor Speed (Dominant Hand Z Score)
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Purdue Pegboard Fine Motor Speed (Non Dominant Hand Z Score)
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Quality of Life in Childhood Epilepsy (QOLCE) Scores
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Red Blood Cells (RBCs) Values
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Visual Perception Standard Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in WASI-II Matrix Reasoning T Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Wechsler Abbreviated Scale of Intelligence (WASI)-II Vocabulary T Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Wechsler Adult Intelligence Scale (WAIS) Coding Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Wechsler Intelligence Scale for Children (WISC) Coding Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in WISC Digit Span Backward Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in WISC Digit Span Forward Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in WISC Longest Digit Span Backward Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in WISC Longest Digit Span Forward Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in WPPSI-IV Receptive Vocabulary T Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment QOL in Epilepsy Scores (QOLIE-31-P) in Participants With Lennox-Gastaut Syndrome
NCT02224573 (67) [back to overview]	Mean Subject/Caregiver Global Impression of Change (S/CGIC) Score
NCT02224573 (67) [back to overview]	Mean Cannabis Withdrawal Scale Score at End of Taper (EOT), the Post-Taper Safety Call, and at Safety Follow-up
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Albumin and Protein
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase, and Gamma Glutamyl Transferase
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Creatinine (Jaffe), Creatinine (Enzymatic), and Bilirubin
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Creatinine Clearance (Schwartz) and Creatinine Clearance (Cockcroft-Gault)
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Platelets, White Blood Cells, Basophils, Eosinophils, Lymphocytes, Monocytes, and Neutrophils
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Sodium, Potassium, Blood Urea Nitrogen, Glucose, Calcium, and High-Density Lipoprotein (HDL) Cholesterol
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in the Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Neutrophils in White Blood Cells (WBCs)
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Vineland Adaptive Behavior Scale, Second Edition (Vineland-II) Scores
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in WAIS Digit Span Backward Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in WAIS Digit Span Backward Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in WAIS Digit Span Forward Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in WAIS Digit Span Forward Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in WAIS Longest Digit Span Backward Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in WAIS Longest Digit Span Backward Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in WAIS Longest Digit Span Forward Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in WAIS Longest Digit Span Forward Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Wechsler Preschool & Primary Scale of Intelligence (WPPSI)-IV Bug Search T Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in WPPSI-IV Matrix Reasoning T Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in WPPSI-IV Matrix Reasoning T Score
NCT02224573 (67) [back to overview]	Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Occurring in ≥5% of Participants in Any Treatment Group
NCT02224573 (67) [back to overview]	Number of Participants With Clinically Significant Electrocardiogram (ECG) Values at the Pre-randomization Baseline of the Core Study and at Any Time Post-dose
NCT02224573 (67) [back to overview]	Number of Participants With Convulsive and Non-convulsive Seizures Greater Than 30 Minutes in Duration (Status Epilepticus)
NCT02224573 (67) [back to overview]	Number of Participants With Inpatient Hospitalizations Due to Epilepsy Since the Previous Visit
NCT02224573 (67) [back to overview]	Number of Participants With the Indicated Responses to Questions Regarding Suicidal Ideation and Behavior Using the Children's Columbia-Suicide Severity Rating Scale (C-SSRS) at Day 1 and at Any Time Post-dose
NCT02224573 (67) [back to overview]	Number of Treatment Responders With Greater Than or Equal to 50% Reduction in Total Seizures
NCT02224573 (67) [back to overview]	Number of Treatment Responders With Greater Than or Equal to 50% Reduction in Total Seizures
NCT02224573 (67) [back to overview]	Percent Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Convulsive Seizure Frequency in Participants With Dravet Syndrome
NCT02224573 (67) [back to overview]	Percent Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Drop Seizure Frequency in Participants With Lennox-Gastaut Syndrome
NCT02224573 (67) [back to overview]	Percent Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Total Seizure Frequency
NCT02224573 (67) [back to overview]	Percent Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Total Seizure Frequency
NCT02224573 (67) [back to overview]	Number of Participants With Changes in the Average Duration of Seizure Subtypes as Assessed by the Participant/Caregiver Global Impression of Change in Seizure Duration (S/CGICSD)
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Erythrocyte Mean Corpuscular Hemoglobin
NCT02224573 (67) [back to overview]	Mean Pediatric Cannabinoid Withdrawal Scale (PCWS) Score at the End of Treatment, the End of Taper, the Post-Taper Safety Call, and at Safety Follow-up
NCT02224573 (67) [back to overview]	Number of Participants With Clinically Significant Changes in the Indicated Vital Sign Values From the Pre-randomization Baseline of the Core Study at Any Time Post-dose
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in a Developmental NEuroPSYchological Assessment (NEPSY)-2 Word Generation Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Body Mass Index (BMI)
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in D-KEFS Letter Sequencing Completion Time Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in D-KEFS Motor Speed Completion Time Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in D-KEFS Number Sequencing Completion Time Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in D-KEFS Number-letter Switching Completion Time Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Delis-Kaplan Executive Function System (D-KEFS) Visual Scanning Completion Time Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Erythrocyte Mean Corpuscular Volume
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Expressive One-Word Picture Vocabulary Test (EOWPVT) Scaled Score
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Hematocrit Values
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Hemoglobin Levels
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Insulin-like Growth Factor-1 (IGF-1) Levels
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Prolactin
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Prothrombin International Normalized Ratio
NCT02224573 (67) [back to overview]	Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Prothrombin Time
NCT02224690 (4) [back to overview]	Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period
NCT02224690 (4) [back to overview]	Number Of Participants With a ≥50% Reduction From Baseline in Drop Seizure Frequency During The Treatment Period
NCT02224690 (4) [back to overview]	Subject/Caregiver Global Impression Of Change Assessment (S/CGIC)
NCT02224690 (4) [back to overview]	Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period
NCT02224703 (3) [back to overview]	Participants With A ≥50% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period
NCT02224703 (3) [back to overview]	Change In Total Seizures During The Treatment Period Compared To Baseline
NCT02224703 (3) [back to overview]	Change In Convulsive Seizures During The Treatment Period Compared To Baseline
NCT02318602 (8) [back to overview]	Percentage of Participants With Adverse Events
NCT02318602 (8) [back to overview]	Vineland Adaptive Behavior Scales (VABS)
NCT02318602 (8) [back to overview]	Percentage of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings
NCT02318602 (8) [back to overview]	Vineland Adaptive Behavior Scales (VABS)
NCT02318602 (8) [back to overview]	Percentage of Participants With Clinically Significant Change From Baseline in Laboratory Values
NCT02318602 (8) [back to overview]	Number of Participants With a Positive Response on the Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT02318602 (8) [back to overview]	Percentage of Participants With Serious Adverse Events
NCT02318602 (8) [back to overview]	Percentage of Participants With Clinically Significant Change From Baseline in Vital Signs
NCT02324673 (32) [back to overview]	Metabolite (7-OH Cannabidiol) to Parent (Cannabidiol) Ratio for Cmax [MRCmax] on Day 1
NCT02324673 (32) [back to overview]	Dose Normalized AUC(0-inf) [AUC(0-inf)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age
NCT02324673 (32) [back to overview]	Dose Normalized Cmax (Cmax/D) for Cannabidiol and Metabolite 7-OH Cannabidiol
NCT02324673 (32) [back to overview]	Elimination Rate (Lambda-z [λz]) for Cannabidiol and Metabolite 7-OH Cannabidiol for Participants ≥2 Years of Age
NCT02324673 (32) [back to overview]	Maximum Plasma Concentration (Cmax) for Cannabidiol and Metabolite 7-hydroxy (7-OH) Cannabidiol
NCT02324673 (32) [back to overview]	Minimum Plasma Concentration (Cmin) for Cannabidiol and Metabolite 7-OH Cannabidiol
NCT02324673 (32) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT02324673 (32) [back to overview]	Time Linearity Index for Cannabidiol and Metabolite 7-OH Cannabidiol in Participants ≥2 Years of Age
NCT02324673 (32) [back to overview]	Time to Cmax (Tmax) for Cannabidiol and Metabolite 7-OH Cannabidiol
NCT02324673 (32) [back to overview]	Metabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 1
NCT02324673 (32) [back to overview]	Metabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 10
NCT02324673 (32) [back to overview]	Metabolite to Parent Ratio for AUC(0-inf) [MRAUC(0-inf)] on Day 1 for Participants ≥2 Years of Age
NCT02324673 (32) [back to overview]	MRCmax on Day 10
NCT02324673 (32) [back to overview]	Oral Clearance (CL/F) for Cannabidiol for Participants ≥2 Years of Age
NCT02324673 (32) [back to overview]	Number of Participants With Suicide Related Thoughts and Behaviors Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT02324673 (32) [back to overview]	Time to Cmax (Tmax) for Cannabidiol and Metabolite 7-OH Cannabidiol
NCT02324673 (32) [back to overview]	Volume of Distribution (Vz/F) of Cannabidiol for Participants ≥2 Years of Age
NCT02324673 (32) [back to overview]	Accumulation Ratio for AUC(0-12) [RAUC(0-12)] on Day 10 for Cannabidiol and Metabolite 7-OH Cannabidiol
NCT02324673 (32) [back to overview]	Accumulation Ratio for Cmax (RCmax) on Day 10 for Cannabidiol and Metabolite 7-OH Cannabidiol
NCT02324673 (32) [back to overview]	Area Under the Plasma-Concentration Time Curve From 0 to 12 Hours Post-dose [AUC(0-12)] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1
NCT02324673 (32) [back to overview]	AUC From Time 0 to Infinity [AUC(0-inf)] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age
NCT02324673 (32) [back to overview]	AUC From Time 0 to the Last Quantifiable Concentration [AUC(0-last)] on Day 1 for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age
NCT02324673 (32) [back to overview]	Half Life (t1/2) for Cannabidiol and Metabolite 7-OH Cannabidiol for Participants ≥2 Years of Age
NCT02324673 (32) [back to overview]	AUC(0-12) for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 10
NCT02324673 (32) [back to overview]	Average Plasma Concentration (Cavg) for Cannabidiol and Metabolite 7-OH Cannabidiol
NCT02324673 (32) [back to overview]	Change From Baseline in Clinical Global Impression of Severity (CGI-S) Assessment
NCT02324673 (32) [back to overview]	Change From Baseline in Daily Seizure Activity
NCT02324673 (32) [back to overview]	Clinical Global Impression of Improvement (CGI-I) Assessment
NCT02324673 (32) [back to overview]	Cmax for Cannabidiol and Metabolite 7-OH Cannabidiol
NCT02324673 (32) [back to overview]	Cmax/D for Cannabidiol and Metabolite 7-OH Cannabidiol
NCT02324673 (32) [back to overview]	Dose Normalized AUC(0-12) [AUC (0-12)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1
NCT02324673 (32) [back to overview]	Dose Normalized AUC(0-12) [AUC (0-12)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 10
NCT02332655 (2) [back to overview]	Number of Seizures Per Month
NCT02332655 (2) [back to overview]	Percentage Change in Seizure Frequency at Most Recent Visit on CBD Compared With Baseline
NCT02504151 (4) [back to overview]	Positive and Negative Syndrome Scale (PANSS) Over Time
NCT02504151 (4) [back to overview]	Quality of Life Scale (QLS) Over Time
NCT02504151 (4) [back to overview]	Clinical Global Impression of Severity Scale Over Time
NCT02504151 (4) [back to overview]	Patient Assessment of Own Functioning Inventory (PAOFI) Over Time
NCT02544750 (6) [back to overview]	Number of Participants Considered Treatment Responders During the OLE Treatment Period
NCT02544750 (6) [back to overview]	Number of Participants With Any TEAE, by Severity
NCT02544750 (6) [back to overview]	Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE)
NCT02544750 (6) [back to overview]	Percent Change From Baseline in the Number of TSC-associated Seizures During the OLE Treatment Period
NCT02544750 (6) [back to overview]	Percent Change From Baseline in Total Seizure Frequency During the OLE Treatment Period
NCT02544750 (6) [back to overview]	Caregiver Global Impression of Change (CGIC) and Subject Global Impression of Change (SGIC) Score During the OLE Treatment Period
NCT02544763 (5) [back to overview]	Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration)
NCT02544763 (5) [back to overview]	Number of Participants With Any Severe Treatment-emergent Adverse Event (TEAE)
NCT02544763 (5) [back to overview]	Percent Change From Baseline in Total Seizures During the Treatment Period (Maintenance and Titration)
NCT02544763 (5) [back to overview]	Change From Baseline in the Caregiver Global Impression of Change (CGIC) or Participant Global Impression of Change (PGIC) Score at the Participant's Last Visit
NCT02544763 (5) [back to overview]	Number of Participants Considered Treatment Responders During the Treatment Period (Maintenance and Titration)
NCT02551731 (9) [back to overview]	Part A: Time to Complete Responder Relapse
NCT02551731 (9) [back to overview]	Part B: Percentage of Participants Experiencing Adverse Events (AEs), Treatment-Emergent AEs (TEAEs), and Serious Adverse Events (SAEs)
NCT02551731 (9) [back to overview]	Part A: Median Reduction in Seizure-burden Comparing Video-EEG at Baseline to Repeat Video-EEG at Day 14
NCT02551731 (9) [back to overview]	Part A: Percentage of Participants With Absence of Infantile Spasms at Day 14
NCT02551731 (9) [back to overview]	Part A: Parent Impression of Efficacy and Tolerability of Study Drug
NCT02551731 (9) [back to overview]	Part A: Percentage of Complete Responders With Relapse
NCT02551731 (9) [back to overview]	Part A: Percentage of Participants Who Are Considered Complete Responders at Day 14
NCT02551731 (9) [back to overview]	Part A: Percentage of Participants With a Partial Response to Treatment
NCT02551731 (9) [back to overview]	Part A: Percentage of Participants With Absence of Hypsarrhythmia at Day 14
NCT02564952 (1) [back to overview]	Number Of Participants Who Experienced Severe OLE-Emergent AEs
NCT02565108 (6) [back to overview]	Pharmacokinetics (PK): Maximum Measured Plasma Concentration (Cmax) Of CLB And N-CLB With GWP42003-P Treatment, Days 1 And 33
NCT02565108 (6) [back to overview]	PK: Geometric Mean Ratios Of CLB And N-CLB For AUCtau On Day 33 Compared With Day 1
NCT02565108 (6) [back to overview]	PK: Time To The Maximum Plasma Concentration (Tmax) Of CLB And N-CLB With GWP42003-P Treatment, Days 1 And 33
NCT02565108 (6) [back to overview]	PK: Geometric Mean Ratios Of CLB And N-CLB For Cmax On Day 33 Compared With Day 1
NCT02565108 (6) [back to overview]	PK: Area Under The Plasma Concentration-Time Curve Over A Dosing Interval, Where Tau Is The Dosing Interval (AUCtau) Of CLB And N-CLB With GWP42003-P Treatment, Days 1 And 33
NCT02565108 (6) [back to overview]	Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs)
NCT02695537 (5) [back to overview]	Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant.
NCT02695537 (5) [back to overview]	Number of Participants With Severe Adverse Events (Increase in Seizure Frequency by More Than 100% Leading to Emergency Room Visit or Hospitalization).
NCT02695537 (5) [back to overview]	Change in Seizure Frequency as Measured in Total Number of Seizures Per Month.
NCT02695537 (5) [back to overview]	Change in Seizure Severity Measured by the Chalfont Seizure Severity Scale (Duncan & Sander, 1991, JNNP).
NCT02695537 (5) [back to overview]	Number of Participants With Change in Resting Blood Pressure or Heart Rate by 25% if Considered Significant by Managing Neurologist.
NCT02700412 (5) [back to overview]	Change in Seizure Frequency as Measured in Total Number of Seizures Per Month.
NCT02700412 (5) [back to overview]	Change in Seizure Severity Measured by the Chalfont Seizure Severity Scale (Duncan & Sander, 1991, JNNP).
NCT02700412 (5) [back to overview]	Number of Participants With Change in Resting Blood Pressure or Heart Rate by 25% if Considered Significant by Managing Neurologist.
NCT02700412 (5) [back to overview]	Number of Participants With Severe Adverse Events (SAEs) (Increase in Seizure Frequency by More Than 100% Leading to Emergency Room Visit or Hospitalization).
NCT02700412 (5) [back to overview]	Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant.
NCT02751359 (2) [back to overview]	Subjective Drug Effects Related to Abuse Liability as Measured by Visual Analog Scales
NCT02751359 (2) [back to overview]	Analgesia: Change From Baseline in Pain Tolerance and Threshold as Measured by the Cold Pressor Test
NCT02759185 (9) [back to overview]	Baseline CAPS-5 Total Severity Score
NCT02759185 (9) [back to overview]	Actigraph Change in Sleep Efficiency
NCT02759185 (9) [back to overview]	Change in Inventory of Depression and Anxiety (IDAS) Social Anxiety Total Scores From Baseline to Stage 1 Primary Endpoint
NCT02759185 (9) [back to overview]	Stage 1 Primary Endpoint CAPS-5 Total Severity Scores (Visit 5)
NCT02759185 (9) [back to overview]	Change in PTSD Checklist (PCL-5) From Baseline to Stage 1 Primary Endpoint
NCT02759185 (9) [back to overview]	Change in Inventory of Psychosocial Functioning (IPF) From Baseline to Stage 1 Primary Endpoint
NCT02759185 (9) [back to overview]	Change in Inventory of Depression and Anxiety (IDAS) General Depression Total Scores From Baseline to Stage 1 Primary Endpoint
NCT02759185 (9) [back to overview]	Change in Insomnia Severity Index (ISI) Scores From Baseline to Stage 1 Primary Endpoint
NCT02759185 (9) [back to overview]	Change in CAPS-5 Total Severity Scores From Baseline to Stage 1 Primary Endpoint (Visit 5)
NCT02818777 (20) [back to overview]	Number of Participants Had Changes in Orthostatic Blood Pressure
NCT02818777 (20) [back to overview]	Severity of Participants Reporting Study-related Adverse Events at Each Dose Level
NCT02818777 (20) [back to overview]	Proportion of Subjects That Drop Out of the Study Due to Study Drug Intolerance
NCT02818777 (20) [back to overview]	Change in Anxiety Short Form
NCT02818777 (20) [back to overview]	Number of Participants Had Changes in Laboratory Values
NCT02818777 (20) [back to overview]	Number of Participants Had Changes in Physical Exam
NCT02818777 (20) [back to overview]	Change From Baseline of REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ)
NCT02818777 (20) [back to overview]	Change in Depression Short Form
NCT02818777 (20) [back to overview]	Change in Emotional and Behavioral Dyscontrol Short Form
NCT02818777 (20) [back to overview]	Change in Fatigue Severity Scale
NCT02818777 (20) [back to overview]	Change in International Restless Legs Syndrome Study Group Rating Scale for Restless
NCT02818777 (20) [back to overview]	Change in MDS-UPDRS Tremor Score (Total of Items 3.17 and 3.18) in the ON State
NCT02818777 (20) [back to overview]	Change in Montreal Cognitive Assessment (MoCA)
NCT02818777 (20) [back to overview]	Change in Movement Disorder Society-Unified Parkinsons Disease Rating Scale Total Score
NCT02818777 (20) [back to overview]	Change in Neuropsychiatric Inventory (NPI)
NCT02818777 (20) [back to overview]	Change in Pain Severity Form
NCT02818777 (20) [back to overview]	Change in Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)
NCT02818777 (20) [back to overview]	Change in Scales for Outcomes in Parkinson's Disease (SCOPA)-Sleep-night Time Sleep
NCT02818777 (20) [back to overview]	Change in Unified Dyskinesia Rating Scale (UDysRS)
NCT02818777 (20) [back to overview]	Number of Participants Had Changes in EKG
NCT02844933 (2) [back to overview]	Change From Baseline In Total Body Weight
NCT02844933 (2) [back to overview]	Change From Baseline in Hyperphagia Behavior as Measured by the Hyperphagia Questionnaire for Clinical Trials (HQ-CT)
NCT02902081 (1) [back to overview]	Positivity Ratings of Social Images
NCT02953548 (16) [back to overview]	Number of Responders
NCT02953548 (16) [back to overview]	Number of Participants With Resolution of Hypsarrhythmia
NCT02953548 (16) [back to overview]	Number of Participants With Severe Treatment-emergent Adverse Events (TEAEs)
NCT02953548 (16) [back to overview]	Number of Participants Free of Clinical Spasms
NCT02953548 (16) [back to overview]	Percentage of Participants Free of Clinical Spasms
NCT02953548 (16) [back to overview]	Percentage of Participants With Resolution of Hypsarrhythmia
NCT02953548 (16) [back to overview]	Percentage of Responders
NCT02953548 (16) [back to overview]	Caregiver Clinical Global Impression of Change (CGIC)
NCT02953548 (16) [back to overview]	Number of Participant With Any Clinically Relevant Urinalysis Parameter Value
NCT02953548 (16) [back to overview]	Number of Participants Experiencing Spasms and Seizures by Subtype
NCT02953548 (16) [back to overview]	Number of Participants With Any Low or High Biochemistry Laboratory Parameter Value
NCT02953548 (16) [back to overview]	Number of Participants With Clinically Significant Electrocardiogram Findings
NCT02953548 (16) [back to overview]	Physician Global Impression of Change (PGIC)
NCT02953548 (16) [back to overview]	Number of Participants With Clinically Significant Physical Examination Findings
NCT02953548 (16) [back to overview]	Number of Participants With Clinically Significant Vital Sign Findings
NCT02953548 (16) [back to overview]	Number of Participants With Any Low or High Hematology Laboratory Parameter Value
NCT02954887 (20) [back to overview]	Change From Baseline in Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score
NCT02954887 (20) [back to overview]	Number of Participants Free of Clinical Spasms
NCT02954887 (20) [back to overview]	Number of Participants With a Resolution of Hypsarrhythmia
NCT02954887 (20) [back to overview]	Number of Participants With Any Clinically Relevant Urinalysis Parameter Value
NCT02954887 (20) [back to overview]	Number of Participants With Any Low or High Biochemistry Laboratory Parameter Value
NCT02954887 (20) [back to overview]	Number of Participants With Any Low or High Hematology Laboratory Parameter Value
NCT02954887 (20) [back to overview]	Number of Responders
NCT02954887 (20) [back to overview]	Percentage of Participants Free of Clinical Spasms
NCT02954887 (20) [back to overview]	Percentage of Participants With a Resolution of Hypsarrhythmia
NCT02954887 (20) [back to overview]	Number of Participants With Severe Treatment-emergent Adverse Events (TEAEs)
NCT02954887 (20) [back to overview]	Percentage of Responders
NCT02954887 (20) [back to overview]	Number of Participants Experiencing Spasms and Seizures by Subtype
NCT02954887 (20) [back to overview]	Number of Participants With Clinically Significant Electrocardiogram Findings
NCT02954887 (20) [back to overview]	Number of Participants With Clinically Significant Physical Examination Findings
NCT02954887 (20) [back to overview]	Number of Participants With Clinically Significant Vital Sign Findings
NCT02954887 (20) [back to overview]	Caregiver Global Impression of Change (CGIC)
NCT02954887 (20) [back to overview]	Physician Global Impression of Change (PGIC)
NCT02954887 (20) [back to overview]	Change From Baseline in Body Weight.
NCT02954887 (20) [back to overview]	Change From Baseline in Head Circumference
NCT02954887 (20) [back to overview]	Change From Baseline in Height
NCT03102918 (1) [back to overview]	Self-report Instruments to Measure Cannabis Use
NCT03248167 (44) [back to overview]	Percentage of Very Heavy Drinking Days
NCT03248167 (44) [back to overview]	Percentage of Very Heavy Drinking Days
NCT03248167 (44) [back to overview]	Percentage of Very Heavy Drinking Days
NCT03248167 (44) [back to overview]	Percentage of Very Heavy Drinking Days
NCT03248167 (44) [back to overview]	Percentage of Very Heavy Drinking Days
NCT03248167 (44) [back to overview]	Number of Participants With No Heavy Drinking Days
NCT03248167 (44) [back to overview]	Number of Drinks Per Day
NCT03248167 (44) [back to overview]	Number of Drinks Per Day
NCT03248167 (44) [back to overview]	Number of Drinks Per Day
NCT03248167 (44) [back to overview]	Number of Participants That Are 'Present and Clear'
NCT03248167 (44) [back to overview]	Number of Participants That Are 'Present and Clear'
NCT03248167 (44) [back to overview]	Number of Participants That Are 'Present and Clear'
NCT03248167 (44) [back to overview]	Number of Participants That Are 'Present and Clear'
NCT03248167 (44) [back to overview]	Number of Participants That Are 'Present and Clear'
NCT03248167 (44) [back to overview]	Number of Participants That Are 'Present and Clear'
NCT03248167 (44) [back to overview]	Number of Participants That Are 'Present and Clear'
NCT03248167 (44) [back to overview]	Number of Participants With No Heavy Drinking Days
NCT03248167 (44) [back to overview]	Number of Participants With No Heavy Drinking Days
NCT03248167 (44) [back to overview]	Number of Participants With No Heavy Drinking Days
NCT03248167 (44) [back to overview]	Number of Participants With No Heavy Drinking Days
NCT03248167 (44) [back to overview]	Number of Participants With No Heavy Drinking Days
NCT03248167 (44) [back to overview]	Number of Participants With No Heavy Drinking Days
NCT03248167 (44) [back to overview]	PCL-5 Total Score
NCT03248167 (44) [back to overview]	PCL-5 Total Score
NCT03248167 (44) [back to overview]	PCL-5 Total Score
NCT03248167 (44) [back to overview]	Percent Carbohydrate Deficient Transferrin (CDT)
NCT03248167 (44) [back to overview]	Percent Carbohydrate Deficient Transferrin (CDT)
NCT03248167 (44) [back to overview]	Percent Carbohydrate Deficient Transferrin (CDT)
NCT03248167 (44) [back to overview]	Percentage of Days Abstinent
NCT03248167 (44) [back to overview]	Percentage of Days Abstinent
NCT03248167 (44) [back to overview]	Percentage of Days Abstinent
NCT03248167 (44) [back to overview]	Percentage of Days Abstinent
NCT03248167 (44) [back to overview]	Percentage of Days Abstinent
NCT03248167 (44) [back to overview]	Percentage of Days Abstinent
NCT03248167 (44) [back to overview]	Percentage of Days Abstinent
NCT03248167 (44) [back to overview]	Percentage of Heavy Drinking Days
NCT03248167 (44) [back to overview]	Percentage of Heavy Drinking Days
NCT03248167 (44) [back to overview]	Percentage of Heavy Drinking Days
NCT03248167 (44) [back to overview]	Percentage of Heavy Drinking Days
NCT03248167 (44) [back to overview]	Percentage of Heavy Drinking Days
NCT03248167 (44) [back to overview]	Percentage of Heavy Drinking Days
NCT03248167 (44) [back to overview]	Percentage of Heavy Drinking Days
NCT03248167 (44) [back to overview]	Percentage of Very Heavy Drinking Days
NCT03248167 (44) [back to overview]	Percentage of Very Heavy Drinking Days
NCT03252756 (51) [back to overview]	Trough CBD Plasma Levels
NCT03252756 (51) [back to overview]	Percentage of Heavy Drinking Days
NCT03252756 (51) [back to overview]	Percent of Heavy Drinking Days
NCT03252756 (51) [back to overview]	Percent of Heavy Drinking Days
NCT03252756 (51) [back to overview]	Percent of Heavy Drinking Days
NCT03252756 (51) [back to overview]	Percent of Heavy Drinking Days
NCT03252756 (51) [back to overview]	Percent of Heavy Drinking Days
NCT03252756 (51) [back to overview]	Percent of Heavy Drinking Days
NCT03252756 (51) [back to overview]	Percent of Heavy Drinking Days
NCT03252756 (51) [back to overview]	Percent of Heavy Drinking Days
NCT03252756 (51) [back to overview]	Penn Alcohol Craving Scale (PACS) Score
NCT03252756 (51) [back to overview]	Beck Anxiety Inventory (BAI) Score
NCT03252756 (51) [back to overview]	Beck Anxiety Inventory (BAI) Score
NCT03252756 (51) [back to overview]	Trough CBD Plasma Levels
NCT03252756 (51) [back to overview]	Trough CBD Plasma Levels
NCT03252756 (51) [back to overview]	Trough CBD Plasma Levels
NCT03252756 (51) [back to overview]	Trough CBD Plasma Levels
NCT03252756 (51) [back to overview]	Percent of Heavy Drinking Days
NCT03252756 (51) [back to overview]	Penn Alcohol Craving Scale (PACS) Score
NCT03252756 (51) [back to overview]	Trough CBD Plasma Levels
NCT03252756 (51) [back to overview]	Beck Anxiety Inventory (BAI) Score
NCT03252756 (51) [back to overview]	Beck Anxiety Inventory (BAI) Score
NCT03252756 (51) [back to overview]	Beck Anxiety Inventory (BAI) Score
NCT03252756 (51) [back to overview]	Beck Anxiety Inventory (BAI) Score
NCT03252756 (51) [back to overview]	Beck Depression Inventory (BDI) Score
NCT03252756 (51) [back to overview]	Beck Depression Inventory (BDI) Score
NCT03252756 (51) [back to overview]	Beck Depression Inventory (BDI) Score
NCT03252756 (51) [back to overview]	Beck Depression Inventory (BDI) Score
NCT03252756 (51) [back to overview]	Beck Depression Inventory (BDI) Score
NCT03252756 (51) [back to overview]	Number of Drinks Per Day
NCT03252756 (51) [back to overview]	Number of Drinks Per Day
NCT03252756 (51) [back to overview]	Number of Drinks Per Day
NCT03252756 (51) [back to overview]	Number of Drinks Per Day
NCT03252756 (51) [back to overview]	Number of Drinks Per Day
NCT03252756 (51) [back to overview]	Number of Drinks Per Day
NCT03252756 (51) [back to overview]	Number of Drinks Per Day
NCT03252756 (51) [back to overview]	Number of Drinks Per Day
NCT03252756 (51) [back to overview]	Number of Drinks Per Day
NCT03252756 (51) [back to overview]	Number of Drinks Per Day
NCT03252756 (51) [back to overview]	Peak CBD Plasma Levels
NCT03252756 (51) [back to overview]	Beck Depression Inventory (BDI) Score
NCT03252756 (51) [back to overview]	Peak CBD Plasma Levels
NCT03252756 (51) [back to overview]	Peak CBD Plasma Levels
NCT03252756 (51) [back to overview]	Peak CBD Plasma Levels
NCT03252756 (51) [back to overview]	Peak CBD Plasma Levels
NCT03252756 (51) [back to overview]	Peak CBD Plasma Levels
NCT03252756 (51) [back to overview]	Peak CBD Plasma Levels
NCT03252756 (51) [back to overview]	Penn Alcohol Craving Scale (PACS) Score
NCT03252756 (51) [back to overview]	Penn Alcohol Craving Scale (PACS) Score
NCT03252756 (51) [back to overview]	Penn Alcohol Craving Scale (PACS) Score
NCT03252756 (51) [back to overview]	Penn Alcohol Craving Scale (PACS) Score
NCT03336242 (5) [back to overview]	Percent Change From Baseline in Time to Absence Seizure During Hyperventilation Testing on Video-EEG at Visit 5
NCT03336242 (5) [back to overview]	Percent Change From Baseline in Absence Seizure Counts Assessed by Video-electroencephalogram (EEG) at Visit 5
NCT03336242 (5) [back to overview]	Number of Participants Seizure-Free at Visit 5
NCT03336242 (5) [back to overview]	Clinical Global Impression of Improvement (CGI-I) Score at Visit 5
NCT03336242 (5) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT03355300 (1) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT03614663 (8) [back to overview]	Number of Participants With Any Improvement - Clinical Global Impressions- Improvement (CGI-I) - Full Analysis Set
NCT03614663 (8) [back to overview]	Number of Participants With Any Improvement - Clinical Global Impressions- Improvement (CGI-I) - Ad Hoc Analysis
NCT03614663 (8) [back to overview]	Aberrant Behavior Checklist-Community, Fragile X Factor Structure (ABC-C FXS) Socially Unresponsive/Lethargic Subscale - Full Analysis Set
NCT03614663 (8) [back to overview]	Aberrant Behavior Checklist-Community Fragile X Factor Structure (ABC-C FXS) Socially Unresponsive/Lethargic Subscale - Ad Hoc Analysis
NCT03614663 (8) [back to overview]	Aberrant Behavior Checklist-Community Fragile X Factor Structure (ABC-C FXS) Social Avoidance Subscale - Full Analysis Set
NCT03614663 (8) [back to overview]	Aberrant Behavior Checklist-Community Fragile X Factor Structure (ABC-C FXS) Social Avoidance Subscale - Ad Hoc Analysis
NCT03614663 (8) [back to overview]	Aberrant Behavior Checklist-Community Fragile X Factor Structure (ABC-C FXS) Irritability Subscale - Full Analysis Set
NCT03614663 (8) [back to overview]	Aberrant Behavior Checklist-Community Fragile X Factor Structure (ABC-C FXS) Irritability Subscale - Ad Hoc Analysis
NCT03805750 (7) [back to overview]	Global Impression of Change
NCT03805750 (7) [back to overview]	Number of Participants Reporting Adverse Events Based on Common Terminology Criteria
NCT03805750 (7) [back to overview]	Number of Participants at Risk for Suicide Based on Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT03805750 (7) [back to overview]	Accelerometry-based Assessment of Tremor Severity
NCT03805750 (7) [back to overview]	Change in Score on a Scale From Baseline of the Tremor Research Group Essential Tremor Rating Scale (TETRAS)
NCT03805750 (7) [back to overview]	Digital Spirography
NCT03805750 (7) [back to overview]	Number of Participants With New Study-related Electrocardiogram (EKG) Abnormalities
NCT03848832 (7) [back to overview]	Change From Baseline in the Mean RSBQ Total Score at Week 24 for the 5 mg/kg/Day GWP42003-P Dose Level Compared With Placebo
NCT03848832 (7) [back to overview]	Change From Baseline in Mean 9-items Motor Behavioral Assessment (MBA-9) Total Score and Subscale Scores at Week 24
NCT03848832 (7) [back to overview]	Change From Baseline in the Mean Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score at Week 24 for the 15 mg/kg/Day GWP42003-P Dose Level Compared With Placebo
NCT03848832 (7) [back to overview]	Change From Baseline in Mean RSBQ Subscale Scores at Week 24
NCT03848832 (7) [back to overview]	Change From Baseline in Mean Clinician Global Impressions - Severity (CGI-S) Score at Week 24
NCT03848832 (7) [back to overview]	Change From Baseline in Mean Children's Sleep Habits Questionnaire (CSHQ) Total Score and Subscale Scores at Week 24
NCT03848832 (7) [back to overview]	Mean Clinical Global Impressions - Improvement (CGI-I) Score at Week 24
NCT03891264 (2) [back to overview]	Changes in Brain Positron Emission Tomography Signal
NCT03891264 (2) [back to overview]	Changes in Pain Outcomes as Measured by Self Report on a 0-10 Numerical Pain Rating Scale (Worst Pain in the Past 24 Hours).
NCT04192370 (1) [back to overview]	Change in Cue-induced Cravings and Anxiety After 3 Days of Cannabidiol Administration
NCT04238754 (7) [back to overview]	Safety as Assessed by Number of Adverse Events
NCT04238754 (7) [back to overview]	Initial Efficacy of Study Drug as Assessed by Area Under the Curve for the Subjective Opiate Withdrawal Scale (SOWS) Scores
NCT04238754 (7) [back to overview]	Change in Withdrawal Scores From Baseline AfterReceiving Placebo
NCT04238754 (7) [back to overview]	Acceptability Assessed by Rating of Medication Acceptance on a 5-point Acceptance Rating Scale
NCT04238754 (7) [back to overview]	Acceptability Assessed by Number of Participants Who Would Recommend the Medication to a Family Member or Friend
NCT04238754 (7) [back to overview]	Number of Participants Whose Aspartate Aminotransferase (AST)/Alanine Aminotransferase (ALT) Levels >3x Upper Limit of Normal
NCT04238754 (7) [back to overview]	Acceptability Assessed by Visual Analog Ratings
NCT04252586 (15) [back to overview]	Number of Participants With At Least One Post Open Label Extension Baseline Flagged ECG Result
NCT04252586 (15) [back to overview]	Number of Participants With Treatment-emergent Clinical Laboratory Parameters From the Baseline at Any Time Post-dose
NCT04252586 (15) [back to overview]	Mean Change From Baseline in 9-item Motor Behavioral Assessment (MBA-9) Total Score at End of Treatment
NCT04252586 (15) [back to overview]	Mean Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) Levels at End of Treatment
NCT04252586 (15) [back to overview]	Number of Participants With Any Treatment-emergent Adverse Events (TEAEs), Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs
NCT04252586 (15) [back to overview]	Number of Participants With Changes in Tanner Staging at the Baseline and at End of Treatment
NCT04252586 (15) [back to overview]	Number of Participants With Clinically Significant Changes in the Vital Sign Values of Pulse Rate From the Baseline at Any Time Post-dose
NCT04252586 (15) [back to overview]	Number of Participants With Clinically Significant Percent Change in Body Weight From the Baseline at Any Time Post-dose
NCT04252586 (15) [back to overview]	Number of Participants With Potentially Clinically Significant Changes in Vital Sign Values of Blood Pressure From the Baseline at Any Time Post-dose
NCT04252586 (15) [back to overview]	Number of Participants With Suicidal Ideation or Behavior at the Baseline and at Any Time Post-dose
NCT04252586 (15) [back to overview]	Mean Clinical Global Impressions-Improvement (CGI-I) Continuous Score at End of Treatment
NCT04252586 (15) [back to overview]	Mean Change From Baseline in Rett Syndrome Behaviour Questionnaire (RSBQ) Overall Score at End of Treatment
NCT04252586 (15) [back to overview]	Number of Participants With Any Changes In Menstruation Cycle at Any Time Post-dose
NCT04252586 (15) [back to overview]	Mean Change From Baseline in Children's Sleep Habits Questionnaire (CSHQ) Total Score at End of Treatment
NCT04252586 (15) [back to overview]	Mean Clinician Global Impressions - Severity Scale (CGI-S) Continuous Score at End of Treatment
NCT04387617 (4) [back to overview]	Total Urinary Symptoms Score
NCT04387617 (4) [back to overview]	The Number of Subjects With Adverse Events
NCT04387617 (4) [back to overview]	Postoperative Rescue Narcotic Use
NCT04387617 (4) [back to overview]	Maximum Pain Intensity Score
NCT04447846 (19) [back to overview]	Neuroscore
NCT04447846 (19) [back to overview]	Modified House Classification Scores
NCT04447846 (19) [back to overview]	Behavior Rating Inventory of Executive Function, Second Edition (BRIEF-2)
NCT04447846 (19) [back to overview]	Safety of Epidiolex
NCT04447846 (19) [back to overview]	Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55)
NCT04447846 (19) [back to overview]	Port-wine Birthmark Score
NCT04447846 (19) [back to overview]	Picture Vocabulary Test
NCT04447846 (19) [back to overview]	Pediatric Neurological Quality of Life (Neuro-QoL)
NCT04447846 (19) [back to overview]	Screen for Child Anxiety Related Disorders (SCARED)
NCT04447846 (19) [back to overview]	Pediatric Evaluation of Disability Inventory Computer Adapted Test
NCT04447846 (19) [back to overview]	ABILHAND Questionnaire
NCT04447846 (19) [back to overview]	Adult Neurological Quality of Life (Neuro-QoL)
NCT04447846 (19) [back to overview]	Behavioral Assessment System for Children, Third Edition (BASC-3)
NCT04447846 (19) [back to overview]	Erhardt Developmental Prehension Assessment Scores
NCT04447846 (19) [back to overview]	List Sorting Working Memory Test
NCT04447846 (19) [back to overview]	Migraine Severity
NCT04447846 (19) [back to overview]	Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V) or Wechsler Adult Intelligence Scale (WAIS-IV)
NCT04447846 (19) [back to overview]	Social Responsiveness Scale, Second Edition (SRS-2)
NCT04447846 (19) [back to overview]	Seizure Frequency
NCT04590495 (14) [back to overview]	Change in Baseline VAMS--Physical Sedation
NCT04590495 (14) [back to overview]	Change in Baseline VAMS for Mental Sedation
NCT04590495 (14) [back to overview]	Change in Baseline TMT Part B
NCT04590495 (14) [back to overview]	Change in Baseline TMT Part A
NCT04590495 (14) [back to overview]	Driving Performance - Number of Collisions.
NCT04590495 (14) [back to overview]	Change in Baseline SRT for Sound #1
NCT04590495 (14) [back to overview]	Change in Baseline SSS
NCT04590495 (14) [back to overview]	Change in Baseline SRT--sound #2
NCT04590495 (14) [back to overview]	Change in Baseline PVT
NCT04590495 (14) [back to overview]	Change in Baseline DSST
NCT04590495 (14) [back to overview]	Driving Performance - Lateral Position in Lane
NCT04590495 (14) [back to overview]	Driving Performance-percent of Time Spent Driving Above Speed Limit
NCT04590495 (14) [back to overview]	Driving Performance - Brake Reaction Time
NCT04590495 (14) [back to overview]	Driving Performance - Percent of Time Spent Out of Lane
NCT04982029 (6) [back to overview]	Attentional Bias
NCT04982029 (6) [back to overview]	Stress-Reactivity (Physiological)
NCT04982029 (6) [back to overview]	Change in Cue-reactivity
NCT04982029 (6) [back to overview]	Stress-reactivity
NCT04982029 (6) [back to overview]	Delayed Discount
NCT04982029 (6) [back to overview]	Decision Making
NCT05209867 (1) [back to overview]	Number of Differentially Expressed Genes

Change in Brief Pain Inventory - Short Form (BPI-SF)

The BPI-SF is a 14-item questionnaire that asks patients to rate pain over the prior week and the degree to which it interferes with activities on a 0 to 10 scale, where 0=no pain and 10=pain as bad as you can imagine. Severity is measured as worst pain, least pain, average pain, and pain right now. The severity composite score was calculated as the arithmetic mean of the four severity items(range 0-10). the minimum value is zero and maximum is 10. A higher score represents a poor outcome. (NCT00530764)
Timeframe: Baseline (Visit 2) and End of Treatment (End of Week 5 or premature termination)

Intervention	Score on scale (Mean)
Sativex High Dose Group	-1.0
Sativex Medium Dose Group	-1.5
Sativex Low Dose Group	-1.3
Placebo	-1.0

Intervention	Score on scale (Mean)
Sativex High Dose Group	0.0
Sativex Medium Dose Group	-0.1
Sativex Low Dose Group	0.0
Placebo	-0.1

Intervention	Score on scale (Mean)
Sativex High Dose Group	-0.4
Sativex Medium Dose Group	-1.0
Sativex Low Dose Group	-1.1
Placebo	-2.9

Intervention	Points on scale (Mean)
Sativex High Dose	-1.0
Sativex Medium Dose	-1.2
Sativex Low Dose	-1.6
Placebo	-0.9

Intervention	Participants (Number)
	Very much improved	Much improved	Slightly improved	No change	Slightly worse	Much worse	Very much worse
Placebo	9	16	28	17	1	1	0
Sativex High Dose Group	6	20	25	13	6	1	2
Sativex Low Dose Group	10	24	19	13	3	1	0
Sativex Medium Dose Group	6	19	26	13	5	0	2

Intervention	Points on scale (Mean)
Sativex High Dose Group	-0.7
Sativex Medium Dose Group	-0.9
Sativex Low Dose Group	-1.5
Placebo	-0.8

Intervention	mmol/l (Mean)
1:1 GWP42003 : GWP42004	-0.03
20:1 GWP42003 : GWP42004	-0.16
GWP42003 and Placebo	-0.08
GWP42004 and Placebo	-0.08
Placebo	-0.06

Intervention	litres (Mean)
1:1 GWP42003 : GWP42004	-0.22
20:1 GWP42003 : GWP42004	-0.75
GWP42003 and Placebo	0.02
GWP42004 and Placebo	-0.29
Placebo	-0.37

Intervention	ratio (Mean)
1:1 GWP42003 : GWP42004	0.03
20:1 GWP42003 : GWP42004	0.04
GWP42003 and Placebo	-0.02
GWP42004 and Placebo	0.02
Placebo	0.01

Intervention	pmol/l (Mean)
1:1 GWP42003 : GWP42004	80.9
20:1 GWP42003 : GWP42004	-156.6
GWP42003 and Placebo	-193.5
GWP42004 and Placebo	83.5
Placebo	-40.8

Intervention	mmol/l (Mean)
1:1 GWP42003 : GWP42004	-0.07
20:1 GWP42003 : GWP42004	1.09
GWP42003 and Placebo	-0.78
GWP42004 and Placebo	0.22
Placebo	0.42

Intervention	ratio (Mean)
1:1 GWP42003 : GWP42004	-0.00
20:1 GWP42003 : GWP42004	-0.00
GWP42003 and Placebo	0.00
GWP42004 and Placebo	-0.00
Placebo	-0.01

Intervention	cm (Mean)
1:1 GWP42003 : GWP42004	0.82
20:1 GWP42003 : GWP42004	-0.17
GWP42003 and Placebo	0.31
GWP42004 and Placebo	-0.39
Placebo	-0.86

Intervention	litres (Mean)
1:1 GWP42003 : GWP42004	0.10
20:1 GWP42003 : GWP42004	0.62
GWP42003 and Placebo	0.42
GWP42004 and Placebo	-0.11
Placebo	0.27

Intervention	litres (Mean)
1:1 GWP42003 : GWP42004	-0.09
20:1 GWP42003 : GWP42004	0.46
GWP42003 and Placebo	0.40
GWP42004 and Placebo	-0.52
Placebo	-0.88

Intervention	umol/l (Mean)
1:1 GWP42003 : GWP42004	-0.19
20:1 GWP42003 : GWP42004	0.18
GWP42003 and Placebo	0.11
GWP42004 and Placebo	0.08
Placebo	0.16

Intervention	mmol/l (Mean)
1:1 GWP42003 : GWP42004	-0.12
20:1 GWP42003 : GWP42004	-0.23
GWP42003 and Placebo	-0.11
GWP42004 and Placebo	-0.11
Placebo	-0.16

Intervention	umol/l (Mean)
1:1 GWP42003 : GWP42004	-2.86
20:1 GWP42003 : GWP42004	-3.51
GWP42003 and Placebo	-4.92
GWP42004 and Placebo	0.64
Placebo	-3.41

Intervention	kg/m^2 (Mean)
1:1 GWP42003 : GWP42004	-0.38
20:1 GWP42003 : GWP42004	-0.02
GWP42003 and Placebo	-0.20
GWP42004 and Placebo	-0.21
Placebo	-0.50

Intervention	percent liver fat (Mean)
1:1 GWP42003 : GWP42004	-1.12
20:1 GWP42003 : GWP42004	0.37
GWP42003 and Placebo	-4.73
GWP42004 and Placebo	0.77
Placebo	-2.95

Intervention	units on a scale (Mean)
1:1 GWP42003 : GWP42004	-1.19
20:1 GWP42003 : GWP42004	-0.84
GWP42003 and Placebo	-0.69
GWP42004 and Placebo	-0.36
Placebo	-0.59

cannabidiol

Description

Related Flora

Cross-References

Synonyms (96)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (3)

Pathways (3)

Protein Targets (45)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (450)

Molecular Functions (136)

Ceullar Components (71)

Bioassays (366)

Research

Studies (3,178)

Study Types

Clinical Trials (260)

Trial Overview

Trial Outcomes

Change in Brief Pain Inventory - Short Form (BPI-SF)

Change in Patient Assessment of Constipation Quality of Life (PAC-QoL)

Change in Montgomery Asberg Depression Rating Scale (MADRS)

Change in Mean Daily NRS Pain Score (Worst Pain).

Change in Cumulative Average Pain Response Curves

Change in Mean Daily NRS Pain Score (Average Pain).

Change in Patient Global Impression of Change - PGIC

Number of Patients With at Least 30% Improvement in Numerical Rating Scale (NRS) Average Pain Score From Baseline

Change in Sleep Disruption NRS

Overall Cognition as Measured on the MATRICS Battery

Verbal Short Term Memory

The Change From Baseline in Mean Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Internal Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Serum High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio After 91 Days (13 Weeks) of Treatment

The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Insulin Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test)

The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Glucose Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test [OGTT])

The Change From Baseline in Mean Waist-to-hip Ratio After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Waist Measurement After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Visceral Abdominal Fat After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Very Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Triglyceride Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Total Subcutaneous Fat After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Total Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Total Internal Fat After 91 Days (13 Weeks) of Treatment

Adverse Events as a Measure of Patient Safety

The Change From Baseline in Mean Total Fat After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Serum Apolipoprotein B Concentration After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Total Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Serum Apolipoprotein B : Apolipoprotein A Ratio After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Serum Apolipoprotein A Concentration After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Body Mass Index After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Total Abdominal Fat After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean % Liver Fat After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Abdominal Adiposity After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Appetite 0-10 Numerical Rating Scale Score After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Beck Depression Inventory-II (BDI-II) Score at the End of 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Body Weight After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean C-peptide Concentration After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Fasting Glucose Concentration After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Fasting Insulin Concentration After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Fructosamine Concentration After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Glycated Haemoglobin Concentration After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Insulin Sensitivity Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean High Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Hip Measurement After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Insulin Resistance Measured by Homeostasis Model Assessment 2 (HOMA2-IR) After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Insulin B Cell Function Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Subcutaneous Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Subcutaneous Abdominal Fat After 91 Days (13 Weeks) of Treatment

The Change From Baseline in Mean Serum Triglyceride Concentration After 91 Days (13 Weeks) of Treatment

Intervention	kg (Mean)
1:1 GWP42003 : GWP42004	-1.05
20:1 GWP42003 : GWP42004	-0.10
GWP42003 and Placebo	-0.46
GWP42004 and Placebo	-0.66
Placebo	-1.64

Intervention	pmol/l (Mean)
1:1 GWP42003 : GWP42004	12.01
20:1 GWP42003 : GWP42004	-6.06
GWP42003 and Placebo	13.44
GWP42004 and Placebo	45.62
Placebo	2.79

Intervention	umol/l (Mean)
1:1 GWP42003 : GWP42004	2.8
20:1 GWP42003 : GWP42004	14.5
GWP42003 and Placebo	-2.6
GWP42004 and Placebo	1.1
Placebo	9.5

Intervention	percent (Mean)
1:1 GWP42003 : GWP42004	0.14
20:1 GWP42003 : GWP42004	0.16
GWP42003 and Placebo	0.08
GWP42004 and Placebo	-0.03
Placebo	0.31

Intervention	percent sensitivity (Mean)
1:1 GWP42003 : GWP42004	-5.26
20:1 GWP42003 : GWP42004	-1.71
GWP42003 and Placebo	1.71
GWP42004 and Placebo	6.47
Placebo	-4.07

Intervention	mmol/l (Mean)
1:1 GWP42003 : GWP42004	-0.04
20:1 GWP42003 : GWP42004	-0.06
GWP42003 and Placebo	-0.11
GWP42004 and Placebo	-0.01
Placebo	-0.02

Intervention	cm (Mean)
1:1 GWP42003 : GWP42004	1.12
20:1 GWP42003 : GWP42004	0.07
GWP42003 and Placebo	0.38
GWP42004 and Placebo	-0.19
Placebo	-0.20

Intervention	IR score (Mean)
1:1 GWP42003 : GWP42004	0.19
20:1 GWP42003 : GWP42004	-0.19
GWP42003 and Placebo	0.35
GWP42004 and Placebo	0.64
Placebo	0.09

Intervention	percent beta function (Mean)
1:1 GWP42003 : GWP42004	8.13
20:1 GWP42003 : GWP42004	-7.64
GWP42003 and Placebo	-1.31
GWP42004 and Placebo	36.59
Placebo	-2.41

Intervention	litres (Mean)
1:1 GWP42003 : GWP42004	-0.3
20:1 GWP42003 : GWP42004	0.5
GWP42003 and Placebo	-0.0
GWP42004 and Placebo	0.1
Placebo	0.3